{ "version": "2.2", "instance": { "qntm6k080726.htm qntmex99-1.htm": { "nsprefix": "qntm", "nsuri": "http://www.quantumbiopharma.com/20260630", "dts": { "schema": { "local": [ "qntm-20260630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions-ea/rol_ifrs_ea-dim_2025-03-27.xsd", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions/rol_full_ifrs-dim_2025-03-27.xsd", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd", "https://xbrl.sec.gov/country/2025/country-2025.xsd", "https://xbrl.sec.gov/dei/2025/dei-2025.xsd", "https://xbrl.sec.gov/sic/2025/sic-2025.xsd", "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd" ] }, "calculationLink": { "local": [ "qntm-20260630_cal.xml" ] }, "definitionLink": { "local": [ "qntm-20260630_def.xml" ], "remote": [ "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions-ea/dim_ifrs_ea_2025-03-27_role-995000.xml", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions/dim_full_ifrs_2025-03-27_role-995000.xml" ] }, "labelLink": { "local": [ "qntm-20260630_lab.xml" ] }, "presentationLink": { "local": [ "qntm-20260630_pre.xml" ] }, "inline": { "local": [ "qntm6k080726.htm", "qntmex99-1.htm" ] } }, "keyStandard": 171, "keyCustom": 264, "axisStandard": 22, "axisCustom": 3, "memberStandard": 16, "memberCustom": 98, "hidden": { "total": 112, "http://www.quantumbiopharma.com/20260630": 104, "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full": 1, "http://xbrl.sec.gov/dei/2025": 7 }, "contextCount": 420, "entityCount": 1, "segmentCount": 118, "elementCount": 729, "unitCount": 11, "baseTaxonomies": { "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full": 567, "http://xbrl.sec.gov/dei/2025": 15 }, "report": { "R1": { "role": "http://www.quantumbiopharma.com/role/DocumentAndEntityInformation", "longName": "000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c0", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "b", "span", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntm6k080726.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "b", "span", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntm6k080726.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet", "longName": "001 - Statement - CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION", "shortName": "CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c1", "name": "ifrs-full:CashAndCashEquivalents", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true }, "uniqueAnchor": { "contextRef": "c1", "name": "ifrs-full:OtherReceivables", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "unique": true } }, "R3": { "role": "http://www.quantumbiopharma.com/role/ConsolidatedIncomeStatement", "longName": "002 - Statement - CONDENSED CONSOLIDATED INTERIM STATEMENTS OF LOSS AND COMPREHENSIVE LOSS", "shortName": "CONDENSED CONSOLIDATED INTERIM STATEMENTS OF LOSS AND COMPREHENSIVE LOSS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c7", "name": "ifrs-full:SellingGeneralAndAdministrativeExpense", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c7", "name": "ifrs-full:SellingGeneralAndAdministrativeExpense", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.quantumbiopharma.com/role/ShareholdersEquityType2or3", "longName": "003 - Statement - CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN SHAREHOLDERS\u2019 EQUITY", "shortName": "CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN SHAREHOLDERS\u2019 EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c13", "name": "ifrs-full:Equity", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c13", "name": "ifrs-full:Equity", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow", "longName": "004 - Statement - CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN CASH FLOWS", "shortName": "CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:ProfitLossFromContinuingOperations", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:ProfitLossFromContinuingOperations", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.quantumbiopharma.com/role/Natureofbusiness", "longName": "005 - Disclosure - Nature of business", "shortName": "Nature of business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "6", "firstAnchor": { "contextRef": "c0", "name": "qntm:DisclosureOfNatureOfBusinessExplanatoryTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "qntm:DisclosureOfNatureOfBusinessExplanatoryTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.quantumbiopharma.com/role/Basisofpresentation", "longName": "006 - Disclosure - Basis of presentation", "shortName": "Basis of presentation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.quantumbiopharma.com/role/NewstandardsamendmentsandinterpretationsadoptedbytheCompany", "longName": "007 - Disclosure - New standards, amendments and interpretations adopted by the Company", "shortName": "New standards, amendments and interpretations adopted by the Company", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.quantumbiopharma.com/role/Otherreceivables", "longName": "008 - Disclosure - Other receivables", "shortName": "Other receivables", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.quantumbiopharma.com/role/Investments", "longName": "009 - Disclosure - Investments", "shortName": "Investments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.quantumbiopharma.com/role/Digitalassets", "longName": "010 - Disclosure - Digital assets", "shortName": "Digital assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c0", "name": "qntm:DisclosureOfDigitalIntangibleAssetsExplanatoryTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "qntm:DisclosureOfDigitalIntangibleAssetsExplanatoryTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.quantumbiopharma.com/role/Intangibleassets", "longName": "011 - Disclosure - Intangible assets", "shortName": "Intangible assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.quantumbiopharma.com/role/Tradeandotherpayables", "longName": "012 - Disclosure - Trade and other payables", "shortName": "Trade and other payables", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.quantumbiopharma.com/role/WarrantsLiability", "longName": "013 - Disclosure - Warrants Liability", "shortName": "Warrants Liability", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c0", "name": "qntm:DisclosureOfWarrantLiabilitiesExplanatoryTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "qntm:DisclosureOfWarrantLiabilitiesExplanatoryTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.quantumbiopharma.com/role/Notespayable", "longName": "014 - Disclosure - Notes payable", "shortName": "Notes payable", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c0", "name": "qntm:DisclosureOfNotePayablesExplanatoryTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "qntm:DisclosureOfNotePayablesExplanatoryTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.quantumbiopharma.com/role/Convertibledebentures", "longName": "015 - Disclosure - Convertible debentures", "shortName": "Convertible debentures", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfDetailedInformationAboutInvestmentPropertyExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfDetailedInformationAboutInvestmentPropertyExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.quantumbiopharma.com/role/Sharecapital", "longName": "016 - Disclosure - Share capital", "shortName": "Share capital", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.quantumbiopharma.com/role/Sharebasedcompensation", "longName": "017 - Disclosure - Share-based compensation", "shortName": "Share-based compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.quantumbiopharma.com/role/Noncontrollinginterests", "longName": "018 - Disclosure - Non-controlling interests", "shortName": "Non-controlling interests", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfNoncontrollingInterestsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfNoncontrollingInterestsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.quantumbiopharma.com/role/Losspershare", "longName": "019 - Disclosure - Loss per share", "shortName": "Loss per share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.quantumbiopharma.com/role/Generalandadministrative", "longName": "020 - Disclosure - General and administrative", "shortName": "General and administrative", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.quantumbiopharma.com/role/Segmentinformation", "longName": "021 - Disclosure - Segment information", "shortName": "Segment information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfOperatingSegmentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfOperatingSegmentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.quantumbiopharma.com/role/Commitmentsandcontingencies", "longName": "022 - Disclosure - Commitments and contingencies", "shortName": "Commitments and contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.quantumbiopharma.com/role/Relatedpartytransactions", "longName": "023 - Disclosure - Related party transactions", "shortName": "Related party transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.quantumbiopharma.com/role/CapitalManagement", "longName": "024 - Disclosure - Capital Management", "shortName": "Capital Management", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.quantumbiopharma.com/role/FinancialInstrumentsandRiskManagement", "longName": "025 - Disclosure - Financial Instruments and Risk Management", "shortName": "Financial Instruments and Risk Management", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.quantumbiopharma.com/role/Subsequentevents", "longName": "026 - Disclosure - Subsequent events", "shortName": "Subsequent events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.quantumbiopharma.com/role/AccountingPoliciesByPolicy", "longName": "996000 - Disclosure - Accounting Policies, by Policy (Policies)", "shortName": "Accounting Policies, by Policy (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "28", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:StatementOfIFRSCompliance", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:StatementOfIFRSCompliance", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.quantumbiopharma.com/role/NatureofbusinessTables", "longName": "996001 - Disclosure - Nature of business (Tables)", "shortName": "Nature of business (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.quantumbiopharma.com/role/OtherreceivablesTables", "longName": "996002 - Disclosure - Other receivables (Tables)", "shortName": "Other receivables (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c0", "name": "qntm:DisclosureOfDetailInformationAboutTradeAndOtherReceivablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "qntm:DisclosureOfDetailInformationAboutTradeAndOtherReceivablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.quantumbiopharma.com/role/InvestmentsTables", "longName": "996003 - Disclosure - Investments (Tables)", "shortName": "Investments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c0", "name": "qntm:DisclosureOfDetailedInformationAboutInvestmentsExplanatoryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "qntm:DisclosureOfDetailedInformationAboutInvestmentsExplanatoryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.quantumbiopharma.com/role/DigitalassetsTables", "longName": "996004 - Disclosure - Digital assets (Tables)", "shortName": "Digital assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c0", "name": "qntm:DisclosureOfDigitalIntangibleAssetsExplanatoryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "table", "qntm:DisclosureOfDigitalIntangibleAssetsExplanatoryTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "qntm:DisclosureOfDigitalIntangibleAssetsExplanatoryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "table", "qntm:DisclosureOfDigitalIntangibleAssetsExplanatoryTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.quantumbiopharma.com/role/IntangibleassetsTables", "longName": "996005 - Disclosure - Intangible assets (Tables)", "shortName": "Intangible assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.quantumbiopharma.com/role/TradeandotherpayablesTables", "longName": "996006 - Disclosure - Trade and other payables (Tables)", "shortName": "Trade and other payables (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c0", "name": "qntm:DisclosureOfDetailedInformationAboutTradeAndOtherPayableExplanatoryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "qntm:DisclosureOfDetailedInformationAboutTradeAndOtherPayableExplanatoryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.quantumbiopharma.com/role/WarrantsLiabilityTables", "longName": "996007 - Disclosure - Warrants Liability (Tables)", "shortName": "Warrants Liability (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c0", "name": "qntm:DisclosureOfDetailedInformationAboutFairBlackScholesWarrantsLiabilityExplanatoryTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "qntm:DisclosureOfWarrantLiabilitiesExplanatoryTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "qntm:DisclosureOfDetailedInformationAboutFairBlackScholesWarrantsLiabilityExplanatoryTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "qntm:DisclosureOfWarrantLiabilitiesExplanatoryTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.quantumbiopharma.com/role/ConvertibledebenturesTables", "longName": "996008 - Disclosure - Convertible debentures (Tables)", "shortName": "Convertible debentures (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "c0", "name": "qntm:DisclosureOfDetailedInformationAboutGainOnChangeInFairValueExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfDetailedInformationAboutInvestmentPropertyExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "qntm:DisclosureOfDetailedInformationAboutGainOnChangeInFairValueExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfDetailedInformationAboutInvestmentPropertyExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.quantumbiopharma.com/role/SharecapitalTables", "longName": "996009 - Disclosure - Share capital (Tables)", "shortName": "Share capital (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "c0", "name": "qntm:DisclosureOfDetailedInformationAboutChangesInWarrantsOutstandingAndWeightedAverageExercisePriceExplanatoryTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "qntm:DisclosureOfDetailedInformationAboutChangesInWarrantsOutstandingAndWeightedAverageExercisePriceExplanatoryTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.quantumbiopharma.com/role/SharebasedcompensationTables", "longName": "996010 - Disclosure - Share-based compensation (Tables)", "shortName": "Share-based compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "c0", "name": "qntm:DisclosureOfNumberOfShareOptionsOutstandingTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "qntm:DisclosureOfNumberOfShareOptionsOutstandingTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.quantumbiopharma.com/role/NoncontrollinginterestsTables", "longName": "996011 - Disclosure - Non-controlling interests (Tables)", "shortName": "Non-controlling interests (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "c0", "name": "qntm:DisclosureOfReconciliationOfNonControllingInterestTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfNoncontrollingInterestsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "qntm:DisclosureOfReconciliationOfNonControllingInterestTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfNoncontrollingInterestsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.quantumbiopharma.com/role/GeneralandadministrativeTables", "longName": "996012 - Disclosure - General and administrative (Tables)", "shortName": "General and administrative (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "c0", "name": "qntm:DisclosureOfDetailedInformationAboutGeneralAndAdministrativeExpenseExplanatoryTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "qntm:DisclosureOfDetailedInformationAboutGeneralAndAdministrativeExpenseExplanatoryTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.quantumbiopharma.com/role/SegmentinformationTables", "longName": "996013 - Disclosure - Segment information (Tables)", "shortName": "Segment information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "c0", "name": "qntm:DisclosureOfDetailedInformationAboutEntitysReportableSegmentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfOperatingSegmentsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "qntm:DisclosureOfDetailedInformationAboutEntitysReportableSegmentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfOperatingSegmentsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.quantumbiopharma.com/role/RelatedpartytransactionsTables", "longName": "996014 - Disclosure - Related party transactions (Tables)", "shortName": "Related party transactions (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "42", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.quantumbiopharma.com/role/NatureofbusinessDetails", "longName": "996015 - Disclosure - Nature of business (Details)", "shortName": "Nature of business (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c52", "name": "qntm:SubscribedShares", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "qntm:DisclosureOfNatureOfBusinessExplanatoryTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c52", "name": "qntm:SubscribedShares", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "qntm:DisclosureOfNatureOfBusinessExplanatoryTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.quantumbiopharma.com/role/ScheduleofownershippercentageinsubsidiariesTable", "longName": "996016 - Disclosure - Nature of business - Schedule of ownership percentage in subsidiaries (Details)", "shortName": "Nature of business - Schedule of ownership percentage in subsidiaries (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c60", "name": "ifrs-full:ProportionOfOwnershipInterestInSubsidiary", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c60", "name": "ifrs-full:ProportionOfOwnershipInterestInSubsidiary", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.quantumbiopharma.com/role/ScheduleofotherreceivablesTable", "longName": "996017 - Disclosure - Other receivables - Schedule of other receivables (Details)", "shortName": "Other receivables - Schedule of other receivables (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c1", "name": "ifrs-full:ValueAddedTaxReceivables", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "qntm:DisclosureOfDetailInformationAboutTradeAndOtherReceivablesExplanatory", "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c1", "name": "ifrs-full:ValueAddedTaxReceivables", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "qntm:DisclosureOfDetailInformationAboutTradeAndOtherReceivablesExplanatory", "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.quantumbiopharma.com/role/InvestmentsDetails", "longName": "996018 - Disclosure - Investments (Details)", "shortName": "Investments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:PurchaseOfInvestmentProperty", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "unique": true } }, "R47": { "role": "http://www.quantumbiopharma.com/role/ScheduleofinvestmentsTable", "longName": "996019 - Disclosure - Investments - Schedule of investments (Details)", "shortName": "Investments - Schedule of investments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c2", "name": "ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "qntm:DisclosureOfDetailedInformationAboutInvestmentsExplanatoryTableTextBlock", "ifrs-full:DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "qntm:DisclosureOfDetailedInformationAboutInvestmentsExplanatoryTableTextBlock", "ifrs-full:DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.quantumbiopharma.com/role/ScheduleoffairvalueofwarrantsoptionpricingmodelassumptionsTable", "longName": "996020 - Disclosure - Investments - Schedule of fair value of warrants option pricing model assumptions (Details)", "shortName": "Investments - Schedule of fair value of warrants option pricing model assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c119", "name": "qntm:SharePriceOFWarrant", "unitRef": "usdPershares", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "td", "tr", "table", "qntm:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodtableTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c119", "name": "qntm:SharePriceOFWarrant", "unitRef": "usdPershares", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "td", "tr", "table", "qntm:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodtableTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.quantumbiopharma.com/role/DigitalassetsDetails", "longName": "996021 - Disclosure - Digital assets (Details)", "shortName": "Digital assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c7", "name": "qntm:UnrealizedLossGainOnChangeInFairValueOfDigitalAssets", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true }, "uniqueAnchor": { "contextRef": "c0", "name": "qntm:InvestedDigitalAssets", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "unique": true } }, "R50": { "role": "http://www.quantumbiopharma.com/role/ScheduleofchangesindigitalassetsbalanceTable", "longName": "996022 - Disclosure - Digital assets - Schedule of changes in digital assets balance (Details)", "shortName": "Digital assets - Schedule of changes in digital assets balance (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c2", "name": "qntm:DigitalAssetsBalance", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ix:continuation", "qntm:DisclosureOfDigitalIntangibleAssetsExplanatoryTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true }, "uniqueAnchor": { "contextRef": "c17", "name": "qntm:DigitalAssetsBalance", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ix:continuation", "qntm:DisclosureOfDigitalIntangibleAssetsExplanatoryTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "unique": true } }, "R51": { "role": "http://www.quantumbiopharma.com/role/ScheduleoffairvaluehierarchyTable", "longName": "996023 - Disclosure - Digital assets - Schedule of fair value hierarchy (Details)", "shortName": "Digital assets - Schedule of fair value hierarchy (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c156", "name": "qntm:DigitalAssetsAtFairValue", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c156", "name": "qntm:DigitalAssetsAtFairValue", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.quantumbiopharma.com/role/ScheduleofintangibleassetsTable", "longName": "996024 - Disclosure - Intangible assets - Schedule of intangible assets (Details)", "shortName": "Intangible assets - Schedule of intangible assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c162", "name": "qntm:IntangibleAssetOtherThanGoodwill", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c162", "name": "qntm:IntangibleAssetOtherThanGoodwill", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.quantumbiopharma.com/role/ScheduleoftradeandotherpayablesTable", "longName": "996025 - Disclosure - Trade and other payables - Schedule of trade and other payables (Details)", "shortName": "Trade and other payables - Schedule of trade and other payables (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c1", "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "qntm:DisclosureOfDetailedInformationAboutTradeAndOtherPayableExplanatoryTableTextBlock", "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c1", "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "qntm:DisclosureOfDetailedInformationAboutTradeAndOtherPayableExplanatoryTableTextBlock", "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.quantumbiopharma.com/role/ScheduleofaccruedliabilitiesTable", "longName": "996026 - Disclosure - Trade and other payables - Schedule of accrued liabilities (Details)", "shortName": "Trade and other payables - Schedule of accrued liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c1", "name": "qntm:ExternalResearchAndDevelopmentFees", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "qntm:DisclosureOfDetailedInformationAboutAccruedExpensesAndOtherLiabilitiesExplanatoryTableTextBlock", "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c1", "name": "qntm:ExternalResearchAndDevelopmentFees", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "qntm:DisclosureOfDetailedInformationAboutAccruedExpensesAndOtherLiabilitiesExplanatoryTableTextBlock", "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.quantumbiopharma.com/role/WarrantsLiabilityDetails", "longName": "996027 - Disclosure - Warrants Liability (Details)", "shortName": "Warrants Liability (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c155", "name": "qntm:GainLossOnFinancialInstrumentsAtFairValueThroughProfitOrLoss", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ifrs-full:DisclosureOfDetailedInformationAboutInvestmentPropertyExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true }, "uniqueAnchor": { "contextRef": "c188", "name": "qntm:GainLossOnFinancialInstrumentsAtFairValueThroughProfitOrLoss", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "unique": true } }, "R56": { "role": "http://www.quantumbiopharma.com/role/ScheduleoffairvaluedeterminedusingblackscholesoptionTable", "longName": "996028 - Disclosure - Warrants Liability - Schedule of fair value determined using black-scholes option (Details)", "shortName": "Warrants Liability - Schedule of fair value determined using black-scholes option (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c166", "name": "qntm:SharePriceOFWarrant", "unitRef": "cadPershares", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "td", "tr", "table", "qntm:DisclosureOfDetailedInformationAboutFairBlackScholesWarrantsLiabilityExplanatoryTextBlock", "qntm:DisclosureOfWarrantLiabilitiesExplanatoryTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c166", "name": "qntm:SharePriceOFWarrant", "unitRef": "cadPershares", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "td", "tr", "table", "qntm:DisclosureOfDetailedInformationAboutFairBlackScholesWarrantsLiabilityExplanatoryTextBlock", "qntm:DisclosureOfWarrantLiabilitiesExplanatoryTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.quantumbiopharma.com/role/NotespayableDetails", "longName": "996029 - Disclosure - Notes payable (Details)", "shortName": "Notes payable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c205", "name": "qntm:BitcoinUnitsHeldAsCollateral", "unitRef": "usdPershares", "xsiNil": "false", "lang": null, "decimals": "5", "ancestors": [ "p", "qntm:DisclosureOfNotePayablesExplanatoryTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c205", "name": "qntm:BitcoinUnitsHeldAsCollateral", "unitRef": "usdPershares", "xsiNil": "false", "lang": null, "decimals": "5", "ancestors": [ "p", "qntm:DisclosureOfNotePayablesExplanatoryTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.quantumbiopharma.com/role/ConvertibledebenturesDetails", "longName": "996030 - Disclosure - Convertible debentures (Details)", "shortName": "Convertible debentures (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c221", "name": "qntm:IssuanceOfConvertibleInstruments", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true }, "uniqueAnchor": { "contextRef": "c214", "name": "qntm:IssuanceOfConvertibleInstruments", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "unique": true } }, "R59": { "role": "http://www.quantumbiopharma.com/role/ScheduleofgainonchangeinfairvalueTable", "longName": "996031 - Disclosure - Convertible debentures - Schedule of gain on change in fair value (Details)", "shortName": "Convertible debentures - Schedule of gain on change in fair value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c244", "name": "qntm:SharePriceCAD", "unitRef": "cadPershares", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c244", "name": "qntm:SharePriceCAD", "unitRef": "cadPershares", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.quantumbiopharma.com/role/ScheduleofconvertibledebenturesTable", "longName": "996032 - Disclosure - Convertible debentures - Schedule of convertible debentures (Details)", "shortName": "Convertible debentures - Schedule of convertible debentures (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c1", "name": "qntm:ProceedsFromIssuanceOfConvertibleNotesAndBonds", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c1", "name": "qntm:ProceedsFromIssuanceOfConvertibleNotesAndBonds", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.quantumbiopharma.com/role/SharecapitalDetails", "longName": "996033 - Disclosure - Share capital (Details)", "shortName": "Share capital (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c0", "name": "qntm:MultipleVotingShares", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true }, "uniqueAnchor": { "contextRef": "c9", "name": "qntm:WarrantsWereExpiredShares", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "link:footnote", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "unique": true } }, "R62": { "role": "http://www.quantumbiopharma.com/role/ScheduleofchangesinsharecapitalTable", "longName": "996034 - Disclosure - Share capital - Schedule of changes in share capital (Details)", "shortName": "Share capital - Schedule of changes in share capital (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c334", "name": "qntm:NumberOfIssuedCapitalOrdinaryShares", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c334", "name": "qntm:NumberOfIssuedCapitalOrdinaryShares", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.quantumbiopharma.com/role/ScheduleofchangesinwarrantsoutstandingandweightedaverageexercisepriceTable", "longName": "996035 - Disclosure - Share capital - Schedule of changes in warrants outstanding and weighted average exercise price (Details)", "shortName": "Share capital - Schedule of changes in warrants outstanding and weighted average exercise price (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c2", "name": "qntm:NumberOfWarrantsOutstandingShares", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "qntm:DisclosureOfDetailedInformationAboutFairValuesAssumptionsOfWarrantsOutstandingExplanatoryTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true }, "uniqueAnchor": { "contextRef": "c0", "name": "qntm:NumberOfWarrantsIssued", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "qntm:DisclosureOfDetailedInformationAboutFairValuesAssumptionsOfWarrantsOutstandingExplanatoryTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "unique": true } }, "R64": { "role": "http://www.quantumbiopharma.com/role/ScheduleofnumberofwarrantsoutstandingandexercisepriceTable", "longName": "996036 - Disclosure - Share capital - Schedule of number of warrants outstanding and exercise price (Details)", "shortName": "Share capital - Schedule of number of warrants outstanding and exercise price (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c1", "name": "qntm:WeightedAverageExercisePriceWarrantsOutstanding", "unitRef": "cadPershares", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "td", "tr", "table", "qntm:DisclosureOfDetailedInformationAboutNumberOfWarrantsOutstandingAndExercisePriceExplanatory", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c1", "name": "qntm:WeightedAverageExercisePriceWarrantsOutstanding", "unitRef": "cadPershares", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "td", "tr", "table", "qntm:DisclosureOfDetailedInformationAboutNumberOfWarrantsOutstandingAndExercisePriceExplanatory", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } }, "R65": { "role": "http://www.quantumbiopharma.com/role/SharebasedcompensationDetails", "longName": "996037 - Disclosure - Share-based compensation (Details)", "shortName": "Share-based compensation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c0", "name": "qntm:ShareOptionsGrantedInSharebasedPaymentArrangement", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "qntm:ShareOptionsGrantedInSharebasedPaymentArrangement", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } }, "R66": { "role": "http://www.quantumbiopharma.com/role/ScheduleofnumberofshareoptionsoutstandingTable", "longName": "996038 - Disclosure - Share-based compensation - Schedule of number of share options outstanding (Details)", "shortName": "Share-based compensation - Schedule of number of share options outstanding (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c2", "name": "ifrs-full:NumberOfOutstandingShareOptions", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "qntm:DisclosureOfNumberOfShareOptionsOutstandingTableTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "ifrs-full:NumberOfOutstandingShareOptions", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "qntm:DisclosureOfNumberOfShareOptionsOutstandingTableTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } }, "R67": { "role": "http://www.quantumbiopharma.com/role/ScheduleoffairvaluesofoptionsgrantedusingtheBlackScholesoptionpricingmodelTable", "longName": "996039 - Disclosure - Share-based compensation - Schedule of fair values of options granted using the Black-Scholes option pricing model (Details)", "shortName": "Share-based compensation - Schedule of fair values of options granted using the Black-Scholes option pricing model (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "c0", "name": "qntm:GrantDateSharePrice", "unitRef": "cadPershares", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "b", "td", "tr", "table", "ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "qntm:GrantDateSharePrice", "unitRef": "cadPershares", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "b", "td", "tr", "table", "ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } }, "R68": { "role": "http://www.quantumbiopharma.com/role/ScheduleofcompanysshareoptionsoutstandingTable", "longName": "996040 - Disclosure - Share-based compensation - Schedule of company\u2019s share options outstanding (Details)", "shortName": "Share-based compensation - Schedule of company\u2019s share options outstanding (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "c1", "name": "qntm:NumberOfShareOptionsOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c1", "name": "qntm:NumberOfShareOptionsOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } }, "R69": { "role": "http://www.quantumbiopharma.com/role/ScheduleoffairvaluesofPSUsgrantedusingtheBlackScholesoptionpricingmodelTable", "longName": "996041 - Disclosure - Share-based compensation - Schedule of fair values of PSUs granted using the Black-Scholes option pricing model (Details)", "shortName": "Share-based compensation - Schedule of fair values of PSUs granted using the Black-Scholes option pricing model (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "c361", "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c361", "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } }, "R70": { "role": "http://www.quantumbiopharma.com/role/ScheduleofsharebasedcompensationTable", "longName": "996042 - Disclosure - Share-based compensation - Schedule of share-based compensation (Details)", "shortName": "Share-based compensation - Schedule of share-based compensation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "c7", "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true }, "uniqueAnchor": { "contextRef": "c367", "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "qntm:DisclosureOfDetailedInformationAboutShareBasedCompensationExplanatoryTableTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "unique": true } }, "R71": { "role": "http://www.quantumbiopharma.com/role/NoncontrollinginterestsDetails", "longName": "996043 - Disclosure - Non-controlling interests (Details)", "shortName": "Non-controlling interests (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "c52", "name": "ifrs-full:PercentageOfVotingEquityInterestsAcquired", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "p", "ifrs-full:DisclosureOfNoncontrollingInterestsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c52", "name": "ifrs-full:PercentageOfVotingEquityInterestsAcquired", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "p", "ifrs-full:DisclosureOfNoncontrollingInterestsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } }, "R72": { "role": "http://www.quantumbiopharma.com/role/ScheduleofreconciliationofnoncontrollinginterestTable", "longName": "996044 - Disclosure - Non-controlling interests - Schedule of reconciliation of non controlling interest (Details)", "shortName": "Non-controlling interests - Schedule of reconciliation of non controlling interest (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "c2", "name": "ifrs-full:NoncontrollingInterests", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true }, "uniqueAnchor": { "contextRef": "c0", "name": "qntm:ComprehensiveIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "qntm:DisclosureOfReconciliationOfNonControllingInterestTableTextBlock", "ifrs-full:DisclosureOfNoncontrollingInterestsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "unique": true } }, "R73": { "role": "http://www.quantumbiopharma.com/role/ScheduleoflosspershareTable", "longName": "996045 - Disclosure - Loss per share - Schedule of loss per share (Details)", "shortName": "Loss per share - Schedule of loss per share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } }, "R74": { "role": "http://www.quantumbiopharma.com/role/ScheduleofgeneralandadministrativeexpenseTable", "longName": "996046 - Disclosure - General and administrative - Schedule of general and administrative expense (Details)", "shortName": "General and administrative - Schedule of general and administrative expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "c7", "name": "ifrs-full:ProfessionalFeesExpense", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "qntm:DisclosureOfDetailedInformationAboutGeneralAndAdministrativeExpenseExplanatoryTextBlock", "ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c7", "name": "ifrs-full:ProfessionalFeesExpense", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "qntm:DisclosureOfDetailedInformationAboutGeneralAndAdministrativeExpenseExplanatoryTextBlock", "ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } }, "R75": { "role": "http://www.quantumbiopharma.com/role/SegmentinformationDetails", "longName": "996047 - Disclosure - Segment information (Details)", "shortName": "Segment information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "c0", "name": "qntm:NumberOfOperatesSegments", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ifrs-full:DisclosureOfOperatingSegmentsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "qntm:NumberOfOperatesSegments", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ifrs-full:DisclosureOfOperatingSegmentsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } }, "R76": { "role": "http://www.quantumbiopharma.com/role/ScheduleofassetandincomebysegmentTable", "longName": "996048 - Disclosure - Segment information - Schedule of asset and income by segment (Details)", "shortName": "Segment information - Schedule of asset and income by segment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "c390", "name": "ifrs-full:RevenueFromInterest", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c390", "name": "ifrs-full:RevenueFromInterest", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } }, "R77": { "role": "http://www.quantumbiopharma.com/role/CommitmentsandcontingenciesDetails", "longName": "996049 - Disclosure - Commitments and contingencies (Details)", "shortName": "Commitments and contingencies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "c396", "name": "qntm:DamagesSoughtValue", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c396", "name": "qntm:DamagesSoughtValue", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } }, "R78": { "role": "http://www.quantumbiopharma.com/role/RelatedpartytransactionsDetails", "longName": "996050 - Disclosure - Related party transactions (Details)", "shortName": "Related party transactions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "c155", "name": "qntm:AccruedManagementBonuses", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c155", "name": "qntm:AccruedManagementBonuses", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } }, "R79": { "role": "http://www.quantumbiopharma.com/role/ScheduleofkeymanagementpersonnelcompensationTable", "longName": "996051 - Disclosure - Related party transactions - Schedule of key management personnel compensation (Details)", "shortName": "Related party transactions - Schedule of key management personnel compensation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "c7", "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c7", "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } }, "R80": { "role": "http://www.quantumbiopharma.com/role/CapitalManagementDetails", "longName": "996052 - Disclosure - Capital Management (Details)", "shortName": "Capital Management (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "c410", "name": "ifrs-full:Equity", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ifrs-full:DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c410", "name": "ifrs-full:Equity", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ifrs-full:DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } }, "R81": { "role": "http://www.quantumbiopharma.com/role/SubsequenteventsDetails", "longName": "996053 - Disclosure - Subsequent events (Details)", "shortName": "Subsequent events (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "c418", "name": "qntm:SoldAnAggregateGrossProceeds", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c418", "name": "qntm:SoldAnAggregateGrossProceeds", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "qntmex99-1.htm", "first": true, "unique": true } } }, "tag": { "qntm_A2ZCryptoCapIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "A2ZCryptoCapIncMember", "presentation": [ "http://www.quantumbiopharma.com/role/InvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "A2ZCryptoCap Inc [Member]", "label": "A2 ZCrypto Cap Inc Member" } } }, "auth_ref": [] }, "qntm_ATMAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ATMAgreementMember", "presentation": [ "http://www.quantumbiopharma.com/role/SharecapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ATM Agreement [Member]", "label": "ATMAgreement Member" } } }, "auth_ref": [] }, "qntm_ATwoZCryptocapIncPointGainMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ATwoZCryptocapIncPointGainMember", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofinvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "A2ZCryptoCap Inc. [Member]", "label": "ATwo ZCryptocap Inc Point Gain Member" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "qntm_AccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "AccountsPayableAndAccruedLiabilities", "crdr": "credit", "presentation": [ "http://www.quantumbiopharma.com/role/RelatedpartytransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and accrued liabilities", "documentation": "The amount of accounts payable and accrued liabilities.", "label": "Accounts Payable And Accrued Liabilities" } } }, "auth_ref": [] }, "qntm_AccretionExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "AccretionExpenses", "crdr": "debit", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofconvertibledebenturesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Accretion expense", "documentation": "Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations.", "label": "Accretion Expenses" } } }, "auth_ref": [] }, "ifrs-full_AccrualsClassifiedAsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AccrualsClassifiedAsCurrent", "crdr": "credit", "calculation": { "http://www.quantumbiopharma.com/role/ScheduleoftradeandotherpayablesTable": { "parentTag": "ifrs-full_TradeAndOtherCurrentPayables", "weight": 1.0, "order": 2.0 }, "http://www.quantumbiopharma.com/role/ScheduleofaccruedliabilitiesTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofaccruedliabilitiesTable", "http://www.quantumbiopharma.com/role/ScheduleoftradeandotherpayablesTable" ], "lang": { "en-us": { "role": { "totalLabel": "Accrued liabilities", "terseLabel": "Accrued liabilities", "label": "Accruals classified as current" } }, "en": { "role": { "documentation": "The amount of accruals classified as current. [Refer: Accruals]" } } }, "auth_ref": [ "r263" ] }, "qntm_AccruedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "AccruedInterest", "crdr": "credit", "calculation": { "http://www.quantumbiopharma.com/role/ScheduleofaccruedliabilitiesTable": { "parentTag": "ifrs-full_AccrualsClassifiedAsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofaccruedliabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued interest", "documentation": "The amount of accrued interest.", "label": "Accrued Interest" } } }, "auth_ref": [] }, "qntm_AccruedManagementBonuses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "AccruedManagementBonuses", "crdr": "debit", "presentation": [ "http://www.quantumbiopharma.com/role/RelatedpartytransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued management bonuses", "documentation": "The amount of accrued management bonuses.", "label": "Accrued Management Bonuses" } } }, "auth_ref": [] }, "qntm_AccumulatedAmortizationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "AccumulatedAmortizationAbstract", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofintangibleassetsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated amortization", "label": "Accumulated Amortization Abstract" } } }, "auth_ref": [] }, "ifrs-full_AccumulatedDepreciationAndAmortisationMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AccumulatedDepreciationAndAmortisationMember", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofintangibleassetsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated depreciation and amortisation [member]", "label": "Accumulated depreciation and amortisation [member]" } } }, "auth_ref": [ "r4", "r241", "r245", "r246", "r247" ] }, "qntm_AcquiredSharePercent": { "xbrltype": "percentItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "AcquiredSharePercent", "presentation": [ "http://www.quantumbiopharma.com/role/NatureofbusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquired share percent", "documentation": "Acquired share percentage.", "label": "Acquired Share Percent" } } }, "auth_ref": [] }, "qntm_AcretionExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "AcretionExpense", "crdr": "debit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "ifrs-full_ProfitLossAttributableToNoncontrollingInterests", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Accretion expense", "documentation": "Accretion expense.", "label": "Acretion Expense" } } }, "auth_ref": [] }, "qntm_AdditionalGrossProceedsForLoanAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "AdditionalGrossProceedsForLoanAgreement", "crdr": "debit", "presentation": [ "http://www.quantumbiopharma.com/role/NatureofbusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional gross proceeds for loan agreement (in Dollars)", "documentation": "The amount of additional gross proceeds for loan agreement.", "label": "Additional Gross Proceeds For Loan Agreement" } } }, "auth_ref": [] }, "qntm_AdditionalPercentagePerAnnum": { "xbrltype": "percentItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "AdditionalPercentagePerAnnum", "presentation": [ "http://www.quantumbiopharma.com/role/ConvertibledebenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional percentage", "documentation": "Additional percentage.", "label": "Additional Percentage Per Annum" } } }, "auth_ref": [] }, "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofintangibleassetsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization", "label": "Additions other than through business combinations, intangible assets other than goodwill" } }, "en": { "role": { "documentation": "The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Total for all business combinations [member]; Intangible assets other than goodwill]" } } }, "auth_ref": [ "r31", "r140" ] }, "qntm_AdjustmentsChangeInFairValueOfInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "AdjustmentsChangeInFairValueOfInvestments", "crdr": "credit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "ifrs-full_ProfitLossAttributableToNoncontrollingInterests", "weight": 1.0, "order": 9.0 }, "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow", "http://www.quantumbiopharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "negatedLabel": "Unrealized loss (gain) in fair value of investments", "negatedTerseLabel": "Change in fair value of investments", "documentation": "Change in fair value of investments.", "label": "Adjustments Change In Fair Value Of Investments" } } }, "auth_ref": [] }, "qntm_AdjustmentsForAccretionExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "AdjustmentsForAccretionExpense", "crdr": "debit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Accretion expense", "documentation": "Adjustments for accretion expense to reconcile profit (loss) to net cash flow from (used in) operating activities.", "label": "Adjustments For Accretion Expense" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInInventories", "crdr": "debit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory", "label": "Adjustments for decrease (increase) in inventories" } } }, "auth_ref": [ "r251" ] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInPrepaidExpenses", "crdr": "debit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and deposits", "label": "Adjustments for decrease (increase) in prepaid expenses" } }, "en": { "role": { "documentation": "Adjustments for the decrease (increase) in prepaid expenses to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Current prepaid expenses; Profit (loss)]" } } }, "auth_ref": [ "r253" ] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables", "crdr": "debit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Other receivables", "label": "Adjustments for decrease (increase) in trade and other receivables" } }, "en": { "role": { "documentation": "Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]" } } }, "auth_ref": [ "r253" ] }, "ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForDepreciationAndAmortisationExpense", "crdr": "debit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Adjustments for depreciation and amortisation expense" } } }, "auth_ref": [ "r252" ] }, "ifrs-full_AdjustmentsForFinanceIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForFinanceIncome", "crdr": "credit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 17.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Finance receivables", "label": "Adjustments for finance income" } } }, "auth_ref": [ "r253" ] }, "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForIncreaseDecreaseInTradeAccountPayable", "crdr": "debit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Trade and other payables", "label": "Adjustments for increase (decrease) in trade accounts payable" } } }, "auth_ref": [ "r251" ] }, "ifrs-full_AdjustmentsForInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForInterestExpense", "crdr": "debit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense", "label": "Adjustments for interest expense" } } }, "auth_ref": [ "r253" ] }, "ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets", "crdr": "debit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Realized (gain) on sale of investments", "label": "Adjustments for losses (gains) on disposal of non-current assets" } } }, "auth_ref": [ "r248" ] }, "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForReconcileProfitLossAbstract", "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Add (deduct) items not affecting cash", "label": "Adjustments to reconcile operating profit (loss) [abstract]" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForSharebasedPayments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForSharebasedPayments", "crdr": "debit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based payments", "label": "Adjustments for share-based payments" } } }, "auth_ref": [ "r252" ] }, "qntm_AggregateGrossProceeds": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "AggregateGrossProceeds", "crdr": "debit", "presentation": [ "http://www.quantumbiopharma.com/role/ConvertibledebenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate gross proceeds", "documentation": "Aggregate gross proceeds.", "label": "Aggregate Gross Proceeds" } } }, "auth_ref": [] }, "qntm_AggregateMonthlyInstallmentsAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "AggregateMonthlyInstallmentsAmount", "crdr": "credit", "presentation": [ "http://www.quantumbiopharma.com/role/RelatedpartytransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate monthly installments (in Dollars)", "documentation": "Aggregate monthly installments.", "label": "Aggregate Monthly Installments Amount" } } }, "auth_ref": [] }, "qntm_AggregatePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "AggregatePercentage", "presentation": [ "http://www.quantumbiopharma.com/role/ConvertibledebenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate percentage", "documentation": "Aggregate percentage.", "label": "Aggregate Percentage" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AmendmentFlag", "presentation": [ "http://www.quantumbiopharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "qntm_AmountOfAggregateGrossProceeds": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "AmountOfAggregateGrossProceeds", "crdr": "debit", "presentation": [ "http://www.quantumbiopharma.com/role/ConvertibledebenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate gross proceeds", "documentation": "Amount of aggregate gross proceeds", "label": "Amount Of Aggregate Gross Proceeds" } } }, "auth_ref": [] }, "ifrs-full_Assets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets" } }, "en": { "role": { "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } } }, "auth_ref": [ "r68", "r69", "r70", "r107", "r109", "r168", "r169", "r195" ] }, "ifrs-full_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AssetsAbstract", "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "label": "Assets [abstract]" } } }, "auth_ref": [] }, "qntm_AssociatedWarrantsShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "AssociatedWarrantsShares", "presentation": [ "http://www.quantumbiopharma.com/role/InvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Associated warrants shares (in Shares)", "documentation": "Associated warrants shares.", "label": "Associated Warrants Shares" } } }, "auth_ref": [] }, "qntm_AssociatedWarrantsValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "AssociatedWarrantsValue", "crdr": "debit", "presentation": [ "http://www.quantumbiopharma.com/role/InvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Associated warrants, value", "documentation": "Associated warrants, value.", "label": "Associated Warrants Value" } } }, "auth_ref": [] }, "qntm_BalanceOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "BalanceOutstanding", "crdr": "debit", "presentation": [ "http://www.quantumbiopharma.com/role/InvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance outstanding (in Dollars)", "documentation": "The amount of balance outstanding.", "label": "Balance Outstanding" } } }, "auth_ref": [] }, "ifrs-full_BasicEarningsLossPerShareFromContinuingOperations": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BasicEarningsLossPerShareFromContinuingOperations", "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Basic and diluted (in Dollars per share)", "label": "Basic earnings (loss) per share from continuing operations" } }, "en": { "role": { "documentation": "Basic earnings (loss) per share from continuing operations. [Refer: Basic earnings (loss) per share; Continuing operations, unless line item indicates otherwise [member]]" } } }, "auth_ref": [ "r19", "r20" ] }, "qntm_BasisOfPresentationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "BasisOfPresentationAbstract", "lang": { "en-us": { "role": { "label": "Basis of presentation [Abstract]" } } }, "auth_ref": [] }, "qntm_BearInterestRatePecent": { "xbrltype": "percentItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "BearInterestRatePecent", "presentation": [ "http://www.quantumbiopharma.com/role/ConvertibledebenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bear interest rate", "documentation": "Bear interest at a rate.", "label": "Bear Interest Rate Pecent" } } }, "auth_ref": [] }, "qntm_BiopharmaceuticalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "BiopharmaceuticalMember", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofassetandincomebysegmentTable" ], "lang": { "en-us": { "role": { "terseLabel": "Biopharmaceutical [Member]", "label": "Biopharmaceutical Member" } } }, "auth_ref": [] }, "qntm_BitcoinMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "BitcoinMember", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofchangesindigitalassetsbalanceTable" ], "lang": { "en-us": { "role": { "terseLabel": "Bitcoin [Member]", "label": "Bitcoin Member" } } }, "auth_ref": [] }, "qntm_BitcoinPledgedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "BitcoinPledgedAmount", "crdr": "credit", "presentation": [ "http://www.quantumbiopharma.com/role/NotespayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bitcoin pledged amount", "documentation": "It represents the bitcoin pledged amount.", "label": "Bitcoin Pledged Amount" } } }, "auth_ref": [] }, "qntm_BitcoinPledgedPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "BitcoinPledgedPerShare", "presentation": [ "http://www.quantumbiopharma.com/role/NotespayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bitcoin pledged per share.", "documentation": "Bitcoin pledged per share.", "label": "Bitcoin Pledged Per Share" } } }, "auth_ref": [] }, "qntm_BitcoinUnitsHeldAsCollateral": { "xbrltype": "perShareItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "BitcoinUnitsHeldAsCollateral", "presentation": [ "http://www.quantumbiopharma.com/role/NotespayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bitcoin units held as collateral (in Dollars per share)", "documentation": "Bitcoin units held as collateral.", "label": "Bitcoin Units Held As Collateral" } } }, "auth_ref": [] }, "qntm_BlackScholesModelHadFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "BlackScholesModelHadFairValue", "crdr": "debit", "presentation": [ "http://www.quantumbiopharma.com/role/InvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Black scholes model had fair value", "documentation": "Black scholes model had fair value.", "label": "Black Scholes Model Had Fair Value" } } }, "auth_ref": [] }, "ifrs-full_Borrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Borrowings", "crdr": "credit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Notes payable", "label": "Borrowings" } }, "en": { "role": { "documentation": "The amount of outstanding funds that the entity is obligated to repay." } } }, "auth_ref": [ "r260" ] }, "ifrs-full_BorrowingsByNameAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BorrowingsByNameAxis", "presentation": [ "http://www.quantumbiopharma.com/role/SharecapitalDetails" ], "lang": { "en-us": { "role": { "label": "Borrowings by name [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r255" ] }, "ifrs-full_BorrowingsByNameDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BorrowingsByNameDomain", "presentation": [ "http://www.quantumbiopharma.com/role/SharecapitalDetails" ], "lang": { "en-us": { "role": { "label": "Borrowings by name [domain]" } }, "en": { "role": { "documentation": "This member stands for all borrowings when disaggregated by name. It also represents the standard value for the 'Borrowings by name' axis if no other member is used. [Refer: Borrowings]" } } }, "auth_ref": [ "r255" ] }, "ifrs-full_BorrowingsInterestRate": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BorrowingsInterestRate", "presentation": [ "http://www.quantumbiopharma.com/role/NatureofbusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt accrued interest rate", "label": "Borrowings, interest rate" } }, "en": { "role": { "documentation": "The interest rate on borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r255" ] }, "ifrs-full_BottomOfRangeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BottomOfRangeMember", "presentation": [ "http://www.quantumbiopharma.com/role/ConvertibledebenturesDetails", "http://www.quantumbiopharma.com/role/InvestmentsDetails", "http://www.quantumbiopharma.com/role/NatureofbusinessDetails", "http://www.quantumbiopharma.com/role/RelatedpartytransactionsDetails", "http://www.quantumbiopharma.com/role/ScheduleoffairvaluedeterminedusingblackscholesoptionTable", "http://www.quantumbiopharma.com/role/ScheduleoffairvaluesofoptionsgrantedusingtheBlackScholesoptionpricingmodelTable", "http://www.quantumbiopharma.com/role/ScheduleofgainonchangeinfairvalueTable", "http://www.quantumbiopharma.com/role/SharecapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bottom of range [member]", "label": "Bottom of range [member]" } }, "en": { "role": { "documentation": "This member stands for the bottom of a range." } } }, "auth_ref": [ "r44", "r72", "r78", "r89", "r124", "r222", "r223", "r255" ] }, "qntm_CFOMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "CFOMember", "presentation": [ "http://www.quantumbiopharma.com/role/SharecapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CFO [Member]", "label": "CFOMember" } } }, "auth_ref": [] }, "qntm_CapitalManagementDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "CapitalManagementDetailsLineItems", "presentation": [ "http://www.quantumbiopharma.com/role/CapitalManagementDetails" ], "lang": { "en-us": { "role": { "label": "Capital Management (Details) [Line Items]" } } }, "auth_ref": [] }, "qntm_CapitalManagementDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "CapitalManagementDetailsTable", "presentation": [ "http://www.quantumbiopharma.com/role/CapitalManagementDetails" ], "lang": { "en-us": { "role": { "label": "Capital Management (Details) [Table]" } } }, "auth_ref": [] }, "ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofintangibleassetsTable" ], "lang": { "en-us": { "role": { "label": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r2", "r3", "r30", "r32", "r38", "r39", "r40", "r41", "r42", "r96", "r97", "r98", "r128", "r129", "r139", "r141", "r145", "r146", "r147", "r148", "r149", "r162", "r163", "r164" ] }, "ifrs-full_CarryingAmountMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CarryingAmountMember", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofintangibleassetsTable" ], "lang": { "en-us": { "role": { "label": "Carrying amount [member]" } } }, "auth_ref": [ "r3", "r32", "r38", "r40", "r41", "r96", "r97", "r98", "r129", "r141", "r145", "r147", "r148", "r162", "r163", "r164" ] }, "ifrs-full_CashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashAndCashEquivalents", "crdr": "debit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet", "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents, beginning of the period", "periodEndLabel": "Cash and cash equivalents, end of the period", "terseLabel": "Cash and cash equivalents", "label": "Cash and cash equivalents" } }, "en": { "role": { "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]" } } }, "auth_ref": [ "r45", "r62", "r125", "r191" ] }, "qntm_CashCommission": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "CashCommission", "crdr": "debit", "presentation": [ "http://www.quantumbiopharma.com/role/SharecapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash commission (in Dollars)", "documentation": "Cash commission.", "label": "Cash Commission" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "totalLabel": "Cash provided by financing activities", "label": "Cash flows from (used in) financing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity, from continuing and discontinued operations." } } }, "auth_ref": [ "r43", "r46" ] }, "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Financing activities", "label": "Cash flows from (used in) financing activities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "totalLabel": "Cash (used in) provided by investing activities", "label": "Cash flows from (used in) investing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents, from continuing and discontinued operations." } } }, "auth_ref": [ "r43", "r46" ] }, "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Investing activities", "label": "Cash flows from (used in) investing activities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInOperatingActivities", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "totalLabel": "Cash used in operating activities", "label": "Cash flows from (used in) operating activities" } } }, "auth_ref": [ "r43", "r46" ] }, "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Operating activities", "label": "Cash flows from (used in) operating activities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_CategoriesOfRelatedPartiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfRelatedPartiesAxis", "presentation": [ "http://www.quantumbiopharma.com/role/ConvertibledebenturesDetails", "http://www.quantumbiopharma.com/role/NotespayableDetails", "http://www.quantumbiopharma.com/role/RelatedpartytransactionsDetails", "http://www.quantumbiopharma.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "label": "Categories of related parties [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r12", "r133" ] }, "ifrs-full_CategoriesOfRelatedPartiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfRelatedPartiesDomain", "presentation": [ "http://www.quantumbiopharma.com/role/ConvertibledebenturesDetails", "http://www.quantumbiopharma.com/role/NotespayableDetails", "http://www.quantumbiopharma.com/role/RelatedpartytransactionsDetails", "http://www.quantumbiopharma.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "label": "Categories of related parties [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used." } } }, "auth_ref": [ "r12", "r133" ] }, "qntm_ChangesInWorkingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ChangesInWorkingCapitalAbstract", "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in non-cash working capital balances", "documentation": "na", "label": "Changes In Working Capital Abstract" } } }, "auth_ref": [] }, "qntm_ChiefExecutiveOfficersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ChiefExecutiveOfficersMember", "presentation": [ "http://www.quantumbiopharma.com/role/RelatedpartytransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Chief Executive Officers [Member]", "label": "Chief Executive Officers Member" } } }, "auth_ref": [] }, "qntm_ChiefFinancialOfficersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ChiefFinancialOfficersMember", "presentation": [ "http://www.quantumbiopharma.com/role/RelatedpartytransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Chief Financial Officer [Member]", "label": "Chief Financial Officers Member" } } }, "auth_ref": [] }, "qntm_ClassACommonSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ClassACommonSharesMember", "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet", "http://www.quantumbiopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Class A Shares", "verboseLabel": "Class A shares", "label": "Class ACommon Shares Member" } } }, "auth_ref": [] }, "qntm_ClassAMultipleVotingSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ClassAMultipleVotingSharesMember", "presentation": [ "http://www.quantumbiopharma.com/role/SharecapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class A Multiple Voting Shares [Member]", "label": "Class AMultiple Voting Shares Member" } } }, "auth_ref": [] }, "qntm_ClassASharesToBeIssuedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ClassASharesToBeIssuedMember", "presentation": [ "http://www.quantumbiopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Class A shares to be issued", "label": "Class AShares To Be Issued Member" } } }, "auth_ref": [] }, "qntm_ClassBCommonSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ClassBCommonSharesMember", "presentation": [ "http://www.quantumbiopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Class B shares", "label": "Class BCommon Shares Member" } } }, "auth_ref": [] }, "qntm_ClassBCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ClassBCommonStockMember", "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet", "http://www.quantumbiopharma.com/role/SharecapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class B Subordinate Shares", "verboseLabel": "Class B Common Stock [Member]", "label": "Class BCommon Stock Member" } } }, "auth_ref": [] }, "qntm_ClassBSubordinateVotingSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ClassBSubordinateVotingSharesMember", "presentation": [ "http://www.quantumbiopharma.com/role/RelatedpartytransactionsDetails", "http://www.quantumbiopharma.com/role/SharecapitalDetails", "http://www.quantumbiopharma.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class B Subordinate Voting Shares [Member]", "label": "Class BSubordinate Voting Shares Member" } } }, "auth_ref": [] }, "qntm_ClassMultipleVotingSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ClassMultipleVotingSharesMember", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofchangesinsharecapitalTable" ], "lang": { "en-us": { "role": { "terseLabel": "Class Multiple Voting Shares [Member]", "label": "Class Multiple Voting Shares Member" } } }, "auth_ref": [] }, "qntm_ClassSubordinateVotingSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ClassSubordinateVotingSharesMember", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofchangesinsharecapitalTable" ], "lang": { "en-us": { "role": { "terseLabel": "Class Subordinate Voting Shares [Member]", "label": "Class Subordinate Voting Shares Member" } } }, "auth_ref": [] }, "qntm_ClassSubordinateVotingSharesOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ClassSubordinateVotingSharesOneMember", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofchangesinsharecapitalTable" ], "lang": { "en-us": { "role": { "terseLabel": "Class Subordinate Voting Shares One Member", "label": "Class Subordinate Voting Shares One Member" } } }, "auth_ref": [] }, "ifrs-full_ClassesOfAssetsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfAssetsAxis", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofnumberofwarrantsoutstandingandexercisepriceTable" ], "lang": { "en-us": { "role": { "label": "Classes of assets [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r24", "r25", "r71", "r77", "r117", "r136", "r170" ] }, "ifrs-full_ClassesOfAssetsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfAssetsDomain", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofnumberofwarrantsoutstandingandexercisepriceTable" ], "lang": { "en-us": { "role": { "label": "Classes of assets [domain]" } }, "en": { "role": { "documentation": "This member stands for a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of assets' axis if no other member is used." } } }, "auth_ref": [ "r24", "r71", "r77", "r117", "r136", "r170" ] }, "ifrs-full_ClassesOfContingentLiabilitiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfContingentLiabilitiesAxis", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleoffairvaluedeterminedusingblackscholesoptionTable", "http://www.quantumbiopharma.com/role/ScheduleoffairvalueofwarrantsoptionpricingmodelassumptionsTable", "http://www.quantumbiopharma.com/role/WarrantsLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Classes of contingent liabilities [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r28", "r95", "r138" ] }, "ifrs-full_ClassesOfContingentLiabilitiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfContingentLiabilitiesDomain", "presentation": [ "http://www.quantumbiopharma.com/role/WarrantsLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Classes of contingent liabilities [domain]" } }, "en": { "role": { "documentation": "This member stands for possible obligations that arise from past events and whose existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the entity; or, present obligations that arise from past events but are not recognised because (a) it is probable that an outflow of resources embodying economic benefits will be required to settle the obligations; or (b) the amount of the obligations cannot be measured with sufficient reliability. It also represents the standard value for the 'Classes of contingent liabilities' axis if no other member is used." } } }, "auth_ref": [ "r29", "r95" ] }, "qntm_ClassesOfDigitalAssetsAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ClassesOfDigitalAssetsAxis", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofchangesindigitalassetsbalanceTable" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of Digital Assets [axis]", "label": "Classes Of Digital Assets Axis" } } }, "auth_ref": [] }, "qntm_ClassesOfDigitalAssetsDomainDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ClassesOfDigitalAssetsDomainDomain", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofchangesindigitalassetsbalanceTable" ], "lang": { "en-us": { "role": { "label": "ClassesOfDigitalAssetsDomain [Domain]" } } }, "auth_ref": [] }, "ifrs-full_ClassesOfFinancialInstrumentsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialInstrumentsAxis", "presentation": [ "http://www.quantumbiopharma.com/role/InvestmentsDetails", "http://www.quantumbiopharma.com/role/ScheduleofinvestmentsTable" ], "lang": { "en-us": { "role": { "label": "Classes of financial instruments [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r97", "r99", "r100", "r101", "r163", "r165" ] }, "ifrs-full_ClassesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialInstrumentsDomain", "presentation": [ "http://www.quantumbiopharma.com/role/InvestmentsDetails", "http://www.quantumbiopharma.com/role/ScheduleofinvestmentsTable" ], "lang": { "en-us": { "role": { "label": "Classes of financial instruments [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]" } } }, "auth_ref": [ "r97", "r99", "r100", "r101", "r163", "r165" ] }, "ifrs-full_ClassesOfOrdinarySharesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfOrdinarySharesAxis", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofinvestmentsTable" ], "lang": { "en-us": { "role": { "label": "Classes of ordinary shares [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r19" ] }, "ifrs-full_ClassesOfOrdinarySharesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfOrdinarySharesDomain", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofinvestmentsTable" ], "lang": { "en-us": { "role": { "label": "Classes of ordinary shares [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Classes of ordinary shares' axis if no other member is used." } } }, "auth_ref": [ "r19" ] }, "ifrs-full_ClassesOfShareCapitalAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfShareCapitalAxis", "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet", "http://www.quantumbiopharma.com/role/InvestmentsDetails", "http://www.quantumbiopharma.com/role/ScheduleofchangesinsharecapitalTable", "http://www.quantumbiopharma.com/role/SharecapitalDetails", "http://www.quantumbiopharma.com/role/ShareholdersEquityType2or3", "http://www.quantumbiopharma.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "label": "Classes of share capital [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r121", "r174", "r204" ] }, "ifrs-full_ClassesOfShareCapitalDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfShareCapitalDomain", "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet", "http://www.quantumbiopharma.com/role/InvestmentsDetails", "http://www.quantumbiopharma.com/role/SharecapitalDetails", "http://www.quantumbiopharma.com/role/ShareholdersEquityType2or3", "http://www.quantumbiopharma.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "label": "Classes of share capital [domain]" } }, "en": { "role": { "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used." } } }, "auth_ref": [ "r121", "r174", "r204" ] }, "qntm_CommissionPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "CommissionPercentage", "presentation": [ "http://www.quantumbiopharma.com/role/SharecapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commission percentage", "documentation": "Commission percentage.", "label": "Commission Percentage" } } }, "auth_ref": [] }, "qntm_CommitmentsAndContingenciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "CommitmentsAndContingenciesAbstract", "lang": { "en-us": { "role": { "label": "Commitments and contingencies [abstract]" } } }, "auth_ref": [] }, "qntm_CommitmentsandcontingenciesDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "CommitmentsandcontingenciesDetailsLineItems", "presentation": [ "http://www.quantumbiopharma.com/role/CommitmentsandcontingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Commitments and contingencies (Details) [Line Items]" } } }, "auth_ref": [] }, "qntm_CommitmentsandcontingenciesDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "CommitmentsandcontingenciesDetailsTable", "presentation": [ "http://www.quantumbiopharma.com/role/CommitmentsandcontingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Commitments and contingencies (Details) [Table]" } } }, "auth_ref": [] }, "qntm_CommonSharesHadAFairValue": { "xbrltype": "sharesItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "CommonSharesHadAFairValue", "presentation": [ "http://www.quantumbiopharma.com/role/InvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common shares had a fair value (in Shares)", "documentation": "Common shares had a fair value.", "label": "Common Shares Had AFair Value" } } }, "auth_ref": [] }, "qntm_CommonSharesplit": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "CommonSharesplit", "presentation": [ "http://www.quantumbiopharma.com/role/NatureofbusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common shares split, description", "documentation": "The description of common share-split.", "label": "Common Sharesplit" } } }, "auth_ref": [] }, "qntm_CompanySettledDescription": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "CompanySettledDescription", "presentation": [ "http://www.quantumbiopharma.com/role/SharecapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Company settled description", "documentation": "Company settled description.", "label": "Company Settled Description" } } }, "auth_ref": [] }, "ifrs-full_ComponentsOfEquityAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComponentsOfEquityAxis", "presentation": [ "http://www.quantumbiopharma.com/role/CapitalManagementDetails", "http://www.quantumbiopharma.com/role/RelatedpartytransactionsDetails", "http://www.quantumbiopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "label": "Components of equity [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r183" ] }, "ifrs-full_ComponentsOfEquityDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComponentsOfEquityDomain", "presentation": [ "http://www.quantumbiopharma.com/role/RelatedpartytransactionsDetails", "http://www.quantumbiopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "label": "Components of equity [domain]" } }, "en": { "role": { "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used." } } }, "auth_ref": [ "r183" ] }, "ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComprehensiveIncomeAttributableToNoncontrollingInterests", "crdr": "credit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Non-controlling interests", "label": "Comprehensive income, attributable to non-controlling interests" } }, "en": { "role": { "documentation": "The amount of comprehensive income attributable to non-controlling interests. [Refer: Comprehensive income; Non-controlling interests]" } } }, "auth_ref": [ "r179", "r209" ] }, "qntm_ComprehensiveIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ComprehensiveIncomeLoss", "crdr": "credit", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofreconciliationofnoncontrollinginterestTable" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss for the period", "documentation": "The amount of net loss for the year.", "label": "Comprehensive Income Loss" } } }, "auth_ref": [] }, "qntm_CondensedConsolidatedInterimStatementsOfChangesInShareholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "CondensedConsolidatedInterimStatementsOfChangesInShareholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Condensed Consolidated Interim Statements Of Changes In Shareholders Equity Abstract" } } }, "auth_ref": [] }, "qntm_ConsultingFeesExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ConsultingFeesExpenses", "crdr": "debit", "calculation": { "http://www.quantumbiopharma.com/role/ScheduleofgeneralandadministrativeexpenseTable": { "parentTag": "qntm_GeneralAndAdministrativeExpenseContinuedAndDiscontinuedOperations", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofgeneralandadministrativeexpenseTable" ], "lang": { "en-us": { "role": { "terseLabel": "Consulting fees", "documentation": "Amount of expenses of consulting fees.", "label": "Consulting Fees Expenses" } } }, "auth_ref": [] }, "ifrs-full_ContractDurationAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ContractDurationAxis", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleoffairvaluedeterminedusingblackscholesoptionTable", "http://www.quantumbiopharma.com/role/WarrantsLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Contract duration [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r225", "r229" ] }, "ifrs-full_ContractDurationDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ContractDurationDomain", "presentation": [ "http://www.quantumbiopharma.com/role/WarrantsLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Contract duration [domain]" } }, "en": { "role": { "documentation": "This member stands for all durations of contracts with customers. It also represents the standard value for the 'Contract duration' axis if no other member is used." } } }, "auth_ref": [ "r225", "r229" ] }, "qntm_ContributedSurplusMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ContributedSurplusMember", "presentation": [ "http://www.quantumbiopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Contributed surplus", "label": "Contributed Surplus Member" } } }, "auth_ref": [] }, "qntm_ConversionBalance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ConversionBalance", "crdr": "credit", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofconvertibledebenturesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion balance", "documentation": "The amount of conversion balance.", "label": "Conversion Balance" } } }, "auth_ref": [] }, "qntm_ConversionFeatureMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ConversionFeatureMember", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofgainonchangeinfairvalueTable" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion Feature [Member]", "label": "Conversion Feature Member" } } }, "auth_ref": [] }, "qntm_ConversionPrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ConversionPrice", "presentation": [ "http://www.quantumbiopharma.com/role/ConvertibledebenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion price (in Dollars per share)", "documentation": "Conversion price.", "label": "Conversion Price" } } }, "auth_ref": [] }, "qntm_ConversionPriceCAD": { "xbrltype": "perShareItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ConversionPriceCAD", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofgainonchangeinfairvalueTable" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion price (CAD) (in Dollars per share)", "documentation": "Conversion price per share.", "label": "Conversion Price CAD" } } }, "auth_ref": [] }, "qntm_ConversionPriceUSD": { "xbrltype": "perShareItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ConversionPriceUSD", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofgainonchangeinfairvalueTable" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion price (in Dollars per share)", "documentation": "Conversion price per share.", "label": "Conversion Price USD" } } }, "auth_ref": [] }, "qntm_ConversionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ConversionValue", "crdr": "credit", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofgainonchangeinfairvalueTable" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion value (in Dollars)", "documentation": "The amount of conversion value.", "label": "Conversion Value" } } }, "auth_ref": [] }, "qntm_ConvertedDebentures": { "xbrltype": "sharesItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ConvertedDebentures", "presentation": [ "http://www.quantumbiopharma.com/role/ConvertibledebenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Converted debentures (in Shares)", "documentation": "Converted debentures.", "label": "Converted Debentures" } } }, "auth_ref": [] }, "qntm_ConvertedDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ConvertedDebt", "crdr": "credit", "presentation": [ "http://www.quantumbiopharma.com/role/ConvertibledebenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Converted debt", "documentation": "Converted debt.", "label": "Converted Debt" } } }, "auth_ref": [] }, "qntm_ConvertedPartialAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ConvertedPartialAmount", "crdr": "debit", "presentation": [ "http://www.quantumbiopharma.com/role/ConvertibledebenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Converted partial amount (in Dollars)", "documentation": "Converted a partial amount.", "label": "Converted Partial Amount" } } }, "auth_ref": [] }, "qntm_ConvertibleDebentureIssuePricePerUnit": { "xbrltype": "perShareItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ConvertibleDebentureIssuePricePerUnit", "presentation": [ "http://www.quantumbiopharma.com/role/ConvertibledebenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issue price per share (in Dollars per share)", "documentation": "Issue price.", "label": "Convertible Debenture Issue Price Per Unit" } } }, "auth_ref": [] }, "qntm_ConvertibleDebentureMonthlyInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ConvertibleDebentureMonthlyInterestRate", "presentation": [ "http://www.quantumbiopharma.com/role/ConvertibledebenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bear interest at a rate", "documentation": "Bear interest rate percentage.", "label": "Convertible Debenture Monthly Interest Rate" } } }, "auth_ref": [] }, "qntm_ConvertibleDebentures": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ConvertibleDebentures", "crdr": "credit", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofconvertibledebenturesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Balance", "documentation": "The amount of convertible debentures.", "label": "Convertible Debentures" } } }, "auth_ref": [] }, "qntm_ConvertibleDebenturesAmountConverted": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ConvertibleDebenturesAmountConverted", "crdr": "debit", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofconvertibledebenturesTable", "http://www.quantumbiopharma.com/role/SharecapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount converted", "verboseLabel": "Convertible debentures amount converted (in Dollars)", "documentation": "Convertible debentures amount converted.", "label": "Convertible Debentures Amount Converted" } } }, "auth_ref": [] }, "qntm_ConvertibleDebenturesAstract": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ConvertibleDebenturesAstract", "lang": { "en-us": { "role": { "label": "Convertible debentures [abstract]" } } }, "auth_ref": [] }, "qntm_ConvertibleDebenturesAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ConvertibleDebenturesAxis", "presentation": [ "http://www.quantumbiopharma.com/role/ConvertibledebenturesDetails", "http://www.quantumbiopharma.com/role/ScheduleofconvertibledebenturesTable", "http://www.quantumbiopharma.com/role/ScheduleofgainonchangeinfairvalueTable" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible debentures [Axis]", "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table.", "label": "Convertible Debentures Axis" } } }, "auth_ref": [] }, "qntm_ConvertibleDebenturesBalance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ConvertibleDebenturesBalance", "crdr": "credit", "presentation": [ "http://www.quantumbiopharma.com/role/ConvertibledebenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible debentures balance", "documentation": "The amount of convertible debentures balance.", "label": "Convertible Debentures Balance" } } }, "auth_ref": [] }, "qntm_ConvertibleDebenturesDomainDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ConvertibleDebenturesDomainDomain", "presentation": [ "http://www.quantumbiopharma.com/role/ConvertibledebenturesDetails", "http://www.quantumbiopharma.com/role/ScheduleofconvertibledebenturesTable", "http://www.quantumbiopharma.com/role/ScheduleofgainonchangeinfairvalueTable" ], "lang": { "en-us": { "role": { "label": "ConvertibleDebenturesDomain [Domain]" } } }, "auth_ref": [] }, "qntm_ConvertibleDebenturesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ConvertibleDebenturesMember", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleoflosspershareTable" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible debentures [Member]", "label": "Convertible Debentures Member" } } }, "auth_ref": [] }, "qntm_ConvertibleDebenturesTotalAmountConverted": { "xbrltype": "sharesItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ConvertibleDebenturesTotalAmountConverted", "presentation": [ "http://www.quantumbiopharma.com/role/SharecapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible Debentures Total Amount Converted", "documentation": "Number of convertible debentures total amount converted.", "label": "Convertible Debentures Total Amount Converted" } } }, "auth_ref": [] }, "qntm_ConvertibledebenturesDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ConvertibledebenturesDetailsLineItems", "presentation": [ "http://www.quantumbiopharma.com/role/ConvertibledebenturesDetails" ], "lang": { "en-us": { "role": { "label": "Convertible debentures (Details) [Line Items]" } } }, "auth_ref": [] }, "qntm_ConvertibledebenturesDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ConvertibledebenturesDetailsTable", "presentation": [ "http://www.quantumbiopharma.com/role/ConvertibledebenturesDetails" ], "lang": { "en-us": { "role": { "label": "Convertible debentures (Details) [Table]" } } }, "auth_ref": [] }, "qntm_ConvertibledebenturesScheduleofconvertibledebenturesDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ConvertibledebenturesScheduleofconvertibledebenturesDetailsLineItems", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofconvertibledebenturesTable" ], "lang": { "en-us": { "role": { "label": "Convertible debentures - Schedule of convertible debentures (Details) [Line Items]" } } }, "auth_ref": [] }, "qntm_ConvertibledebenturesScheduleofconvertibledebenturesDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ConvertibledebenturesScheduleofconvertibledebenturesDetailsTable", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofconvertibledebenturesTable" ], "lang": { "en-us": { "role": { "label": "Convertible debentures - Schedule of convertible debentures (Details) [Table]" } } }, "auth_ref": [] }, "qntm_ConvertibledebenturesScheduleofgainonchangeinfairvalueDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ConvertibledebenturesScheduleofgainonchangeinfairvalueDetailsLineItems", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofgainonchangeinfairvalueTable" ], "lang": { "en-us": { "role": { "label": "Convertible debentures - Schedule of gain on change in fair value (Details) [Line Items]" } } }, "auth_ref": [] }, "qntm_ConvertibledebenturesScheduleofgainonchangeinfairvalueDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ConvertibledebenturesScheduleofgainonchangeinfairvalueDetailsTable", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofgainonchangeinfairvalueTable" ], "lang": { "en-us": { "role": { "label": "Convertible debentures - Schedule of gain on change in fair value (Details) [Table]" } } }, "auth_ref": [] }, "ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CorporateInformationAndStatementOfIFRSComplianceAbstract", "lang": { "en-us": { "role": { "label": "Corporate information [abstract]" } } }, "auth_ref": [] }, "ifrs-full_CounterpartiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CounterpartiesAxis", "presentation": [ "http://www.quantumbiopharma.com/role/CommitmentsandcontingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Counterparties [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r102" ] }, "ifrs-full_CounterpartiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CounterpartiesDomain", "presentation": [ "http://www.quantumbiopharma.com/role/CommitmentsandcontingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Counterparties [domain]" } }, "en": { "role": { "documentation": "This member stands for the parties to the transaction other than the entity. It also represents the standard value for the 'Counterparties' axis if no other member is used." } } }, "auth_ref": [ "r102" ] }, "ifrs-full_CurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentAssets", "crdr": "debit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet", "http://www.quantumbiopharma.com/role/ScheduleofassetandincomebysegmentTable" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "terseLabel": "Current assets", "label": "Current assets" } }, "en": { "role": { "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]" } } }, "auth_ref": [ "r57", "r196", "r221" ] }, "ifrs-full_CurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentAssetsAbstract", "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets", "label": "Current assets [abstract]" } } }, "auth_ref": [] }, "ifrs-full_CurrentDebtInstrumentsIssued": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentDebtInstrumentsIssued", "crdr": "credit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible debentures", "label": "Current debt instruments issued" } }, "en": { "role": { "documentation": "The amount of current debt instruments issued. [Refer: Debt instruments issued]" } } }, "auth_ref": [ "r260" ] }, "ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentDeferredIncomeOtherThanCurrentContractLiabilities", "crdr": "credit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative liabilities", "label": "Current deferred income other than current contract liabilities" } }, "en": { "role": { "documentation": "The amount of current deferred income other than current contract liabilities. [Refer: Deferred income other than contract liabilities]" } } }, "auth_ref": [ "r260", "r263" ] }, "qntm_CurrentDigitalAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "CurrentDigitalAssets", "crdr": "debit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Digital assets", "documentation": "The amount of current digital assets.", "label": "Current Digital Assets" } } }, "auth_ref": [] }, "qntm_CurrentDigitalAssetsRestricted": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "CurrentDigitalAssetsRestricted", "crdr": "debit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Digital assets - restricted", "documentation": "The amount of current digital assets restricted.", "label": "Current Digital Assets Restricted" } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.quantumbiopharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "ifrs-full_CurrentInvestments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentInvestments", "crdr": "debit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet", "http://www.quantumbiopharma.com/role/ScheduleofinvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Investments", "verboseLabel": "Current", "label": "Current investments" } }, "en": { "role": { "documentation": "The amount of current investments." } } }, "auth_ref": [ "r260" ] }, "ifrs-full_CurrentLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentLeaseLiabilities", "crdr": "credit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Lease obligations", "label": "Current lease liabilities" } }, "en": { "role": { "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r75" ] }, "ifrs-full_CurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentLiabilities", "crdr": "credit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet", "http://www.quantumbiopharma.com/role/ScheduleofassetandincomebysegmentTable" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "terseLabel": "Current liabilities", "label": "Current liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period." } } }, "auth_ref": [ "r59", "r197", "r221" ] }, "ifrs-full_CurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentLiabilitiesAbstract", "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities", "label": "Current liabilities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_CurrentPrepaidExpenses": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentPrepaidExpenses", "crdr": "debit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and deposits", "label": "Current prepaid expenses" } }, "en": { "role": { "documentation": "The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised." } } }, "auth_ref": [ "r258" ] }, "ifrs-full_CurrentWarrantLiability": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentWarrantLiability", "crdr": "credit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants liability", "label": "Current warrant liability" } }, "en": { "role": { "documentation": "The amount of current warrant liabilities. [Refer: Warrant liability]" } } }, "auth_ref": [ "r260" ] }, "qntm_DamagesSeeksValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "DamagesSeeksValue", "crdr": "debit", "presentation": [ "http://www.quantumbiopharma.com/role/CommitmentsandcontingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Damages seeks, value.", "documentation": "Damages seeks, value.", "label": "Damages Seeks Value" } } }, "auth_ref": [] }, "qntm_DamagesSoughtValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "DamagesSoughtValue", "crdr": "debit", "presentation": [ "http://www.quantumbiopharma.com/role/CommitmentsandcontingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Seeking damages", "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.", "label": "Damages Sought Value" } } }, "auth_ref": [] }, "qntm_DebentureDerivativeLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "DebentureDerivativeLiabilities", "crdr": "credit", "presentation": [ "http://www.quantumbiopharma.com/role/ConvertibledebenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debenture derivative liabilities", "documentation": "The amount of debenture derivative liabilities.", "label": "Debenture Derivative Liabilities" } } }, "auth_ref": [] }, "qntm_DebentureForGrossProceeds": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "DebentureForGrossProceeds", "crdr": "debit", "presentation": [ "http://www.quantumbiopharma.com/role/ConvertibledebenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debenture for gross proceeds", "documentation": "The amount of debenture for gross proceeds.", "label": "Debenture For Gross Proceeds" } } }, "auth_ref": [] }, "qntm_DebentureInterestRatePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "DebentureInterestRatePercentage", "presentation": [ "http://www.quantumbiopharma.com/role/ConvertibledebenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debenture interest rate (as a percent)", "documentation": "Percentage of debenture interest rate.", "label": "Debenture Interest Rate Percentage" } } }, "auth_ref": [] }, "qntm_DebenturePrice": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "DebenturePrice", "crdr": "debit", "presentation": [ "http://www.quantumbiopharma.com/role/ConvertibledebenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debenture price", "documentation": "The amount of debenture price.", "label": "Debenture Price" } } }, "auth_ref": [] }, "qntm_DebentureUnitMatureTearm": { "xbrltype": "durationItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "DebentureUnitMatureTearm", "presentation": [ "http://www.quantumbiopharma.com/role/ConvertibledebenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debenture unit mature tearm", "documentation": "Debenture unit mature tearm.", "label": "Debenture Unit Mature Tearm" } } }, "auth_ref": [] }, "qntm_DebentureUnitsIssued": { "xbrltype": "sharesItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "DebentureUnitsIssued", "presentation": [ "http://www.quantumbiopharma.com/role/RelatedpartytransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debenture units issued (in Shares)", "documentation": "Debenture units issued.", "label": "Debenture Units Issued" } } }, "auth_ref": [] }, "qntm_DebenturesConvertedToSubordinateShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "DebenturesConvertedToSubordinateShares", "presentation": [ "http://www.quantumbiopharma.com/role/SharecapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debentures converted to subordinate shares", "documentation": "The number of debentures converted to subordinate shares.", "label": "Debentures Converted To Subordinate Shares" } } }, "auth_ref": [] }, "qntm_DebenturesUnits": { "xbrltype": "sharesItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "DebenturesUnits", "presentation": [ "http://www.quantumbiopharma.com/role/ConvertibledebenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debentures units (in Shares)", "documentation": "Debentures units.", "label": "Debentures Units" } } }, "auth_ref": [] }, "qntm_December2024DebentureUnitsIssuedOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "December2024DebentureUnitsIssuedOneMember", "presentation": [ "http://www.quantumbiopharma.com/role/ConvertibledebenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "December 2024 Debenture Units Issued One [Member]", "label": "December2024 Debenture Units Issued One Member" } } }, "auth_ref": [] }, "qntm_December2024DebentureUnitsIssuedTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "December2024DebentureUnitsIssuedTwoMember", "presentation": [ "http://www.quantumbiopharma.com/role/ConvertibledebenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "December 2024 Debenture Units Issued Two [Member]", "label": "December2024 Debenture Units Issued Two Member" } } }, "auth_ref": [] }, "qntm_DecemberTwentyTwentyFourWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "DecemberTwentyTwentyFourWarrantsMember", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleoffairvaluedeterminedusingblackscholesoptionTable", "http://www.quantumbiopharma.com/role/WarrantsLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "December 2024 Warrants [Member]", "verboseLabel": "December Twenty Twenty Four Warrants [Member]", "label": "December Twenty Twenty Four Warrants Member" } } }, "auth_ref": [] }, "qntm_DeemedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "DeemedPricePerShare", "presentation": [ "http://www.quantumbiopharma.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deemed price per share (in Dollars per share)", "documentation": "It represents the deemed price per share.", "label": "Deemed Price Per Share" } } }, "auth_ref": [] }, "ifrs-full_DepreciationAndAmortisationExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DepreciationAndAmortisationExpense", "crdr": "debit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Depreciation and amortisation expense" } }, "en": { "role": { "documentation": "The amount of depreciation and amortisation expense. Depreciation and amortisation are the systematic allocations of depreciable amounts of assets over their useful lives." } } }, "auth_ref": [ "r63", "r106", "r111", "r178", "r213", "r232" ] }, "qntm_DerivativeFinancialInstruments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "DerivativeFinancialInstruments", "crdr": "credit", "presentation": [ "http://www.quantumbiopharma.com/role/ConvertibledebenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of warrants", "documentation": "Fair value of warrants.", "label": "Derivative Financial Instruments" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyForFunctionalCurrencyExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForFunctionalCurrencyExplanatory", "presentation": [ "http://www.quantumbiopharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Functional currency and presentation currency", "label": "Description of accounting policy for functional currency [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for the currency of the primary economic environment in which the entity operates." } } }, "auth_ref": [ "r259" ] }, "qntm_DescriptionOfCommonShare": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "DescriptionOfCommonShare", "presentation": [ "http://www.quantumbiopharma.com/role/ConvertibledebenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Description of common share", "documentation": "A description of common share.", "label": "Description Of Common Share" } } }, "auth_ref": [] }, "qntm_DescriptionOfConversionPrice": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "DescriptionOfConversionPrice", "presentation": [ "http://www.quantumbiopharma.com/role/ConvertibledebenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Description of conversion price", "documentation": "Description of conversion price.", "label": "Description Of Conversion Price" } } }, "auth_ref": [] }, "qntm_DescriptionOfDistributionOfSharesToShareholders": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "DescriptionOfDistributionOfSharesToShareholders", "presentation": [ "http://www.quantumbiopharma.com/role/NatureofbusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Description of distribution of shares to shareholders", "documentation": "Description of distribution of shares to shareholders.", "label": "Description Of Distribution Of Shares To Shareholders" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations", "presentation": [ "http://www.quantumbiopharma.com/role/NewstandardsamendmentsandinterpretationsadoptedbytheCompany" ], "lang": { "en-us": { "role": { "terseLabel": "New standards, amendments and interpretations adopted by the Company", "label": "Disclosure of expected impact of initial application of new standards or interpretations [text block]" } } }, "auth_ref": [ "r47", "r126" ] }, "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleoffairvaluesofoptionsgrantedusingtheBlackScholesoptionpricingmodelTable" ], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility", "label": "Expected volatility, share options granted" } }, "en": { "role": { "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time." } } }, "auth_ref": [ "r91" ] }, "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleoffairvaluesofoptionsgrantedusingtheBlackScholesoptionpricingmodelTable" ], "lang": { "en-us": { "role": { "terseLabel": "Risk free interest rate", "label": "Risk free interest rate, share options granted" } }, "en": { "role": { "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]" } } }, "auth_ref": [ "r91" ] }, "qntm_DescriptionRelatedToCourtDispute": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "DescriptionRelatedToCourtDispute", "presentation": [ "http://www.quantumbiopharma.com/role/CommitmentsandcontingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Description related to court dispute", "documentation": "Description related to court dispute.", "label": "Description Related To Court Dispute" } } }, "auth_ref": [] }, "qntm_DescriptionofuseOfEstimatesAndJudgmentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "DescriptionofuseOfEstimatesAndJudgmentsExplanatory", "presentation": [ "http://www.quantumbiopharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Use of estimates and judgments", "documentation": "Descriptionofuse of estimates and judgments explanatory.", "label": "Descriptionofuse Of Estimates And Judgments Explanatory" } } }, "auth_ref": [] }, "qntm_DigitalAssetsAdditions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "DigitalAssetsAdditions", "crdr": "debit", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofchangesindigitalassetsbalanceTable" ], "lang": { "en-us": { "role": { "terseLabel": "Additions", "documentation": "The amount of additions.", "label": "Digital Assets Additions" } } }, "auth_ref": [] }, "qntm_DigitalAssetsAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "DigitalAssetsAtFairValue", "crdr": "debit", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleoffairvaluehierarchyTable" ], "lang": { "en-us": { "role": { "terseLabel": "Digital assets, at fair value", "documentation": "The amount of digital assets, at fair value.", "label": "Digital Assets At Fair Value" } } }, "auth_ref": [] }, "qntm_DigitalAssetsBalance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "DigitalAssetsBalance", "crdr": "debit", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofchangesindigitalassetsbalanceTable" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance", "periodEndLabel": "Balance", "documentation": "The amount of digital assets balance.", "label": "Digital Assets Balance" } } }, "auth_ref": [] }, "qntm_DigitalAssetsDispositions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "DigitalAssetsDispositions", "crdr": "debit", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofchangesindigitalassetsbalanceTable" ], "lang": { "en-us": { "role": { "terseLabel": "Dispositions", "documentation": "The amount of dispositions.", "label": "Digital Assets Dispositions" } } }, "auth_ref": [] }, "qntm_DigitalAssetsSold": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "DigitalAssetsSold", "crdr": "debit", "presentation": [ "http://www.quantumbiopharma.com/role/DigitalassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Digital assets sold", "documentation": "The amount of digital assets sold.", "label": "Digital Assets Sold" } } }, "auth_ref": [] }, "qntm_DigitalassetsScheduleofchangesindigitalassetsbalanceDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "DigitalassetsScheduleofchangesindigitalassetsbalanceDetailsLineItems", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofchangesindigitalassetsbalanceTable" ], "lang": { "en-us": { "role": { "label": "Digital assets - Schedule of changes in digital assets balance (Details) [Line Items]" } } }, "auth_ref": [] }, "qntm_DigitalassetsScheduleofchangesindigitalassetsbalanceDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "DigitalassetsScheduleofchangesindigitalassetsbalanceDetailsTable", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofchangesindigitalassetsbalanceTable" ], "lang": { "en-us": { "role": { "label": "Digital assets - Schedule of changes in digital assets balance (Details) [Table]" } } }, "auth_ref": [] }, "qntm_DigitalassetsScheduleoffairvaluehierarchyDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "DigitalassetsScheduleoffairvaluehierarchyDetailsLineItems", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleoffairvaluehierarchyTable" ], "lang": { "en-us": { "role": { "label": "Digital assets - Schedule of fair value hierarchy (Details) [Line Items]" } } }, "auth_ref": [] }, "qntm_DigitalassetsScheduleoffairvaluehierarchyDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "DigitalassetsScheduleoffairvaluehierarchyDetailsTable", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleoffairvaluehierarchyTable" ], "lang": { "en-us": { "role": { "label": "Digital assets - Schedule of fair value hierarchy (Details) [Table]" } } }, "auth_ref": [] }, "ifrs-full_DilutedEarningsLossPerShareFromContinuingOperations": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DilutedEarningsLossPerShareFromContinuingOperations", "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted - continuing operations (in Dollars per share)", "label": "Diluted earnings (loss) per share from continuing operations" } }, "en": { "role": { "documentation": "Diluted earnings (loss) per share from continuing operations. [Refer: Continuing operations, unless line item indicates otherwise [member]; Diluted earnings (loss) per share]" } } }, "auth_ref": [ "r19", "r20" ] }, "ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleoflosspershareTable" ], "lang": { "en-us": { "role": { "terseLabel": "Dilutive effect of convertible instruments on number of ordinary shares", "label": "Dilutive effect of convertible instruments on weighted average number of ordinary shares" } }, "en": { "role": { "documentation": "The potential dilutive effect on the weighted average number of ordinary shares that relate to the assumed conversion of the entity's convertible instruments." } } }, "auth_ref": [ "r243" ] }, "qntm_DirectorsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "DirectorsMember", "presentation": [ "http://www.quantumbiopharma.com/role/RelatedpartytransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Directors [Member]", "label": "Directors Member" } } }, "auth_ref": [] }, "ifrs-full_DirectorsRemunerationExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DirectorsRemunerationExpense", "crdr": "debit", "presentation": [ "http://www.quantumbiopharma.com/role/RelatedpartytransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Director\u2019s compensation", "label": "Directors' remuneration expense, operating" } } }, "auth_ref": [ "r258" ] }, "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "presentation": [ "http://www.quantumbiopharma.com/role/Basisofpresentation" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of presentation", "label": "Disclosure of basis of preparation of financial statements [text block]" } } }, "auth_ref": [ "r256" ] }, "ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "presentation": [ "http://www.quantumbiopharma.com/role/Commitmentsandcontingencies" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies", "label": "Disclosure of commitments and contingent liabilities [text block]" } }, "en": { "role": { "documentation": "The disclosure of commitments and contingent liabilities. [Refer: Classes of contingent liabilities [domain]]" } } }, "auth_ref": [ "r256" ] }, "qntm_DisclosureOfComparativePoliciestextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "DisclosureOfComparativePoliciestextBlock", "presentation": [ "http://www.quantumbiopharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Comparative figures", "documentation": "The disclosure of accounting policies for comparative.", "label": "Disclosure Of Comparative Policiestext Block" } } }, "auth_ref": [] }, "qntm_DisclosureOfDetailInformationAboutTradeAndOtherReceivablesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "DisclosureOfDetailInformationAboutTradeAndOtherReceivablesExplanatory", "presentation": [ "http://www.quantumbiopharma.com/role/OtherreceivablesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of other receivables", "label": "Disclosure Of Detail Information About Trade And Other Receivables Explanatory" } } }, "auth_ref": [] }, "qntm_DisclosureOfDetailedInformationAboutAccruedExpensesAndOtherLiabilitiesExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "DisclosureOfDetailedInformationAboutAccruedExpensesAndOtherLiabilitiesExplanatoryTableTextBlock", "presentation": [ "http://www.quantumbiopharma.com/role/TradeandotherpayablesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of accrued liabilities", "documentation": "Disclosure of detailed information about accrued expenses and other liabilities explanatory.", "label": "Disclosure Of Detailed Information About Accrued Expenses And Other Liabilities Explanatory Table Text Block" } } }, "auth_ref": [] }, "qntm_DisclosureOfDetailedInformationAboutChangesInWarrantsOutstandingAndWeightedAverageExercisePriceExplanatoryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "DisclosureOfDetailedInformationAboutChangesInWarrantsOutstandingAndWeightedAverageExercisePriceExplanatoryTextBlock", "presentation": [ "http://www.quantumbiopharma.com/role/SharecapitalTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of changes in share capital", "documentation": "Disclosure of warrants outstanding and weighted average exercise price explanatory.", "label": "Disclosure Of Detailed Information About Changes In Warrants Outstanding And Weighted Average Exercise Price Explanatory Text Block" } } }, "auth_ref": [] }, "qntm_DisclosureOfDetailedInformationAboutConvertibleDebenturesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "DisclosureOfDetailedInformationAboutConvertibleDebenturesExplanatory", "presentation": [ "http://www.quantumbiopharma.com/role/ConvertibledebenturesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of convertible debentures", "documentation": "Disclosure of convertible debentures explanatory.", "label": "Disclosure Of Detailed Information About Convertible Debentures Explanatory" } } }, "auth_ref": [] }, "qntm_DisclosureOfDetailedInformationAboutEntitysReportableSegmentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "DisclosureOfDetailedInformationAboutEntitysReportableSegmentsExplanatory", "presentation": [ "http://www.quantumbiopharma.com/role/SegmentinformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of asset and income by segment", "documentation": "Schedule of asset and income by segment.", "label": "Disclosure Of Detailed Information About Entitys Reportable Segments Explanatory" } } }, "auth_ref": [] }, "qntm_DisclosureOfDetailedInformationAboutFairBlackScholesWarrantsLiabilityExplanatoryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "DisclosureOfDetailedInformationAboutFairBlackScholesWarrantsLiabilityExplanatoryTextBlock", "presentation": [ "http://www.quantumbiopharma.com/role/WarrantsLiabilityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of fair value determined using black-scholes option", "documentation": "Schedule of fair black scholes warrants liability.", "label": "Disclosure Of Detailed Information About Fair Black Scholes Warrants Liability Explanatory Text Block" } } }, "auth_ref": [] }, "qntm_DisclosureOfDetailedInformationAboutFairValueHierarchyExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "DisclosureOfDetailedInformationAboutFairValueHierarchyExplanatoryTableTextBlock", "presentation": [ "http://www.quantumbiopharma.com/role/DigitalassetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of fair value hierarchy", "documentation": "Disclosure of detailed information about fair value hierarchy explanatory.", "label": "Disclosure Of Detailed Information About Fair Value Hierarchy Explanatory Table Text Block" } } }, "auth_ref": [] }, "qntm_DisclosureOfDetailedInformationAboutFairValuesAssumptionsOfWarrantsOutstandingExplanatoryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "DisclosureOfDetailedInformationAboutFairValuesAssumptionsOfWarrantsOutstandingExplanatoryTextBlock", "presentation": [ "http://www.quantumbiopharma.com/role/SharecapitalTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of changes in share capital", "documentation": "Disclosure of fair values assumptions of warrants outstanding explanatory.", "label": "Disclosure Of Detailed Information About Fair Values Assumptions Of Warrants Outstanding Explanatory Text Block" } } }, "auth_ref": [] }, "qntm_DisclosureOfDetailedInformationAboutGainOnChangeInFairValueExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "DisclosureOfDetailedInformationAboutGainOnChangeInFairValueExplanatory", "presentation": [ "http://www.quantumbiopharma.com/role/ConvertibledebenturesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of gain on change in fair value", "documentation": "Disclosure of gain on change in fair value explanatory.", "label": "Disclosure Of Detailed Information About Gain On Change In Fair Value Explanatory" } } }, "auth_ref": [] }, "qntm_DisclosureOfDetailedInformationAboutGeneralAndAdministrativeExpenseExplanatoryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "DisclosureOfDetailedInformationAboutGeneralAndAdministrativeExpenseExplanatoryTextBlock", "presentation": [ "http://www.quantumbiopharma.com/role/GeneralandadministrativeTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of general and administrative expense", "documentation": "Tabular disclosure of General and administrative expenses.", "label": "Disclosure Of Detailed Information About General And Administrative Expense Explanatory Text Block" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "presentation": [ "http://www.quantumbiopharma.com/role/IntangibleassetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of intangible assets", "label": "Disclosure of detailed information about intangible assets [text block]" } }, "en": { "role": { "documentation": "The disclosure of detailed information about intangible assets. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r33", "r142" ] }, "ifrs-full_DisclosureOfDetailedInformationAboutInvestmentPropertyExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutInvestmentPropertyExplanatory", "presentation": [ "http://www.quantumbiopharma.com/role/Convertibledebentures" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible debentures", "label": "Disclosure of detailed information about investment property [text block]" } }, "en": { "role": { "documentation": "The disclosure of detailed information about investment property. [Refer: Investment property]" } } }, "auth_ref": [ "r36" ] }, "qntm_DisclosureOfDetailedInformationAboutInvestmentsExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "DisclosureOfDetailedInformationAboutInvestmentsExplanatoryTableTextBlock", "presentation": [ "http://www.quantumbiopharma.com/role/InvestmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of investments", "documentation": "The disclosure of disclosure of detailed information about investments.", "label": "Disclosure Of Detailed Information About Investments Explanatory Table Text Block" } } }, "auth_ref": [] }, "qntm_DisclosureOfDetailedInformationAboutNumberOfWarrantsOutstandingAndExercisePriceExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "DisclosureOfDetailedInformationAboutNumberOfWarrantsOutstandingAndExercisePriceExplanatory", "presentation": [ "http://www.quantumbiopharma.com/role/SharecapitalTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of number of warrants outstanding and exercise price", "label": "Disclosure Of Detailed Information About Number Of Warrants Outstanding And Exercise Price Explanatory" } } }, "auth_ref": [] }, "qntm_DisclosureOfDetailedInformationAboutShareBasedCompensationExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "DisclosureOfDetailedInformationAboutShareBasedCompensationExplanatoryTableTextBlock", "presentation": [ "http://www.quantumbiopharma.com/role/SharebasedcompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of share-based compensation", "documentation": "Disclosure of detailed information about share based compensation explanatory.", "label": "Disclosure Of Detailed Information About Share Based Compensation Explanatory Table Text Block" } } }, "auth_ref": [] }, "qntm_DisclosureOfDetailedInformationAboutTradeAndOtherPayableExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "DisclosureOfDetailedInformationAboutTradeAndOtherPayableExplanatoryTableTextBlock", "presentation": [ "http://www.quantumbiopharma.com/role/TradeandotherpayablesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of trade and other payables", "documentation": "Disclosure of detailed information about trade and other payable explanatory.", "label": "Disclosure Of Detailed Information About Trade And Other Payable Explanatory Table Text Block" } } }, "auth_ref": [] }, "qntm_DisclosureOfDigitalIntangibleAssetsExplanatoryAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "DisclosureOfDigitalIntangibleAssetsExplanatoryAbstract", "lang": { "en-us": { "role": { "label": "Digital assets [abstract]" } } }, "auth_ref": [] }, "qntm_DisclosureOfDigitalIntangibleAssetsExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "DisclosureOfDigitalIntangibleAssetsExplanatoryTableTextBlock", "presentation": [ "http://www.quantumbiopharma.com/role/DigitalassetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of changes in digital assets balance", "documentation": "The disclosure of digital intangible assets explanatory.", "label": "Disclosure Of Digital Intangible Assets Explanatory Table Text Block" } } }, "auth_ref": [] }, "qntm_DisclosureOfDigitalIntangibleAssetsExplanatoryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "DisclosureOfDigitalIntangibleAssetsExplanatoryTextBlock", "presentation": [ "http://www.quantumbiopharma.com/role/Digitalassets" ], "lang": { "en-us": { "role": { "terseLabel": "Digital assets", "documentation": "The disclosure of digital intangible assets explanatory.", "label": "Disclosure Of Digital Intangible Assets Explanatory Text Block" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfEarningsPerShareExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfEarningsPerShareExplanatory", "presentation": [ "http://www.quantumbiopharma.com/role/Losspershare" ], "lang": { "en-us": { "role": { "terseLabel": "Loss per share", "label": "Disclosure of earnings per share [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r23" ] }, "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory", "presentation": [ "http://www.quantumbiopharma.com/role/Subsequentevents" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent events", "label": "Disclosure of events after reporting period [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for events after the reporting period." } } }, "auth_ref": [ "r1" ] }, "ifrs-full_DisclosureOfFinancialInstrumentsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsAbstract", "lang": { "en-us": { "role": { "label": "Financial Instruments and Risk Management [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsExplanatory", "presentation": [ "http://www.quantumbiopharma.com/role/FinancialInstrumentsandRiskManagement" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments and Risk Management", "label": "Disclosure of financial instruments [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for financial instruments." } } }, "auth_ref": [ "r103" ] }, "ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfGeneralAndAdministrativeExpenseExplanatory", "presentation": [ "http://www.quantumbiopharma.com/role/Generalandadministrative" ], "lang": { "en-us": { "role": { "terseLabel": "General and administrative", "label": "Disclosure of general and administrative expense [text block]" } } }, "auth_ref": [ "r256" ] }, "ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory", "presentation": [ "http://www.quantumbiopharma.com/role/SharebasedcompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of fair values of PSUs granted using the Black-Scholes option pricing model", "label": "Disclosure of indirect measurement of fair value of goods or services received, other equity instruments granted during period [text block]" } }, "en": { "role": { "documentation": "The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's other equity instruments (ie other than share options)." } } }, "auth_ref": [ "r93" ] }, "ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory", "presentation": [ "http://www.quantumbiopharma.com/role/SharebasedcompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of fair values of options granted using the Black-Scholes option pricing model", "label": "Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]" } }, "en": { "role": { "documentation": "The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options." } } }, "auth_ref": [ "r92" ] }, "qntm_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodtableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodtableTextBlock", "presentation": [ "http://www.quantumbiopharma.com/role/InvestmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of fair value of warrants option pricing model assumptions", "documentation": "The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options.", "label": "Disclosure Of Indirect Measurement Of Fair Value Of Goods Or Services Received Share Options Granted During Periodtable Text Block" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "presentation": [ "http://www.quantumbiopharma.com/role/RelatedpartytransactionsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of key management personnel compensation", "label": "Disclosure of information about key management personnel [text block]" } }, "en": { "role": { "documentation": "The disclosure of information about key management personnel. [Refer: Key management personnel of entity or parent [member]]" } } }, "auth_ref": [ "r256" ] }, "ifrs-full_DisclosureOfIntangibleAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIntangibleAssetsAbstract", "lang": { "en-us": { "role": { "label": "Intangible assets [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfIntangibleAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIntangibleAssetsExplanatory", "presentation": [ "http://www.quantumbiopharma.com/role/Intangibleassets" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets", "label": "Disclosure of intangible assets [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for intangible assets." } } }, "auth_ref": [ "r35" ] }, "qntm_DisclosureOfInvestmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "DisclosureOfInvestmentsAbstract", "lang": { "en-us": { "role": { "label": "Investments [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory", "presentation": [ "http://www.quantumbiopharma.com/role/Investments" ], "lang": { "en-us": { "role": { "terseLabel": "Investments", "label": "Disclosure of investments other than investments accounted for using equity method [text block]" } }, "en": { "role": { "documentation": "The disclosure of investments other than investments accounted for using the equity method. [Refer: Investments other than investments accounted for using equity method]" } } }, "auth_ref": [ "r256" ] }, "qntm_DisclosureOfNatureOfBusinessExplanatoryAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "DisclosureOfNatureOfBusinessExplanatoryAbstract", "lang": { "en-us": { "role": { "label": "Nature of business [abstract]" } } }, "auth_ref": [] }, "qntm_DisclosureOfNatureOfBusinessExplanatoryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "DisclosureOfNatureOfBusinessExplanatoryTextBlock", "presentation": [ "http://www.quantumbiopharma.com/role/Natureofbusiness" ], "lang": { "en-us": { "role": { "terseLabel": "Nature of business", "documentation": "Disclosure of nature of business explanatory text block.", "label": "Disclosure Of Nature Of Business Explanatory Text Block" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNoncontrollingInterestsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNoncontrollingInterestsExplanatory", "presentation": [ "http://www.quantumbiopharma.com/role/Noncontrollinginterests" ], "lang": { "en-us": { "role": { "terseLabel": "Non-controlling interests", "label": "Disclosure of non-controlling interests [text block]" } }, "en": { "role": { "documentation": "The disclosure of non-controlling interests. [Refer: Non-controlling interests]" } } }, "auth_ref": [ "r256" ] }, "qntm_DisclosureOfNotePayablesExplanatoryAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "DisclosureOfNotePayablesExplanatoryAbstract", "lang": { "en-us": { "role": { "label": "Notes payable [abstract]" } } }, "auth_ref": [] }, "qntm_DisclosureOfNotePayablesExplanatoryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "DisclosureOfNotePayablesExplanatoryTextBlock", "presentation": [ "http://www.quantumbiopharma.com/role/Notespayable" ], "lang": { "en-us": { "role": { "terseLabel": "Notes payable", "documentation": "Disclosure of note payables explanatory.", "label": "Disclosure Of Note Payables Explanatory Text Block" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory", "presentation": [ "http://www.quantumbiopharma.com/role/SharebasedcompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of company\u2019s share options outstanding", "label": "Disclosure of number and weighted average remaining contractual life of outstanding share options [text block]" } }, "en": { "role": { "documentation": "The disclosure of the number and weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r89" ] }, "qntm_DisclosureOfNumberOfShareOptionsOutstandingTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "DisclosureOfNumberOfShareOptionsOutstandingTableTextBlock", "presentation": [ "http://www.quantumbiopharma.com/role/SharebasedcompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of number of share options outstanding", "documentation": "Disclosure of number of share options outstanding.", "label": "Disclosure Of Number Of Share Options Outstanding Table Text Block" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory", "presentation": [ "http://www.quantumbiopharma.com/role/CapitalManagement" ], "lang": { "en-us": { "role": { "terseLabel": "Capital Management", "label": "Disclosure of objectives, policies and processes for managing capital [text block]" } }, "en": { "role": { "documentation": "The disclosure of information that enables users of financial statements to evaluate the entity's objectives, policies and processes for managing capital." } } }, "auth_ref": [ "r184" ] }, "ifrs-full_DisclosureOfOperatingSegmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfOperatingSegmentsAbstract", "lang": { "en-us": { "role": { "label": "Segment information [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfOperatingSegmentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfOperatingSegmentsExplanatory", "presentation": [ "http://www.quantumbiopharma.com/role/Segmentinformation" ], "lang": { "en-us": { "role": { "terseLabel": "Segment information", "label": "Disclosure of operating segments [text block]" } }, "en": { "role": { "documentation": "The disclosure of operating segments. [Refer: Operating segments [member]]" } } }, "auth_ref": [ "r107" ] }, "qntm_DisclosureOfReconciliationOfNonControllingInterestTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "DisclosureOfReconciliationOfNonControllingInterestTableTextBlock", "presentation": [ "http://www.quantumbiopharma.com/role/NoncontrollinginterestsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of reconciliation of non controlling interest", "documentation": "Disclosure of reconciliation of non controlling interest.", "label": "Disclosure Of Reconciliation Of Non Controlling Interest Table Text Block" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfRelatedPartyExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfRelatedPartyExplanatory", "presentation": [ "http://www.quantumbiopharma.com/role/Relatedpartytransactions" ], "lang": { "en-us": { "role": { "terseLabel": "Related party transactions", "label": "Disclosure of related party [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for related parties." } } }, "auth_ref": [ "r13" ] }, "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "presentation": [ "http://www.quantumbiopharma.com/role/Sharecapital" ], "lang": { "en-us": { "role": { "terseLabel": "Share capital", "label": "Disclosure of share capital, reserves and other equity interest [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for share capital, reserves and other equity interest." } } }, "auth_ref": [ "r122", "r175", "r205" ] }, "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory", "presentation": [ "http://www.quantumbiopharma.com/role/Sharebasedcompensation" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation", "label": "Disclosure of share-based payment arrangements [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for share-based payment arrangements." } } }, "auth_ref": [ "r79" ] }, "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory", "presentation": [ "http://www.quantumbiopharma.com/role/NatureofbusinessTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of ownership percentage in subsidiaries", "label": "Disclosure of subsidiaries [text block]" } }, "en": { "role": { "documentation": "The disclosure of subsidiaries. [Refer: Total for all subsidiaries [member]]" } } }, "auth_ref": [ "r16", "r18", "r66", "r166" ] }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract", "lang": { "en-us": { "role": { "label": "Share based compensation [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTradeAndOtherPayablesExplanatory", "presentation": [ "http://www.quantumbiopharma.com/role/Tradeandotherpayables" ], "lang": { "en-us": { "role": { "terseLabel": "Trade and other payables", "label": "Disclosure of trade and other payables [text block]" } }, "en": { "role": { "documentation": "The disclosure of trade and other payables. [Refer: Trade and other payables]" } } }, "auth_ref": [ "r256" ] }, "ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTradeAndOtherReceivablesExplanatory", "presentation": [ "http://www.quantumbiopharma.com/role/Otherreceivables" ], "lang": { "en-us": { "role": { "terseLabel": "Other receivables", "label": "Disclosure of trade and other receivables [text block]" } }, "en": { "role": { "documentation": "The disclosure of trade and other receivables. [Refer: Trade and other receivables]" } } }, "auth_ref": [ "r256" ] }, "qntm_DisclosureOfWarrantLiabilitiesExplanatoryAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "DisclosureOfWarrantLiabilitiesExplanatoryAbstract", "lang": { "en-us": { "role": { "label": "Warrants Liability [abstract]" } } }, "auth_ref": [] }, "qntm_DisclosureOfWarrantLiabilitiesExplanatoryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "DisclosureOfWarrantLiabilitiesExplanatoryTextBlock", "presentation": [ "http://www.quantumbiopharma.com/role/WarrantsLiability" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants Liability", "documentation": "The entire disclosure of warrant liabilities.", "label": "Disclosure Of Warrant Liabilities Explanatory Text Block" } } }, "auth_ref": [] }, "qntm_DocumentAndEntityInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "DocumentAndEntityInformationAbstract", "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.quantumbiopharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.quantumbiopharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.quantumbiopharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentInformationTable", "presentation": [ "http://www.quantumbiopharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.quantumbiopharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentType", "presentation": [ "http://www.quantumbiopharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "qntm_DogecoinMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "DogecoinMember", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofchangesindigitalassetsbalanceTable" ], "lang": { "en-us": { "role": { "terseLabel": "Dogecoin [Member]", "label": "Dogecoin Member" } } }, "auth_ref": [] }, "qntm_DrinkLabIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "DrinkLabIncMember", "presentation": [ "http://www.quantumbiopharma.com/role/CommitmentsandcontingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Drink Lab Inc [Member]", "label": "Drink Lab Inc Member" } } }, "auth_ref": [] }, "ifrs-full_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Loss Per Share [abstract]" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.quantumbiopharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.quantumbiopharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.quantumbiopharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressCountry", "presentation": [ "http://www.quantumbiopharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Country", "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.quantumbiopharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.quantumbiopharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.quantumbiopharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r240" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFileNumber", "presentation": [ "http://www.quantumbiopharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityRegistrantName", "presentation": [ "http://www.quantumbiopharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r240" ] }, "ifrs-full_Equity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Equity", "crdr": "credit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/CapitalManagementDetails", "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet", "http://www.quantumbiopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "totalLabel": "Shareholders equity", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "terseLabel": "Equity balance", "label": "Equity" } }, "en": { "role": { "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities." } } }, "auth_ref": [ "r48", "r50", "r68", "r69", "r70", "r134", "r150", "r168", "r169", "r177", "r195", "r200" ] }, "ifrs-full_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Share capital [abstract]" } } }, "auth_ref": [] }, "ifrs-full_EquityAndLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EquityAndLiabilities", "crdr": "credit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and shareholders\u2019 equity", "label": "Equity and liabilities" } }, "en": { "role": { "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]" } } }, "auth_ref": [ "r195" ] }, "ifrs-full_EquityAndLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EquityAndLiabilitiesAbstract", "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "SHAREHOLDERS' EQUITY", "label": "Equity and liabilities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_EquityAttributableToOwnersOfParent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EquityAttributableToOwnersOfParent", "crdr": "credit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "Equity attributable to shareholders of the Company", "label": "Equity attributable to owners of parent" } }, "en": { "role": { "documentation": "The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest." } } }, "auth_ref": [ "r194" ] }, "qntm_EthereumMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "EthereumMember", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofchangesindigitalassetsbalanceTable" ], "lang": { "en-us": { "role": { "terseLabel": "ETH [Member]", "label": "Ethereum Member" } } }, "auth_ref": [] }, "qntm_ExerciseOfOptionShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ExerciseOfOptionShares", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofchangesinsharecapitalTable" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of options, shares", "documentation": "Number exercise of options, shares.", "label": "Exercise Of Option Shares" } } }, "auth_ref": [] }, "qntm_ExerciseOfOptionsAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ExerciseOfOptionsAmount", "crdr": "credit", "presentation": [ "http://www.quantumbiopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of options", "documentation": "The amount of exercise of options.", "label": "Exercise Of Options Amount" } } }, "auth_ref": [] }, "qntm_ExerciseOfOptionsShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ExerciseOfOptionsShares", "presentation": [ "http://www.quantumbiopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of options (in Shares)", "documentation": "The increase (decrease) in the number of exercise of options shares issued.", "label": "Exercise Of Options Shares" } } }, "auth_ref": [] }, "qntm_ExerciseOfRSUsAmountinDollars": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ExerciseOfRSUsAmountinDollars", "crdr": "credit", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofchangesinsharecapitalTable" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of RSUs, amount (in Dollars)", "documentation": "The amount of exercise of RSUs, amount.", "label": "Exercise Of RSUs Amountin Dollars" } } }, "auth_ref": [] }, "qntm_ExerciseOfRSUsShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ExerciseOfRSUsShares", "presentation": [ "http://www.quantumbiopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of RSUs (in Shares)", "documentation": "The increase (decrease) in the number of exercise of RSU shares issued.", "label": "Exercise Of RSUs Shares" } } }, "auth_ref": [] }, "qntm_ExerciseOfRestrictedStockUnits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ExerciseOfRestrictedStockUnits", "crdr": "credit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow", "http://www.quantumbiopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "negatedLabel": "Exercise of RSUs", "documentation": "The amount represents the exercise of restricted stock units (RSU's).", "label": "Exercise Of Restricted Stock Units" } } }, "auth_ref": [] }, "qntm_ExerciseOfWarrantsAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ExerciseOfWarrantsAmount", "crdr": "credit", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofchangesinsharecapitalTable", "http://www.quantumbiopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of warrants", "verboseLabel": "Exercise of warrants, amount (in Dollars)", "documentation": "The amount of exercise of warrants.", "label": "Exercise Of Warrants Amount" } } }, "auth_ref": [] }, "qntm_ExerciseOfWarrantsShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ExerciseOfWarrantsShares", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofchangesinsharecapitalTable", "http://www.quantumbiopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of warrants (in Shares)", "verboseLabel": "Exercise of warrants, shares", "documentation": "The increase (decrease) in the number of exercise of warrants shares issued.", "label": "Exercise Of Warrants Shares" } } }, "auth_ref": [] }, "qntm_ExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ExercisePrice", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofgainonchangeinfairvalueTable" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise price (in Dollars per share)", "documentation": "The amount of exercise price per share.", "label": "Exercise Price" } } }, "auth_ref": [] }, "qntm_ExercisePriceFiveSixZeroMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ExercisePriceFiveSixZeroMember", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofcompanysshareoptionsoutstandingTable" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise price\t5.60", "label": "Exercise Price Five Six Zero Member" } } }, "auth_ref": [] }, "qntm_ExercisePriceOfShareOption": { "xbrltype": "perShareItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ExercisePriceOfShareOption", "presentation": [ "http://www.quantumbiopharma.com/role/ConvertibledebenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise price (in Dollars per share)", "documentation": "Exercise price per share.", "label": "Exercise Price Of Share Option" } } }, "auth_ref": [] }, "qntm_ExercisePriceOfWarrants": { "xbrltype": "perShareItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ExercisePriceOfWarrants", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleoffairvaluedeterminedusingblackscholesoptionTable", "http://www.quantumbiopharma.com/role/ScheduleoffairvalueofwarrantsoptionpricingmodelassumptionsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise price", "documentation": "Represents the price per share of excercise price of warrants.", "label": "Exercise Price Of Warrants" } } }, "auth_ref": [] }, "ifrs-full_ExercisePriceShareOptionsGranted2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ExercisePriceShareOptionsGranted2019", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleoffairvaluesofoptionsgrantedusingtheBlackScholesoptionpricingmodelTable" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise price (in Dollars per share)", "label": "Exercise price, share options granted" } }, "en": { "role": { "documentation": "The exercise price of share options granted." } } }, "auth_ref": [ "r91" ] }, "qntm_ExercisePriceSixPointFiveZeroMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ExercisePriceSixPointFiveZeroMember", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofcompanysshareoptionsoutstandingTable" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise price 6.50", "label": "Exercise Price Six Point Five Zero Member" } } }, "auth_ref": [] }, "qntm_ExercisePriceTwentyFourFiveZeroMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ExercisePriceTwentyFourFiveZeroMember", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofcompanysshareoptionsoutstandingTable" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise price 24.50", "label": "Exercise Price Twenty Four Five Zero Member" } } }, "auth_ref": [] }, "qntm_ExercisePricesPerShares": { "xbrltype": "perShareItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ExercisePricesPerShares", "presentation": [ "http://www.quantumbiopharma.com/role/RelatedpartytransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise prices per shares", "documentation": "Exercise prices per shares.", "label": "Exercise Prices Per Shares" } } }, "auth_ref": [] }, "qntm_ExercisesOfOptionsAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ExercisesOfOptionsAmount", "crdr": "credit", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofchangesinsharecapitalTable" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of options, amount (in Dollars)", "documentation": "The amount of exercise of options, amount.", "label": "Exercises Of Options Amount" } } }, "auth_ref": [] }, "qntm_ExercisesOfRSUsShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ExercisesOfRSUsShares", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofchangesinsharecapitalTable" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of RSUs, shares", "documentation": "Number of exercise of RSUs, shares.", "label": "Exercises Of RSUs Shares" } } }, "auth_ref": [] }, "ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ExpectedDividendAsPercentageShareOptionsGranted", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleoffairvaluesofoptionsgrantedusingtheBlackScholesoptionpricingmodelTable" ], "lang": { "en-us": { "role": { "terseLabel": "Expected dividend yield", "label": "Expected dividend as percentage, share options granted" } }, "en": { "role": { "documentation": "The percentage of an expected dividend used to calculate the fair value of share options granted." } } }, "auth_ref": [ "r91" ] }, "qntm_ExpectedLife": { "xbrltype": "durationItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ExpectedLife", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleoffairvaluesofoptionsgrantedusingtheBlackScholesoptionpricingmodelTable" ], "lang": { "en-us": { "role": { "terseLabel": "Expected life", "documentation": "Expected life.", "label": "Expected Life" } } }, "auth_ref": [] }, "qntm_ExpectedLifeOfWarrant": { "xbrltype": "durationItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ExpectedLifeOfWarrant", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofgainonchangeinfairvalueTable" ], "lang": { "en-us": { "role": { "terseLabel": "Expected life", "documentation": "Represents average expected life of warrants.", "label": "Expected Life Of Warrant" } } }, "auth_ref": [] }, "qntm_ExpectedLifeOfWarrants": { "xbrltype": "durationItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ExpectedLifeOfWarrants", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleoffairvaluedeterminedusingblackscholesoptionTable", "http://www.quantumbiopharma.com/role/ScheduleoffairvalueofwarrantsoptionpricingmodelassumptionsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Expected life", "documentation": "Represents average expected life of warrants.", "label": "Expected Life Of Warrants" } } }, "auth_ref": [] }, "qntm_ExpectedVolatilityOfWarrant": { "xbrltype": "percentItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ExpectedVolatilityOfWarrant", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofgainonchangeinfairvalueTable" ], "lang": { "en-us": { "role": { "terseLabel": "Expected Volatility", "documentation": "Represents expected volatility of warrants.", "label": "Expected Volatility Of Warrant" } } }, "auth_ref": [] }, "qntm_ExpectedVolatilityOfWarrants": { "xbrltype": "percentItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ExpectedVolatilityOfWarrants", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleoffairvaluedeterminedusingblackscholesoptionTable", "http://www.quantumbiopharma.com/role/ScheduleoffairvalueofwarrantsoptionpricingmodelassumptionsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility", "documentation": "Represents expected volatility of warrants.", "label": "Expected Volatility Of Warrants" } } }, "auth_ref": [] }, "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ExpenseFromSharebasedPaymentTransactionsWithEmployees", "crdr": "debit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedIncomeStatement", "http://www.quantumbiopharma.com/role/ScheduleofsharebasedcompensationTable" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based payments", "verboseLabel": "Share-based compensation", "label": "Expense from share-based payment transactions with employees, operating" } } }, "auth_ref": [ "r258" ] }, "qntm_ExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ExpensesAbstract", "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Expenses", "label": "Expenses Abstract" } } }, "auth_ref": [] }, "ifrs-full_ExplanationOfShareOptionsInSharebasedPaymentArrangement": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ExplanationOfShareOptionsInSharebasedPaymentArrangement", "presentation": [ "http://www.quantumbiopharma.com/role/SharebasedcompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Description of share-based payment arrangement", "label": "Description of share-based payment arrangement" } }, "en": { "role": { "documentation": "The description of a share-based payment arrangement that existed at any time during the reporting period. [Refer: Types of share-based payment arrangements [domain]]" } } }, "auth_ref": [ "r80", "r152" ] }, "qntm_ExternalResearchAndDevelopmentFees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ExternalResearchAndDevelopmentFees", "crdr": "credit", "calculation": { "http://www.quantumbiopharma.com/role/ScheduleofaccruedliabilitiesTable": { "parentTag": "ifrs-full_AccrualsClassifiedAsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofaccruedliabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "External research and development fees", "documentation": "The amount of external research and development fees.", "label": "External Research And Development Fees" } } }, "auth_ref": [] }, "qntm_FSDBiosciencesIncInUSAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "FSDBiosciencesIncInUSAMember", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofownershippercentageinsubsidiariesTable" ], "lang": { "en-us": { "role": { "terseLabel": "FSD Biosciences Inc in USA Member", "documentation": "FSD Biosciences Inc in USA.", "label": "FSDBiosciences Inc In USAMember" } } }, "auth_ref": [] }, "qntm_FSDPharmaAustraliaPtyLtdInAustraliaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "FSDPharmaAustraliaPtyLtdInAustraliaMember", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofownershippercentageinsubsidiariesTable" ], "lang": { "en-us": { "role": { "terseLabel": "FSD Pharma Australia Pty Ltd in Australia Member", "documentation": "FSD Pharma Australia Pty Ltd in Australia Member.", "label": "FSDPharma Australia Pty Ltd In Australia Member" } } }, "auth_ref": [] }, "qntm_FSDStrategicInvestmentsIncInCanadaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "FSDStrategicInvestmentsIncInCanadaMember", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofownershippercentageinsubsidiariesTable" ], "lang": { "en-us": { "role": { "terseLabel": "FSD Strategic Investments Inc in canada Member", "label": "FSDStrategic Investments Inc In Canada Member" } } }, "auth_ref": [] }, "qntm_FVPharmaIncinCanadaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "FVPharmaIncinCanadaMember", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofownershippercentageinsubsidiariesTable" ], "lang": { "en-us": { "role": { "terseLabel": "FV Pharma Inc.in Canada Member", "documentation": "FV Pharma Inc.in Canada Member.", "label": "FVPharma Incin Canada Member" } } }, "auth_ref": [] }, "qntm_FairValueOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "FairValueOfCommonStock", "crdr": "credit", "presentation": [ "http://www.quantumbiopharma.com/role/InvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of common stock", "documentation": "Fair value of common stock.", "label": "Fair Value Of Common Stock" } } }, "auth_ref": [] }, "qntm_FairValueOfConversionFeatureAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "FairValueOfConversionFeatureAmount", "crdr": "credit", "presentation": [ "http://www.quantumbiopharma.com/role/ConvertibledebenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of conversion feature amount", "documentation": "Fair value of conversion feature amount.", "label": "Fair Value Of Conversion Feature Amount" } } }, "auth_ref": [] }, "qntm_FairValueOfDerivativeFinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "FairValueOfDerivativeFinancialLiabilities", "crdr": "credit", "presentation": [ "http://www.quantumbiopharma.com/role/ConvertibledebenturesDetails", "http://www.quantumbiopharma.com/role/ScheduleofconvertibledebenturesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Value of conversion option", "verboseLabel": "Value of conversion", "documentation": "Value of conversion option.", "label": "Fair Value Of Derivative Financial Liabilities" } } }, "auth_ref": [] }, "qntm_FairValueOfFinancialInstrumentsAtInitialRecognition": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "FairValueOfFinancialInstrumentsAtInitialRecognition", "crdr": "credit", "presentation": [ "http://www.quantumbiopharma.com/role/ConvertibledebenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Initial fair value of the warrants", "documentation": "Initial fair value of the warrants.", "label": "Fair Value Of Financial Instruments At Initial Recognition" } } }, "auth_ref": [] }, "qntm_FairValueOfRemainingShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "FairValueOfRemainingShares", "presentation": [ "http://www.quantumbiopharma.com/role/InvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of the remaining shares (in Shares)", "documentation": "Fair value of the remaining shares.", "label": "Fair Value Of Remaining Shares" } } }, "auth_ref": [] }, "qntm_FairValueOfRemainingWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "FairValueOfRemainingWarrants", "presentation": [ "http://www.quantumbiopharma.com/role/WarrantsLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of remaining warrants (in Shares)", "documentation": "Fair value of remaining warrants.", "label": "Fair Value Of Remaining Warrants" } } }, "auth_ref": [] }, "qntm_FairValueOfTheWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "FairValueOfTheWarrants", "crdr": "credit", "presentation": [ "http://www.quantumbiopharma.com/role/ConvertibledebenturesDetails", "http://www.quantumbiopharma.com/role/WarrantsLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of the warrants", "documentation": "Fair value of the warrants.", "label": "Fair Value Of The Warrants" } } }, "auth_ref": [] }, "ifrs-full_FinanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinanceCosts", "crdr": "debit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "ifrs-full_ProfitLossAttributableToNoncontrollingInterests", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Finance expense, net", "label": "Finance costs" } } }, "auth_ref": [ "r210" ] }, "qntm_FirstVestingTrancheShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "FirstVestingTrancheShares", "presentation": [ "http://www.quantumbiopharma.com/role/SharebasedcompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "First vesting tranche shares", "documentation": "First vesting tranche shares.", "label": "First Vesting Tranche Shares" } } }, "auth_ref": [] }, "ifrs-full_ForeignExchangeLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ForeignExchangeLoss", "crdr": "debit", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofinvestmentsTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Effects of foreign exchange", "label": "Foreign exchange loss" } } }, "auth_ref": [ "r7", "r130", "r186" ] }, "qntm_ForeignExchangeRate": { "xbrltype": "perShareItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ForeignExchangeRate", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleoffairvaluedeterminedusingblackscholesoptionTable" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign exchange rate", "documentation": "Foreign exchange rate price per share.", "label": "Foreign Exchange Rate" } } }, "auth_ref": [] }, "qntm_ForeignExchangeRateUsed": { "xbrltype": "percentItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ForeignExchangeRateUsed", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofgainonchangeinfairvalueTable" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign exchange rate", "documentation": "Foreign exchange rate.", "label": "Foreign Exchange Rate Used" } } }, "auth_ref": [] }, "qntm_GainLossOnChangeInFairValueOfDerivativeLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "GainLossOnChangeInFairValueOfDerivativeLiabilities", "crdr": "credit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 12.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow", "http://www.quantumbiopharma.com/role/InvestmentsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Change in fair value of derivative liabilities and warrant liability", "terseLabel": "Loss on change in fair value", "documentation": "Gain (loss) on change in fair value of derivative liabilities.", "label": "Gain Loss On Change In Fair Value Of Derivative Liabilities" } } }, "auth_ref": [] }, "qntm_GainLossOnFinancialInstrumentsAtFairValueThroughProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "GainLossOnFinancialInstrumentsAtFairValueThroughProfitOrLoss", "crdr": "credit", "presentation": [ "http://www.quantumbiopharma.com/role/ConvertibledebenturesDetails", "http://www.quantumbiopharma.com/role/WarrantsLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain on change in fair value", "documentation": "The amount of gain on change in fair value.", "label": "Gain Loss On Financial Instruments At Fair Value Through Profit Or Loss" } } }, "auth_ref": [] }, "qntm_GainLossOnFinancialInstrumentsAtFairValueTotal": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "GainLossOnFinancialInstrumentsAtFairValueTotal", "crdr": "credit", "presentation": [ "http://www.quantumbiopharma.com/role/ConvertibledebenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "gain (loss) on fair value total", "documentation": "The amount of gain (loss) on change in fair value taotal.", "label": "Gain Loss On Financial Instruments At Fair Value Total" } } }, "auth_ref": [] }, "qntm_GainOnSaleOfInvestment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "GainOnSaleOfInvestment", "crdr": "credit", "presentation": [ "http://www.quantumbiopharma.com/role/InvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain on sale of investment", "documentation": "Gain on sale of investment.", "label": "Gain On Sale Of Investment" } } }, "auth_ref": [] }, "qntm_GainOnSettlementOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "GainOnSettlementOfDebt", "crdr": "credit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "ifrs-full_ProfitLossAttributableToNoncontrollingInterests", "weight": 1.0, "order": 4.0 }, "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 16.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow", "http://www.quantumbiopharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "negatedLabel": "Loss (gain) on settlement of debt", "negatedTerseLabel": "(Gain) on settlement of debt", "documentation": "Gain on settlement of debt.", "label": "Gain On Settlement Of Debt" } } }, "auth_ref": [] }, "ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GainsLossesOnChangeInFairValueOfDerivatives", "crdr": "credit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "ifrs-full_ProfitLossAttributableToNoncontrollingInterests", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "negatedLabel": "Loss (gain) in fair value of derivative liabilities and warrant liability", "label": "Gains (losses) on change in fair value of derivatives" } }, "en": { "role": { "documentation": "The gains (losses) resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]" } } }, "auth_ref": [ "r264" ] }, "ifrs-full_GainsLossesOnDisposalsOfInvestments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GainsLossesOnDisposalsOfInvestments", "crdr": "credit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "ifrs-full_ProfitLossAttributableToNoncontrollingInterests", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "negatedLabel": "Realized (gain) on sale of investments", "label": "Gains (losses) on disposals of investments" } }, "en": { "role": { "documentation": "The gains (losses) on disposals of investments." } } }, "auth_ref": [ "r212" ] }, "ifrs-full_GainsLossesOnFairValueAdjustmentInvestmentProperty": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GainsLossesOnFairValueAdjustmentInvestmentProperty", "presentation": [ "http://www.quantumbiopharma.com/role/ConvertibledebenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share price", "label": "Gains (losses) on fair value adjustment, investment property" } }, "en": { "role": { "documentation": "The gains (losses) from changes in the fair value of investment property. [Refer: Investment property]" } } }, "auth_ref": [ "r37", "r144" ] }, "qntm_GainsLossesOnForeignExchangeDifferencesOnTranslationRecognisedInProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "GainsLossesOnForeignExchangeDifferencesOnTranslationRecognisedInProfitOrLoss", "crdr": "credit", "calculation": { "http://www.quantumbiopharma.com/role/ScheduleofgeneralandadministrativeexpenseTable": { "parentTag": "qntm_GeneralAndAdministrativeExpenseContinuedAndDiscontinuedOperations", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofgeneralandadministrativeexpenseTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Foreign exchange loss (gain)", "documentation": "Foreign exchange (gain) loss.", "label": "Gains Losses On Foreign Exchange Differences On Translation Recognised In Profit Or Loss" } } }, "auth_ref": [] }, "ifrs-full_GainsOnDisposalsOfInvestments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GainsOnDisposalsOfInvestments", "crdr": "credit", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofinvestmentsTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Disposals", "label": "Gains on disposals of investments" } }, "en": { "role": { "documentation": "The gain on the disposal of investments." } } }, "auth_ref": [ "r212" ] }, "qntm_GameStopCorpMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "GameStopCorpMember", "presentation": [ "http://www.quantumbiopharma.com/role/InvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "GameStop Corp [Member]", "label": "Game Stop Corp Member" } } }, "auth_ref": [] }, "qntm_GamestopMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "GamestopMember", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofinvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Gamestop [Member]", "label": "Gamestop Member" } } }, "auth_ref": [] }, "qntm_GeneralAndAdministrativeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "GeneralAndAdministrativeAbstract", "lang": { "en-us": { "role": { "label": "General and administrative [abstract]" } } }, "auth_ref": [] }, "qntm_GeneralAndAdministrativeExpenseContinuedAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "GeneralAndAdministrativeExpenseContinuedAndDiscontinuedOperations", "crdr": "debit", "calculation": { "http://www.quantumbiopharma.com/role/ScheduleofgeneralandadministrativeexpenseTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofgeneralandadministrativeexpenseTable" ], "lang": { "en-us": { "role": { "totalLabel": "General and administrative expense", "documentation": "Represents amount of general and administrative expense continued and discontinued operations.", "label": "General And Administrative Expense Continued And Discontinued Operations" } } }, "auth_ref": [] }, "qntm_GeniusGroupLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "GeniusGroupLimitedMember", "presentation": [ "http://www.quantumbiopharma.com/role/InvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Genius Group Limited [Member]", "label": "Genius Group Limited Member" } } }, "auth_ref": [] }, "qntm_GeniusGroupLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "GeniusGroupLtdMember", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofinvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Genius Group Ltd [Member]", "label": "Genius Group Ltd Member" } } }, "auth_ref": [] }, "qntm_GrantDateSharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "GrantDateSharePrice", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleoffairvaluesofoptionsgrantedusingtheBlackScholesoptionpricingmodelTable" ], "lang": { "en-us": { "role": { "terseLabel": "Grant date share price (in Dollars per share)", "documentation": "Grant date share price.", "label": "Grant Date Share Price" } } }, "auth_ref": [] }, "qntm_GrossProceeds": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "GrossProceeds", "crdr": "debit", "presentation": [ "http://www.quantumbiopharma.com/role/DigitalassetsDetails", "http://www.quantumbiopharma.com/role/SharecapitalDetails", "http://www.quantumbiopharma.com/role/WarrantsLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross proceeds", "verboseLabel": "Total gross proceeds", "netLabel": "Gross proceeds (in Dollars)", "documentation": "The amount of gross proceeds to entered into a loan agreement.", "label": "Gross Proceeds" } } }, "auth_ref": [] }, "qntm_GuaranteedInvestmentCertificateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "GuaranteedInvestmentCertificateMember", "presentation": [ "http://www.quantumbiopharma.com/role/InvestmentsDetails", "http://www.quantumbiopharma.com/role/ScheduleofinvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Guaranteed Investment Certificate [Member]", "label": "Guaranteed Investment Certificate Member" } } }, "auth_ref": [] }, "qntm_HugeBiopharmaAustraliaPtyLtdInAustraliaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "HugeBiopharmaAustraliaPtyLtdInAustraliaMember", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofownershippercentageinsubsidiariesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Huge Biopharma Australia Pty Ltd in Australia Member", "documentation": "Huge Biopharma Australia Pty Ltd in Australia Member.", "label": "Huge Biopharma Australia Pty Ltd In Australia Member" } } }, "auth_ref": [] }, "qntm_ISharesSilverTrustMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ISharesSilverTrustMember", "presentation": [ "http://www.quantumbiopharma.com/role/InvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "iShares Silver Trust [Member]", "label": "IShares Silver Trust Member" } } }, "auth_ref": [] }, "ifrs-full_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Profit or loss [abstract]" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseInCashAndCashEquivalents", "crdr": "debit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase (decrease)", "label": "Increase (decrease) in cash and cash equivalents after effect of exchange rate changes" } }, "en": { "role": { "documentation": "The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]" } } }, "auth_ref": [ "r45", "r125" ] }, "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions", "crdr": "credit", "presentation": [ "http://www.quantumbiopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based payments", "label": "Increase (decrease) through share-based payment transactions, equity" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]" } } }, "auth_ref": [ "r182" ] }, "qntm_IncreaseDescreaseInDeferredIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "IncreaseDescreaseInDeferredIncome", "crdr": "credit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 18.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Deferred income", "documentation": "Deferred income", "label": "Increase Descrease In Deferred Income" } } }, "auth_ref": [] }, "qntm_IncurredANetGainOnSettlementOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "IncurredANetGainOnSettlementOfDebt", "crdr": "credit", "presentation": [ "http://www.quantumbiopharma.com/role/SharecapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Incurred a net gain on settlement of debt (in Dollars)", "documentation": "The amount of incurred a net gain on settlement of debt.", "label": "Incurred ANet Gain On Settlement Of Debt" } } }, "auth_ref": [] }, "qntm_InformationOfWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "InformationOfWarrantMember", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofchangesinsharecapitalTable" ], "lang": { "en-us": { "role": { "terseLabel": "Information Of Warrant [Member]", "label": "Information Of Warrant Member" } } }, "auth_ref": [] }, "qntm_InitialRecognitionOfCompoundFinancialInstruments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "InitialRecognitionOfCompoundFinancialInstruments", "crdr": "credit", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofconvertibledebenturesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Initial recognition of debt", "documentation": "The amount of initial recognition of debt.", "label": "Initial Recognition Of Compound Financial Instruments" } } }, "auth_ref": [] }, "qntm_InitialValueAllocatedToWarrant": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "InitialValueAllocatedToWarrant", "crdr": "debit", "presentation": [ "http://www.quantumbiopharma.com/role/ConvertibledebenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Initial value allocated to the warrant", "documentation": "Initial value allocated to the warrant.", "label": "Initial Value Allocated To Warrant" } } }, "auth_ref": [] }, "qntm_InnovetMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "InnovetMember", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofintangibleassetsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Innovet [Member]", "label": "Innovet Member" } } }, "auth_ref": [] }, "qntm_IntangibleAssetOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "IntangibleAssetOtherThanGoodwill", "crdr": "debit", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofintangibleassetsTable" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance", "periodEndLabel": "Balance", "documentation": "The amount of intangible asset other than goodwill.", "label": "Intangible Asset Other Than Goodwill" } } }, "auth_ref": [] }, "ifrs-full_IntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IntangibleAssetsOtherThanGoodwill", "crdr": "debit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet", "http://www.quantumbiopharma.com/role/ScheduleofintangibleassetsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets, net", "verboseLabel": "Net book value", "label": "Intangible assets other than goodwill" } }, "en": { "role": { "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]" } } }, "auth_ref": [ "r32", "r141", "r188" ] }, "qntm_IntangibleassetsScheduleofintangibleassetsDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "IntangibleassetsScheduleofintangibleassetsDetailsLineItems", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofintangibleassetsTable" ], "lang": { "en-us": { "role": { "label": "Intangible assets - Schedule of intangible assets (Details) [Line Items]" } } }, "auth_ref": [] }, "qntm_IntangibleassetsScheduleofintangibleassetsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "IntangibleassetsScheduleofintangibleassetsDetailsTable", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofintangibleassetsTable" ], "lang": { "en-us": { "role": { "label": "Intangible assets - Schedule of intangible assets (Details) [Table]" } } }, "auth_ref": [] }, "ifrs-full_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestExpense", "crdr": "debit", "presentation": [ "http://www.quantumbiopharma.com/role/ConvertibledebenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense", "label": "Interest expense" } }, "en": { "role": { "documentation": "The amount of expense arising from interest." } } }, "auth_ref": [ "r65", "r105", "r111" ] }, "qntm_InterestPenalty": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "InterestPenalty", "crdr": "debit", "presentation": [ "http://www.quantumbiopharma.com/role/ConvertibledebenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest penalty", "documentation": "Interest penalty.", "label": "Interest Penalty" } } }, "auth_ref": [] }, "qntm_InterestRateCreditSpreadComponent": { "xbrltype": "percentItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "InterestRateCreditSpreadComponent", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofgainonchangeinfairvalueTable" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Spread", "documentation": "Credit spread percentage.", "label": "Interest Rate Credit Spread Component" } } }, "auth_ref": [] }, "ifrs-full_InterestReceivable": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestReceivable", "crdr": "debit", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofotherreceivablesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Interest receivable", "label": "Interest receivable" } }, "en": { "role": { "documentation": "The amount of interest recognised as a receivable." } } }, "auth_ref": [ "r258" ] }, "ifrs-full_InterestRevenueExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestRevenueExpense", "crdr": "credit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "ifrs-full_ProfitLossAttributableToNoncontrollingInterests", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest expense (income)", "label": "Interest income (expense), operating" } } }, "auth_ref": [ "r107", "r111", "r264" ] }, "ifrs-full_Inventories": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Inventories", "crdr": "debit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory", "label": "Current inventories" } }, "en": { "role": { "documentation": "The amount of current inventories. [Refer: Inventories]" } } }, "auth_ref": [ "r6", "r123", "r189", "r235" ] }, "qntm_InvestedDigitalAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "InvestedDigitalAssets", "crdr": "debit", "presentation": [ "http://www.quantumbiopharma.com/role/DigitalassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Invested in additional digital assets", "documentation": "The amount of invested digital assets.", "label": "Invested Digital Assets" } } }, "auth_ref": [] }, "qntm_InvestmentSharePricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "InvestmentSharePricePerShare", "presentation": [ "http://www.quantumbiopharma.com/role/InvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment share price per share (in Dollars per share)", "documentation": "Investment share price per share.", "label": "Investment Share Price Per Share" } } }, "auth_ref": [] }, "qntm_InvestmentsDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "InvestmentsDetailsLineItems", "presentation": [ "http://www.quantumbiopharma.com/role/InvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Investments (Details) [Line Items]" } } }, "auth_ref": [] }, "qntm_InvestmentsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "InvestmentsDetailsTable", "presentation": [ "http://www.quantumbiopharma.com/role/InvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Investments (Details) [Table]" } } }, "auth_ref": [] }, "ifrs-full_InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod", "crdr": "debit", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofinvestmentsTable" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Investments other than investments accounted for using equity method" } }, "en": { "role": { "documentation": "The amount of investments other than investments accounted for using the equity method. [Refer: Investments accounted for using equity method]" } } }, "auth_ref": [ "r260" ] }, "qntm_InvestmentsScheduleoffairvalueofwarrantsoptionpricingmodelassumptionsDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "InvestmentsScheduleoffairvalueofwarrantsoptionpricingmodelassumptionsDetailsLineItems", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleoffairvalueofwarrantsoptionpricingmodelassumptionsTable" ], "lang": { "en-us": { "role": { "label": "Investments - Schedule of fair value of warrants option pricing model assumptions (Details) [Line Items]" } } }, "auth_ref": [] }, "qntm_InvestmentsScheduleoffairvalueofwarrantsoptionpricingmodelassumptionsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "InvestmentsScheduleoffairvalueofwarrantsoptionpricingmodelassumptionsDetailsTable", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleoffairvalueofwarrantsoptionpricingmodelassumptionsTable" ], "lang": { "en-us": { "role": { "label": "Investments - Schedule of fair value of warrants option pricing model assumptions (Details) [Table]" } } }, "auth_ref": [] }, "qntm_InvestmentsScheduleofinvestmentsDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "InvestmentsScheduleofinvestmentsDetailsLineItems", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofinvestmentsTable" ], "lang": { "en-us": { "role": { "label": "Investments - Schedule of investments (Details) [Line Items]" } } }, "auth_ref": [] }, "qntm_InvestmentsScheduleofinvestmentsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "InvestmentsScheduleofinvestmentsDetailsTable", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofinvestmentsTable" ], "lang": { "en-us": { "role": { "label": "Investments - Schedule of investments (Details) [Table]" } } }, "auth_ref": [] }, "qntm_InvestorRelationsExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "InvestorRelationsExpenses", "crdr": "debit", "calculation": { "http://www.quantumbiopharma.com/role/ScheduleofgeneralandadministrativeexpenseTable": { "parentTag": "qntm_GeneralAndAdministrativeExpenseContinuedAndDiscontinuedOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofgeneralandadministrativeexpenseTable" ], "lang": { "en-us": { "role": { "terseLabel": "Investor relations", "documentation": "Information about investor relations.", "label": "Investor Relations Expenses" } } }, "auth_ref": [] }, "qntm_IssuanceOfConvertibleInstruments": { "xbrltype": "sharesItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "IssuanceOfConvertibleInstruments", "presentation": [ "http://www.quantumbiopharma.com/role/ConvertibledebenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of convertible debentures issued (in Shares)", "documentation": "Number of convertible debentures issued.", "label": "Issuance Of Convertible Instruments" } } }, "auth_ref": [] }, "ifrs-full_IssueOfConvertibleInstruments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IssueOfConvertibleInstruments", "crdr": "credit", "presentation": [ "http://www.quantumbiopharma.com/role/ConvertibledebenturesDetails", "http://www.quantumbiopharma.com/role/SharecapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total gross proceeds", "verboseLabel": "Proceeds from convertible debentures (in Dollars)", "label": "Issue of convertible instruments" } }, "en": { "role": { "documentation": "The change in equity resulting from the issuing of convertible instruments." } } }, "auth_ref": [ "r257" ] }, "ifrs-full_IssueOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IssueOfEquity", "crdr": "credit", "presentation": [ "http://www.quantumbiopharma.com/role/InvestmentsDetails", "http://www.quantumbiopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued", "verboseLabel": "Share value", "label": "Issue of equity" } }, "en": { "role": { "documentation": "The increase in equity through the issue of equity instruments." } } }, "auth_ref": [ "r182" ] }, "qntm_IssuedBonusShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "IssuedBonusShares", "presentation": [ "http://www.quantumbiopharma.com/role/RelatedpartytransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issued bonus shares (in Shares)", "documentation": "Issued bonus shares.", "label": "Issued Bonus Shares" } } }, "auth_ref": [] }, "ifrs-full_IssuedCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IssuedCapital", "crdr": "credit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Share capital", "label": "Issued capital" } }, "en": { "role": { "documentation": "The nominal value of capital issued." } } }, "auth_ref": [ "r231", "r238" ] }, "ifrs-full_IssuedCapitalMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IssuedCapitalMember", "presentation": [ "http://www.quantumbiopharma.com/role/CapitalManagementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issued capital [member]", "label": "Issued capital [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing issued capital." } } }, "auth_ref": [ "r183" ] }, "ifrs-full_IssuedCapitalOrdinaryShares": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IssuedCapitalOrdinaryShares", "crdr": "credit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet", "http://www.quantumbiopharma.com/role/ScheduleofchangesinsharecapitalTable" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance (in Dollars)", "periodEndLabel": "Balance (in Dollars)", "terseLabel": "Class A Multiple Voting Shares to be issued", "label": "Issued capital, ordinary shares" } }, "en": { "role": { "documentation": "The nominal value of capital arising from issuing ordinary shares. [Refer: Issued capital]" } } }, "auth_ref": [ "r262" ] }, "ifrs-full_IssuedCapitalPreferenceShares": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IssuedCapitalPreferenceShares", "crdr": "credit", "presentation": [ "http://www.quantumbiopharma.com/role/SharebasedcompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Surplus amount transfer to share capital (in Dollars)", "label": "Issued capital, preference shares" } }, "en": { "role": { "documentation": "The nominal value of capital arising from issuing preference shares. [Refer: Issued capital]" } } }, "auth_ref": [ "r262" ] }, "qntm_IssuedWarrantsAttachedToItsConvertibleDebenture": { "xbrltype": "sharesItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "IssuedWarrantsAttachedToItsConvertibleDebenture", "presentation": [ "http://www.quantumbiopharma.com/role/WarrantsLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issued warrants attached to convertible debenture (in Shares)", "documentation": "Issued warrants attached to convertible debenture.", "label": "Issued Warrants Attached To Its Convertible Debenture" } } }, "auth_ref": [] }, "qntm_ItemsThatMayBeSubsequentlyReclassifiedToLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ItemsThatMayBeSubsequentlyReclassifiedToLossAbstract", "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Items that may be subsequently reclassified to loss:", "label": "Items That May Be Subsequently Reclassified To Loss Abstract" } } }, "auth_ref": [] }, "qntm_JZRGoldIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "JZRGoldIncMember", "presentation": [ "http://www.quantumbiopharma.com/role/InvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "JZR Gold Inc [Member]", "label": "JZRGold Inc Member" } } }, "auth_ref": [] }, "qntm_JZRGoldWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "JZRGoldWarrantsMember", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofinvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "JZR Gold [Member]", "label": "JZRGold Warrants Member" } } }, "auth_ref": [] }, "qntm_January2025DebenturesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "January2025DebenturesMember", "presentation": [ "http://www.quantumbiopharma.com/role/SharecapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "January 2025 Debentures [Member]", "label": "January2025 Debentures Member" } } }, "auth_ref": [] }, "qntm_JanuaryTwentiethTwentyTwentyFiveMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "JanuaryTwentiethTwentyTwentyFiveMember", "presentation": [ "http://www.quantumbiopharma.com/role/WarrantsLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "January 20, 2025 Warrants [Member]", "verboseLabel": "January twentieth, twenty twenty five [Member]", "label": "January Twentieth Twenty Twenty Five Member" } } }, "auth_ref": [] }, "qntm_JanuaryTwentyTwentyFiveMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "JanuaryTwentyTwentyFiveMember", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleoffairvaluedeterminedusingblackscholesoptionTable" ], "lang": { "en-us": { "role": { "terseLabel": "January 2025 Warrants [Member]", "label": "January Twenty Twenty Five Member" } } }, "auth_ref": [] }, "ifrs-full_KeyManagementPersonnelCompensation": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "KeyManagementPersonnelCompensation", "crdr": "debit", "calculation": { "http://www.quantumbiopharma.com/role/ScheduleofkeymanagementpersonnelcompensationTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofkeymanagementpersonnelcompensationTable" ], "lang": { "en-us": { "role": { "totalLabel": "Key management personnel compensation", "label": "Key management personnel compensation, operating" } } }, "auth_ref": [ "r11", "r132" ] }, "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "KeyManagementPersonnelCompensationSharebasedPayment", "crdr": "debit", "calculation": { "http://www.quantumbiopharma.com/role/ScheduleofkeymanagementpersonnelcompensationTable": { "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofkeymanagementpersonnelcompensationTable", "http://www.quantumbiopharma.com/role/SharebasedcompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based payments", "verboseLabel": "Share based compensation (in Dollars)", "label": "Key management personnel compensation, share-based payment" } } }, "auth_ref": [ "r10" ] }, "ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "crdr": "debit", "calculation": { "http://www.quantumbiopharma.com/role/ScheduleofkeymanagementpersonnelcompensationTable": { "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofkeymanagementpersonnelcompensationTable" ], "lang": { "en-us": { "role": { "terseLabel": "Salaries, benefits, bonuses and consulting fees", "label": "Key management personnel compensation, short-term employee benefits, operating" } } }, "auth_ref": [ "r9" ] }, "qntm_LINKMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "LINKMember", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofchangesindigitalassetsbalanceTable" ], "lang": { "en-us": { "role": { "terseLabel": "LINK [Member]", "label": "LINKMember" } } }, "auth_ref": [] }, "ifrs-full_Level1OfFairValueHierarchyMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Level1OfFairValueHierarchyMember", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleoffairvaluehierarchyTable" ], "lang": { "en-us": { "role": { "terseLabel": "Level 1 of fair value hierarchy [member]", "label": "Level 1 of fair value hierarchy [member]" } }, "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date." } } }, "auth_ref": [ "r5", "r26", "r27", "r69", "r137", "r169" ] }, "ifrs-full_Level2OfFairValueHierarchyMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Level2OfFairValueHierarchyMember", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleoffairvaluehierarchyTable" ], "lang": { "en-us": { "role": { "terseLabel": "Level 2 of fair value hierarchy [member]", "label": "Level 2 of fair value hierarchy [member]" } }, "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly." } } }, "auth_ref": [ "r26", "r27", "r69", "r137", "r169" ] }, "ifrs-full_Level3OfFairValueHierarchyMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Level3OfFairValueHierarchyMember", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleoffairvaluehierarchyTable" ], "lang": { "en-us": { "role": { "terseLabel": "Level 3 of fair value hierarchy [member]", "label": "Level 3 of fair value hierarchy [member]" } }, "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are unobservable inputs for the asset or liability. Unobservable inputs are inputs for which market data are not available and that are developed using the best information available about the assumptions that the market participants would use when pricing the asset or liability." } } }, "auth_ref": [ "r26", "r27", "r69", "r137", "r169" ] }, "ifrs-full_LevelsOfFairValueHierarchyAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LevelsOfFairValueHierarchyAxis", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleoffairvaluehierarchyTable" ], "lang": { "en-us": { "role": { "label": "Levels of fair value hierarchy [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r5", "r69", "r169" ] }, "ifrs-full_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities" } }, "en": { "role": { "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } } }, "auth_ref": [ "r68", "r69", "r70", "r107", "r110", "r168", "r169", "r195" ] }, "ifrs-full_LiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LiabilitiesAbstract", "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES", "label": "Liabilities [abstract]" } } }, "auth_ref": [] }, "qntm_LicenseMaintenanceFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "LicenseMaintenanceFee", "crdr": "debit", "presentation": [ "http://www.quantumbiopharma.com/role/CommitmentsandcontingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "License maintenance fee (in Dollars)", "documentation": "Represents amount of license maintenance fee.", "label": "License Maintenance Fee" } } }, "auth_ref": [] }, "ifrs-full_LongtermDeposits": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LongtermDeposits", "crdr": "debit", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofinvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Long term deposits", "label": "Long-term deposits" } }, "en": { "role": { "documentation": "The amount of long-term deposits held by the entity." } } }, "auth_ref": [ "r260" ] }, "qntm_LossOnIssuanceOfConvertible": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "LossOnIssuanceOfConvertible", "crdr": "credit", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofconvertibledebenturesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Loss on issuance of convertible", "documentation": "Loss on issuance of convertible.", "label": "Loss On Issuance Of Convertible" } } }, "auth_ref": [] }, "qntm_LossOnIssuanceOfConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "LossOnIssuanceOfConvertibleDebt", "crdr": "debit", "presentation": [ "http://www.quantumbiopharma.com/role/ConvertibledebenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss on issuance of convertible debt", "documentation": "The amount of loss on issuance of convertible debt.", "label": "Loss On Issuance Of Convertible Debt" } } }, "auth_ref": [] }, "qntm_LosspershareScheduleoflosspershareDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "LosspershareScheduleoflosspershareDetailsLineItems", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleoflosspershareTable" ], "lang": { "en-us": { "role": { "label": "Loss per share - Schedule of loss per share (Details) [Line Items]" } } }, "auth_ref": [] }, "qntm_LosspershareScheduleoflosspershareDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "LosspershareScheduleoflosspershareDetailsTable", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleoflosspershareTable" ], "lang": { "en-us": { "role": { "label": "Loss per share - Schedule of loss per share (Details) [Table]" } } }, "auth_ref": [] }, "qntm_LucidMsAndLucidPsychMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "LucidMsAndLucidPsychMember", "presentation": [ "http://www.quantumbiopharma.com/role/CommitmentsandcontingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lucid Ms And Lucid Psych [Member]", "label": "Lucid Ms And Lucid Psych Member" } } }, "auth_ref": [] }, "qntm_LucidMsAndLucidPsychTopMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "LucidMsAndLucidPsychTopMember", "presentation": [ "http://www.quantumbiopharma.com/role/CommitmentsandcontingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lucid Ms And Lucid Psych Top [Member]", "label": "Lucid Ms And Lucid Psych Top Member" } } }, "auth_ref": [] }, "qntm_LucidPsycheceuticalsIncInCanadaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "LucidPsycheceuticalsIncInCanadaMember", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofownershippercentageinsubsidiariesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Lucid Psycheceuticals Inc. in Canada Member", "documentation": "Lucid Psycheceuticals Inc. in Canada Member.", "label": "Lucid Psycheceuticals Inc In Canada Member" } } }, "auth_ref": [] }, "qntm_March202026DebenturesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "March202026DebenturesMember", "presentation": [ "http://www.quantumbiopharma.com/role/ConvertibledebenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "March 20, 2026 Debentures [Member]", "label": "March202026 Debentures Member" } } }, "auth_ref": [] }, "qntm_March2026DebentureUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "March2026DebentureUnitsMember", "presentation": [ "http://www.quantumbiopharma.com/role/ConvertibledebenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "March 2026 Debenture Units [Member]", "label": "March2026 Debenture Units Member" } } }, "auth_ref": [] }, "qntm_March2026DebentureUnitsOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "March2026DebentureUnitsOneMember", "presentation": [ "http://www.quantumbiopharma.com/role/ConvertibledebenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "March 2026 Debenture Units [Member]", "label": "March2026 Debenture Units One Member" } } }, "auth_ref": [] }, "qntm_March2026DebenturesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "March2026DebenturesMember", "presentation": [ "http://www.quantumbiopharma.com/role/SharecapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "March 2026 Debentures [Member]", "label": "March2026 Debentures Member" } } }, "auth_ref": [] }, "qntm_March282025DebenturesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "March282025DebenturesMember", "presentation": [ "http://www.quantumbiopharma.com/role/SharecapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "March 28, 2025 Debentures [Member]", "label": "March282025 Debentures Member" } } }, "auth_ref": [] }, "qntm_March62025DebenturesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "March62025DebenturesMember", "presentation": [ "http://www.quantumbiopharma.com/role/SharecapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "March 6, 2025 Debentures [Member]", "label": "March62025 Debentures Member" } } }, "auth_ref": [] }, "qntm_March62025December2024DebenturesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "March62025December2024DebenturesMember", "presentation": [ "http://www.quantumbiopharma.com/role/SharecapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "March 6, 2025 December 2024 Debentures [Member]", "label": "March62025 December2024 Debentures Member" } } }, "auth_ref": [] }, "qntm_MarchSixthTwoThousandTwentyFiveMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "MarchSixthTwoThousandTwentyFiveMember", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleoffairvaluedeterminedusingblackscholesoptionTable", "http://www.quantumbiopharma.com/role/WarrantsLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "March 6, 2025 Warrants [Member]", "verboseLabel": "March sixth, two thousand twenty five [Member]", "label": "March Sixth Two Thousand Twenty Five Member" } } }, "auth_ref": [] }, "qntm_MarchTwentiethTwoThousandTwentyFiveMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "MarchTwentiethTwoThousandTwentyFiveMember", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleoffairvaluedeterminedusingblackscholesoptionTable" ], "lang": { "en-us": { "role": { "terseLabel": "March 28, 2025 Warrants [Member]", "label": "March Twentieth Two Thousand Twenty Five Member" } } }, "auth_ref": [] }, "qntm_MarchTwentyEightTwoThousandTwentyFiveMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "MarchTwentyEightTwoThousandTwentyFiveMember", "presentation": [ "http://www.quantumbiopharma.com/role/WarrantsLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "March 28, 2025 Warrants [Member]", "verboseLabel": "March twenty eight, two thousand twenty five [Member]", "netLabel": "August 2020 Warrants [Member]", "label": "March Twenty Eight Two Thousand Twenty Five Member" } } }, "auth_ref": [] }, "qntm_MarchTwentyTwentySixWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "MarchTwentyTwentySixWarrantsMember", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleoffairvaluedeterminedusingblackscholesoptionTable" ], "lang": { "en-us": { "role": { "terseLabel": "March 20, 2026 Warrants [Member]", "label": "March Twenty Twenty Six Warrants Member" } } }, "auth_ref": [] }, "qntm_MarchTwentyTwoThousandTwentySixMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "MarchTwentyTwoThousandTwentySixMember", "presentation": [ "http://www.quantumbiopharma.com/role/WarrantsLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "March Twenty Two Thousand Twenty Six Member", "label": "March Twenty Two Thousand Twenty Six Member" } } }, "auth_ref": [] }, "qntm_MaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "MaturityDate", "presentation": [ "http://www.quantumbiopharma.com/role/InvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maturity date", "documentation": "Maturity date.", "label": "Maturity Date" } } }, "auth_ref": [] }, "qntm_MaximumMilestonePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "MaximumMilestonePayments", "crdr": "credit", "presentation": [ "http://www.quantumbiopharma.com/role/CommitmentsandcontingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum milestone payments (in Dollars)", "documentation": "Maximum milestone payments.", "label": "Maximum Milestone Payments" } } }, "auth_ref": [] }, "qntm_MinimumMilestonePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "MinimumMilestonePayments", "crdr": "credit", "presentation": [ "http://www.quantumbiopharma.com/role/CommitmentsandcontingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum milestone payments", "documentation": "Minimum milestone payments.", "label": "Minimum Milestone Payments" } } }, "auth_ref": [] }, "qntm_MultipleVotingShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "MultipleVotingShares", "presentation": [ "http://www.quantumbiopharma.com/role/SharecapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Multiple voting shares", "documentation": "Multiple voting shares.", "label": "Multiple Voting Shares" } } }, "auth_ref": [] }, "qntm_NatureofbusinessDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "NatureofbusinessDetailsLineItems", "presentation": [ "http://www.quantumbiopharma.com/role/NatureofbusinessDetails" ], "lang": { "en-us": { "role": { "label": "Nature of business (Details) [Line Items]" } } }, "auth_ref": [] }, "qntm_NatureofbusinessDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "NatureofbusinessDetailsTable", "presentation": [ "http://www.quantumbiopharma.com/role/NatureofbusinessDetails" ], "lang": { "en-us": { "role": { "label": "Nature of business (Details) [Table]" } } }, "auth_ref": [] }, "qntm_NatureofbusinessScheduleofownershippercentageinsubsidiariesDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "NatureofbusinessScheduleofownershippercentageinsubsidiariesDetailsLineItems", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofownershippercentageinsubsidiariesTable" ], "lang": { "en-us": { "role": { "label": "Nature of business - Schedule of ownership percentage in subsidiaries (Details) [Line Items]" } } }, "auth_ref": [] }, "qntm_NatureofbusinessScheduleofownershippercentageinsubsidiariesDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "NatureofbusinessScheduleofownershippercentageinsubsidiariesDetailsTable", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofownershippercentageinsubsidiariesTable" ], "lang": { "en-us": { "role": { "label": "Nature of business - Schedule of ownership percentage in subsidiaries (Details) [Table]" } } }, "auth_ref": [] }, "qntm_NetLossAttributableToAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "NetLossAttributableToAbstract", "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss attributable to:", "label": "Net Loss Attributable To Abstract" } } }, "auth_ref": [] }, "qntm_NetLossPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "NetLossPerShareAbstract", "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Net (loss) per share", "label": "Net Loss Per Share Abstract" } } }, "auth_ref": [] }, "qntm_NonCashTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "NonCashTransactionsAbstract", "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash transactions", "documentation": "Noncash Transactions Abstract", "label": "Non Cash Transactions Abstract" } } }, "auth_ref": [] }, "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NonadjustingEventsAfterReportingPeriodAxis", "presentation": [ "http://www.quantumbiopharma.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "label": "Non-adjusting events after reporting period [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r0", "r127" ] }, "ifrs-full_NonadjustingEventsAfterReportingPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NonadjustingEventsAfterReportingPeriodDomain", "presentation": [ "http://www.quantumbiopharma.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "label": "Non-adjusting events after reporting period [domain]" } }, "en": { "role": { "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used." } } }, "auth_ref": [ "r0", "r127" ] }, "ifrs-full_NoncontrollingInterests": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncontrollingInterests", "crdr": "credit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet", "http://www.quantumbiopharma.com/role/ScheduleofreconciliationofnoncontrollinginterestTable" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance", "periodEndLabel": "Balance", "terseLabel": "Non-controlling interests", "label": "Non-controlling interests" } }, "en": { "role": { "documentation": "The amount of equity in a subsidiary not attributable, directly or indirectly, to a parent. [Refer: Total for all subsidiaries [member]]" } } }, "auth_ref": [ "r52", "r55", "r193" ] }, "qntm_NoncontrollingInterestsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "NoncontrollingInterestsAbstract", "lang": { "en-us": { "role": { "label": "Non-controlling interests [abstract]" } } }, "auth_ref": [] }, "ifrs-full_NoncontrollingInterestsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncontrollingInterestsMember", "presentation": [ "http://www.quantumbiopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Non-controlling interests", "label": "Non-controlling interests [member]" } }, "en": { "role": { "documentation": "This member stands for equity in a subsidiary not attributable, directly or indirectly, to the parent." } } }, "auth_ref": [ "r183" ] }, "ifrs-full_NoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentAssets", "crdr": "debit", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofassetandincomebysegmentTable" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current assets", "label": "Non-current assets" } }, "en": { "role": { "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]" } } }, "auth_ref": [ "r58", "r196", "r221" ] }, "ifrs-full_NoncurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentAssetsAbstract", "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current assets", "label": "Non-current assets [abstract]" } } }, "auth_ref": [] }, "ifrs-full_NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod", "crdr": "debit", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofinvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Non current", "label": "Non-current investments other than investments accounted for using equity method" } }, "en": { "role": { "documentation": "The amount of non-current investments other than investments accounted for using the equity method. [Refer: Investments accounted for using equity method; Non-current assets; Investments other than investments accounted for using equity method]" } } }, "auth_ref": [ "r260" ] }, "ifrs-full_NotesAndDebenturesIssued": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NotesAndDebenturesIssued", "crdr": "credit", "presentation": [ "http://www.quantumbiopharma.com/role/SharecapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Notes and debentures issued (in Dollars)", "label": "Notes and debentures issued" } }, "en": { "role": { "documentation": "The amount of notes and debentures issued by the entity." } } }, "auth_ref": [ "r258" ] }, "ifrs-full_NotesAndOtherExplanatoryInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NotesAndOtherExplanatoryInformationAbstract", "lang": { "en-us": { "role": { "label": "Notes and other explanatory information [abstract]" } } }, "auth_ref": [] }, "qntm_NotesPayableAccruedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "NotesPayableAccruedInterest", "crdr": "credit", "presentation": [ "http://www.quantumbiopharma.com/role/NotespayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued interest", "documentation": "The amount of accrued interest.", "label": "Notes Payable Accrued Interest" } } }, "auth_ref": [] }, "qntm_NotesPayableAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "NotesPayableAmount", "crdr": "credit", "presentation": [ "http://www.quantumbiopharma.com/role/NotespayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Notes payable balance", "documentation": "The amount of notes payable amount.", "label": "Notes Payable Amount" } } }, "auth_ref": [] }, "qntm_NotesPayableObtainedLoanFromPrimaryCustodian": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "NotesPayableObtainedLoanFromPrimaryCustodian", "crdr": "debit", "presentation": [ "http://www.quantumbiopharma.com/role/NotespayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Obtained loan from primary custodian", "documentation": "The amount of notes payable obtained loan from primary custodian.", "label": "Notes Payable Obtained Loan From Primary Custodian" } } }, "auth_ref": [] }, "qntm_NotespayableDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "NotespayableDetailsLineItems", "presentation": [ "http://www.quantumbiopharma.com/role/NotespayableDetails" ], "lang": { "en-us": { "role": { "label": "Notes payable (Details) [Line Items]" } } }, "auth_ref": [] }, "qntm_NotespayableDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "NotespayableDetailsTable", "presentation": [ "http://www.quantumbiopharma.com/role/NotespayableDetails" ], "lang": { "en-us": { "role": { "label": "Notes payable (Details) [Table]" } } }, "auth_ref": [] }, "qntm_NumberOfCommonSharesConverted": { "xbrltype": "decimalItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "NumberOfCommonSharesConverted", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleoffairvaluesofPSUsgrantedusingtheBlackScholesoptionpricingmodelTable" ], "lang": { "en-us": { "role": { "terseLabel": "Converted to common shares", "documentation": "Converted to Class B Common shares.", "label": "Number Of Common Shares Converted" } } }, "auth_ref": [] }, "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleoffairvaluesofPSUsgrantedusingtheBlackScholesoptionpricingmodelTable" ], "lang": { "en-us": { "role": { "terseLabel": "Granted", "label": "Number of other equity instruments granted in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement." } } }, "auth_ref": [ "r93", "r254" ] }, "qntm_NumberOfIssuedCapitalOrdinaryShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "NumberOfIssuedCapitalOrdinaryShares", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofchangesinsharecapitalTable" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance", "periodEndLabel": "Balance", "documentation": "Number of issued capital ordinary shares.", "label": "Number Of Issued Capital Ordinary Shares" } } }, "auth_ref": [] }, "qntm_NumberOfOperatesSegments": { "xbrltype": "integerItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "NumberOfOperatesSegments", "presentation": [ "http://www.quantumbiopharma.com/role/SegmentinformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of operates segments", "documentation": "Number of operates segments.", "label": "Number Of Operates Segments" } } }, "auth_ref": [] }, "qntm_NumberOfOptionOutstandingShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "NumberOfOptionOutstandingShares", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofcompanysshareoptionsoutstandingTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number outstanding", "documentation": "Number of option outstanding shares.", "label": "Number Of Option Outstanding Shares" } } }, "auth_ref": [] }, "ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleoffairvaluesofPSUsgrantedusingtheBlackScholesoptionpricingmodelTable" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding", "label": "Number of other equity instruments outstanding in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement." } } }, "auth_ref": [ "r254" ] }, "ifrs-full_NumberOfOutstandingShareOptions": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfOutstandingShareOptions", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleoffairvaluesofPSUsgrantedusingtheBlackScholesoptionpricingmodelTable", "http://www.quantumbiopharma.com/role/ScheduleofnumberofshareoptionsoutstandingTable" ], "lang": { "en-us": { "role": { "periodStartLabel": "Number of options, Outstanding Ending", "periodEndLabel": "Outstanding", "terseLabel": "Number of options, Outstanding Ending", "label": "Number of share options outstanding in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of share options outstanding in a share-based payment arrangement." } } }, "auth_ref": [ "r81", "r86", "r89", "r153", "r158" ] }, "qntm_NumberOfShareOptionGrantedInShareBasedPaymentArrangement": { "xbrltype": "sharesItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "NumberOfShareOptionGrantedInShareBasedPaymentArrangement", "presentation": [ "http://www.quantumbiopharma.com/role/SharebasedcompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of share granted", "documentation": "Number of share granted.", "label": "Number Of Share Option Granted In Share Based Payment Arrangement" } } }, "auth_ref": [] }, "ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfShareOptionsExercisableInSharebasedPaymentArrangement", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofcompanysshareoptionsoutstandingTable", "http://www.quantumbiopharma.com/role/ScheduleofnumberofshareoptionsoutstandingTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number of options, Exercisable", "verboseLabel": "Number exercisable\t(in exercisable)", "label": "Number of share options exercisable in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of share options exercisable in a share-based payment arrangement." } } }, "auth_ref": [ "r87", "r159" ] }, "ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfShareOptionsExercisedInSharebasedPaymentArrangement", "presentation": [ "http://www.quantumbiopharma.com/role/SharebasedcompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share options were exercised (in options)", "label": "Number of share options exercised in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of share options exercised in a share-based payment arrangement." } } }, "auth_ref": [ "r84", "r156" ] }, "ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfShareOptionsExpiredInSharebasedPaymentArrangement", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofnumberofshareoptionsoutstandingTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of options, Expired", "label": "Number of share options expired in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of share options expired in a share-based payment arrangement." } } }, "auth_ref": [ "r85", "r157" ] }, "ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofnumberofshareoptionsoutstandingTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of options,Cancelled", "label": "Number of share options forfeited in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of share options forfeited in a share-based payment arrangement." } } }, "auth_ref": [ "r83", "r155" ] }, "ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfShareOptionsGrantedInSharebasedPaymentArrangement", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofnumberofshareoptionsoutstandingTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number of options, Granted", "label": "Number of share options granted in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of share options granted in a share-based payment arrangement." } } }, "auth_ref": [ "r82", "r154" ] }, "qntm_NumberOfShareOptionsGrantedInSharebasedPaymentArrangements": { "xbrltype": "integerItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "NumberOfShareOptionsGrantedInSharebasedPaymentArrangements", "presentation": [ "http://www.quantumbiopharma.com/role/SharebasedcompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of share-based payment granted share option (in individual)", "documentation": "Number of share-based payment granted share option.", "label": "Number Of Share Options Granted In Sharebased Payment Arrangements" } } }, "auth_ref": [] }, "qntm_NumberOfShareOptionsOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "NumberOfShareOptionsOutstanding", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofcompanysshareoptionsoutstandingTable" ], "lang": { "en-us": { "role": { "terseLabel": "Options outstanding, Exercise price", "documentation": "Options outstanding, exercise price.", "label": "Number Of Share Options Outstanding" } } }, "auth_ref": [] }, "qntm_NumberOfSharesAcquired": { "xbrltype": "sharesItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "NumberOfSharesAcquired", "presentation": [ "http://www.quantumbiopharma.com/role/InvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares acquired (in Shares)", "documentation": "Number of shares acquired.", "label": "Number Of Shares Acquired" } } }, "auth_ref": [] }, "qntm_NumberOfSharesGranted": { "xbrltype": "sharesItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "NumberOfSharesGranted", "presentation": [ "http://www.quantumbiopharma.com/role/RelatedpartytransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of performance share units granted (in Shares)", "documentation": "Repr\u00e4sentant the number of performance share units granted.", "label": "Number Of Shares Granted" } } }, "auth_ref": [] }, "ifrs-full_NumberOfSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfSharesIssued", "presentation": [ "http://www.quantumbiopharma.com/role/InvestmentsDetails", "http://www.quantumbiopharma.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchased shares (in Shares)", "verboseLabel": "Number of shares issued", "label": "Number of shares issued" } }, "en": { "role": { "documentation": "The number of shares issued by the entity." } } }, "auth_ref": [ "r257" ] }, "ifrs-full_NumberOfSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfSharesOutstanding", "presentation": [ "http://www.quantumbiopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance (in Shares)", "periodEndLabel": "Balance (in Shares)", "label": "Number of shares outstanding" } }, "en": { "role": { "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]" } } }, "auth_ref": [ "r119", "r172", "r202" ] }, "qntm_NumberOfVotePerShare": { "xbrltype": "integerItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "NumberOfVotePerShare", "presentation": [ "http://www.quantumbiopharma.com/role/SharecapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of vote per Share (in vote)", "documentation": "Number of vote per Share.", "label": "Number Of Vote Per Share" } } }, "auth_ref": [] }, "qntm_NumberOfWarrantsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "NumberOfWarrantsExercised", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofchangesinwarrantsoutstandingandweightedaverageexercisepriceTable" ], "lang": { "en-us": { "role": { "terseLabel": "Exercised", "documentation": "Number of warrants, exercised.", "label": "Number Of Warrants Exercised" } } }, "auth_ref": [] }, "qntm_NumberOfWarrantsExpired": { "xbrltype": "sharesItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "NumberOfWarrantsExpired", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofchangesinwarrantsoutstandingandweightedaverageexercisepriceTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number of warrants, Expired", "documentation": "Represents number of warrants expired.", "label": "Number Of Warrants Expired" } } }, "auth_ref": [] }, "qntm_NumberOfWarrantsIssued": { "xbrltype": "sharesItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "NumberOfWarrantsIssued", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofchangesinwarrantsoutstandingandweightedaverageexercisepriceTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number of warrants, Issued", "documentation": "Represents number of warrants issued during period.", "label": "Number Of Warrants Issued" } } }, "auth_ref": [] }, "qntm_NumberOfWarrantsOutstandingShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "NumberOfWarrantsOutstandingShares", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofchangesinwarrantsoutstandingandweightedaverageexercisepriceTable", "http://www.quantumbiopharma.com/role/ScheduleofnumberofwarrantsoutstandingandexercisepriceTable" ], "lang": { "en-us": { "role": { "periodStartLabel": "Number of warrants, Outstanding", "periodEndLabel": "Number of warrants, Outstanding", "terseLabel": "Number of warrants outstanding", "documentation": "Number of warrants outstanding shares.", "label": "Number Of Warrants Outstanding Shares" } } }, "auth_ref": [] }, "qntm_OfficeAndGeneralAdministrative": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "OfficeAndGeneralAdministrative", "crdr": "debit", "calculation": { "http://www.quantumbiopharma.com/role/ScheduleofgeneralandadministrativeexpenseTable": { "parentTag": "qntm_GeneralAndAdministrativeExpenseContinuedAndDiscontinuedOperations", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofgeneralandadministrativeexpenseTable" ], "lang": { "en-us": { "role": { "terseLabel": "Office and general administrative", "documentation": "Office and general administrative.", "label": "Office And General Administrative" } } }, "auth_ref": [] }, "ifrs-full_OperatingExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OperatingExpense", "crdr": "debit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedIncomeStatement", "http://www.quantumbiopharma.com/role/ScheduleofassetandincomebysegmentTable" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "terseLabel": "Total operating expenses", "label": "Operating expense, operating" } } }, "auth_ref": [ "r264" ] }, "qntm_OperationalExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "OperationalExpenses", "crdr": "credit", "calculation": { "http://www.quantumbiopharma.com/role/ScheduleofaccruedliabilitiesTable": { "parentTag": "ifrs-full_AccrualsClassifiedAsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofaccruedliabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Operational expenses", "documentation": "The amount of operational expenses.", "label": "Operational Expenses" } } }, "auth_ref": [] }, "qntm_OrdinaryStockSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "OrdinaryStockSharesMember", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofinvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Ordinary Stock Shares [Member]", "label": "Ordinary Stock Shares Member" } } }, "auth_ref": [] }, "ifrs-full_OtherComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncome", "crdr": "credit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedIncomeStatement", "http://www.quantumbiopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive loss", "terseLabel": "Comprehensive loss for the period", "label": "Other comprehensive income" } } }, "auth_ref": [ "r61", "r181", "r207", "r211" ] }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation", "crdr": "credit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "ifrs-full_OtherComprehensiveIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Exchange gain on translation of foreign operations", "label": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations" } }, "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r198", "r211" ] }, "ifrs-full_OtherIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherIncome", "crdr": "credit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "ifrs-full_ProfitLossAttributableToNoncontrollingInterests", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "negatedLabel": "Other income", "label": "Other income" } } }, "auth_ref": [ "r14", "r232", "r233" ] }, "ifrs-full_OtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherReceivables", "crdr": "debit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Other receivables", "label": "Other receivables" } }, "en": { "role": { "documentation": "The amount receivable by the entity that it does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r230", "r237" ] }, "qntm_OtherReceivables_1": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "OtherReceivables_1", "crdr": "credit", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofotherreceivablesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Other receivables", "documentation": "Other receivables.", "label": "Other Receivables_1" } } }, "auth_ref": [] }, "ifrs-full_ParValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ParValuePerShare", "presentation": [ "http://www.quantumbiopharma.com/role/InvestmentsDetails", "http://www.quantumbiopharma.com/role/SharecapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Price per share", "verboseLabel": "Shares price per shares (in Dollars per share)", "label": "Par value per share" } }, "en": { "role": { "documentation": "The nominal value per share." } } }, "auth_ref": [ "r118", "r171", "r201" ] }, "qntm_PaymentToAcquireInvestmentSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "PaymentToAcquireInvestmentSecurities", "crdr": "debit", "presentation": [ "http://www.quantumbiopharma.com/role/InvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "PaymentToAcquireInvestmentSecurities", "documentation": "Payment to acquire investment securities.", "label": "Payment To Acquire Investment Securities" } } }, "auth_ref": [] }, "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities", "crdr": "credit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Payment of lease obligation", "label": "Payments of lease liabilities, classified as financing activities" } }, "en": { "role": { "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r220" ] }, "qntm_PercentageOfMaximumPurchaseDeemedOutstandingShares": { "xbrltype": "percentItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "PercentageOfMaximumPurchaseDeemedOutstandingShares", "presentation": [ "http://www.quantumbiopharma.com/role/NatureofbusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of maximum purchase deemed outstanding shares", "documentation": "Percentage of maximum purchase deemed outstanding shares.", "label": "Percentage Of Maximum Purchase Deemed Outstanding Shares" } } }, "auth_ref": [] }, "ifrs-full_PercentageOfVotingEquityInterestsAcquired": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PercentageOfVotingEquityInterestsAcquired", "presentation": [ "http://www.quantumbiopharma.com/role/NoncontrollinginterestsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisition percentage", "label": "Percentage of voting equity interests acquired" } }, "en": { "role": { "documentation": "The percentage of voting equity interests acquired in a business combination. [Refer: Total for all business combinations [member]]" } } }, "auth_ref": [ "r94", "r161" ] }, "qntm_PerformanceShareUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "PerformanceShareUnitsMember", "presentation": [ "http://www.quantumbiopharma.com/role/RelatedpartytransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance Share Units [Member]", "label": "Performance Share Units Member" } } }, "auth_ref": [] }, "qntm_PrincipalAmountSecuredConvertibleDebenture": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "PrincipalAmountSecuredConvertibleDebenture", "crdr": "debit", "presentation": [ "http://www.quantumbiopharma.com/role/ConvertibledebenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Principal amount secured convertible debenture", "documentation": "Principal amount secured convertible debenture.", "label": "Principal Amount Secured Convertible Debenture" } } }, "auth_ref": [] }, "qntm_PrismicPharmaceuticalIncPrismicInUSAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "PrismicPharmaceuticalIncPrismicInUSAMember", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofownershippercentageinsubsidiariesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Prismic Pharmaceuticals Inc.(\u201cPrismic) in USA Member", "label": "Prismic Pharmaceutical Inc Prismic In USAMember" } } }, "auth_ref": [] }, "ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromBorrowingsClassifiedAsFinancingActivities", "crdr": "debit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from loans", "label": "Proceeds from borrowings, classified as financing activities" } }, "en": { "role": { "documentation": "The cash inflow from borrowings obtained. [Refer: Borrowings]" } } }, "auth_ref": [ "r219" ] }, "ifrs-full_ProceedsFromExerciseOfOptions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromExerciseOfOptions", "crdr": "debit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow", "http://www.quantumbiopharma.com/role/SharebasedcompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from share options exercised", "verboseLabel": "Total gross proceeds (in Dollars)", "label": "Proceeds from exercise of options" } }, "en": { "role": { "documentation": "The cash inflow from the exercise of options." } } }, "auth_ref": [ "r250" ] }, "ifrs-full_ProceedsFromExerciseOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromExerciseOfWarrants", "crdr": "debit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from exercise of warrants", "label": "Proceeds from exercise of warrants" } }, "en": { "role": { "documentation": "The cash inflow from the exercise of share purchase warrants." } } }, "auth_ref": [ "r250" ] }, "qntm_ProceedsFromFairValueInvestment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ProceedsFromFairValueInvestment", "crdr": "credit", "presentation": [ "http://www.quantumbiopharma.com/role/InvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from fair value investment", "documentation": "Proceeds from fair value investment.", "label": "Proceeds From Fair Value Investment" } } }, "auth_ref": [] }, "qntm_ProceedsFromISharesToBeIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ProceedsFromISharesToBeIssued", "crdr": "debit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from shares to be issued", "documentation": "The cash inflow from issuing shares.", "label": "Proceeds From IShares To Be Issued" } } }, "auth_ref": [] }, "qntm_ProceedsFromIssuanceOfConvertibleNotesAndBonds": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ProceedsFromIssuanceOfConvertibleNotesAndBonds", "crdr": "credit", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofconvertibledebenturesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds", "documentation": "Proceeds from issuance of convertible notes and bonds.", "label": "Proceeds From Issuance Of Convertible Notes And Bonds" } } }, "auth_ref": [] }, "ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromIssueOfBondsNotesAndDebentures", "crdr": "debit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from convertible debentures", "label": "Proceeds from issue of bonds, notes and debentures" } }, "en": { "role": { "documentation": "The cash inflow from the issuing of bonds, notes and debentures." } } }, "auth_ref": [ "r250" ] }, "qntm_ProceedsFromIssuingCommonShares": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ProceedsFromIssuingCommonShares", "crdr": "debit", "presentation": [ "http://www.quantumbiopharma.com/role/NatureofbusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross proceeds for loan agreement (in Dollars)", "documentation": "The amount of gross proceeds to entered into a loan agreement.", "label": "Proceeds From Issuing Common Shares" } } }, "auth_ref": [] }, "ifrs-full_ProceedsFromIssuingOtherEquityInstruments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromIssuingOtherEquityInstruments", "crdr": "debit", "presentation": [ "http://www.quantumbiopharma.com/role/SharecapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuing other equity instruments (in Dollars)", "label": "Proceeds from issuing other equity instruments" } }, "en": { "role": { "documentation": "The cash inflow from issuing equity instruments that the entity does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r218" ] }, "ifrs-full_ProceedsFromIssuingShares": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromIssuingShares", "crdr": "debit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow", "http://www.quantumbiopharma.com/role/SharecapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of shares, net", "verboseLabel": "Proceeds from issuing shares (in Dollars)", "label": "Proceeds from issuing shares" } }, "en": { "role": { "documentation": "The cash inflow from issuing shares." } } }, "auth_ref": [ "r218" ] }, "ifrs-full_ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities", "crdr": "debit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of digital assets", "label": "Proceeds from sales of intangible assets, classified as investing activities" } }, "en": { "role": { "documentation": "The cash inflow from sales of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r217" ] }, "ifrs-full_ProceedsFromSalesOfInvestmentProperty": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromSalesOfInvestmentProperty", "crdr": "debit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of investments", "label": "Proceeds from sales of investment property" } }, "en": { "role": { "documentation": "The cash inflow from sales of investment property. [Refer: Investment property]" } } }, "auth_ref": [ "r249" ] }, "ifrs-full_ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod", "crdr": "debit", "presentation": [ "http://www.quantumbiopharma.com/role/InvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of investment", "label": "Proceeds from sales of investments accounted for using equity method" } }, "en": { "role": { "documentation": "The cash inflow from sales of investments accounted for using the equity method. [Refer: Investments accounted for using equity method]" } } }, "auth_ref": [ "r249" ] }, "qntm_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodC3": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodC3", "crdr": "debit", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofinvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Change in fair value through profit or loss", "documentation": "Change in fair value through profit or loss.", "label": "Proceeds From Sales Of Investments Other Than Investments Accounted For Using Equity Method C3" } } }, "auth_ref": [] }, "qntm_ProceedsFromSalesOfRedemptionOfInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ProceedsFromSalesOfRedemptionOfInvestments", "crdr": "debit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Redemption of investments", "documentation": "The cash inflow from sales of redemption of investments.", "label": "Proceeds From Sales Of Redemption Of Investments" } } }, "auth_ref": [] }, "ifrs-full_ProductsAndServicesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProductsAndServicesAxis", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofassetandincomebysegmentTable" ], "lang": { "en-us": { "role": { "label": "Products and services [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r113", "r224", "r228" ] }, "qntm_ProfessionalAndOtherFees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ProfessionalAndOtherFees", "crdr": "credit", "calculation": { "http://www.quantumbiopharma.com/role/ScheduleofaccruedliabilitiesTable": { "parentTag": "ifrs-full_AccrualsClassifiedAsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofaccruedliabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Professional and other fees", "documentation": "The amount of professional and other fees.", "label": "Professional And Other Fees" } } }, "auth_ref": [] }, "ifrs-full_ProfessionalFeesExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfessionalFeesExpense", "crdr": "debit", "calculation": { "http://www.quantumbiopharma.com/role/ScheduleofgeneralandadministrativeexpenseTable": { "parentTag": "qntm_GeneralAndAdministrativeExpenseContinuedAndDiscontinuedOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofgeneralandadministrativeexpenseTable" ], "lang": { "en-us": { "role": { "terseLabel": "Professional fees", "label": "Professional fees expense" } } }, "auth_ref": [ "r258" ] }, "ifrs-full_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedIncomeStatement", "http://www.quantumbiopharma.com/role/ScheduleofassetandincomebysegmentTable" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "terseLabel": "Net (loss) income", "label": "Profit (loss)" } }, "en": { "role": { "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r49", "r51", "r107", "r108", "r135", "r151", "r180", "r206", "r221", "r226" ] }, "ifrs-full_ProfitLossAttributableToNoncontrollingInterests": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossAttributableToNoncontrollingInterests", "crdr": "credit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "ifrs-full_OtherComprehensiveIncome", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "label": "Profit (loss), attributable to non-controlling interests" } }, "en": { "role": { "documentation": "The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]" } } }, "auth_ref": [ "r54", "r208" ] }, "ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects", "crdr": "credit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Equity owners of the Company", "label": "Profit (loss), attributable to ordinary equity holders of parent entity, used in calculating diluted earnings per share" } }, "en": { "role": { "documentation": "The profit (loss) attributable to ordinary equity holders of the parent entity, adjusted for the effects of all dilutive potential ordinary shares. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r21" ] }, "ifrs-full_ProfitLossFromContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossFromContinuingOperations", "crdr": "credit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss", "label": "Profit (loss) from continuing operations" } }, "en": { "role": { "documentation": "The profit (loss) from continuing operations. [Refer: Continuing operations, unless line item indicates otherwise [member]; Profit (loss)]" } } }, "auth_ref": [ "r60", "r107", "r108", "r206" ] }, "ifrs-full_ProfitLossFromOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossFromOperatingActivities", "crdr": "credit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "ifrs-full_ProfitLossAttributableToNoncontrollingInterests", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Profit (loss) from operating activities" } } }, "auth_ref": [ "r215", "r264" ] }, "ifrs-full_PropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Equipment, net", "label": "Property, plant and equipment" } }, "en": { "role": { "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]" } } }, "auth_ref": [ "r3", "r129", "r187" ] }, "ifrs-full_ProportionOfOwnershipInterestInSubsidiary": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProportionOfOwnershipInterestInSubsidiary", "presentation": [ "http://www.quantumbiopharma.com/role/NatureofbusinessDetails", "http://www.quantumbiopharma.com/role/ScheduleofownershippercentageinsubsidiariesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Subsidiaries percentage", "verboseLabel": "Ownership percentage", "label": "Proportion of ownership interest in subsidiary" } }, "en": { "role": { "documentation": "The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Total for all subsidiaries [member]]" } } }, "auth_ref": [ "r15", "r17", "r56" ] }, "ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProportionOfOwnershipInterestsHeldByNoncontrollingInterests", "presentation": [ "http://www.quantumbiopharma.com/role/NoncontrollinginterestsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership interest", "label": "Proportion of ownership interests held by non-controlling interests" } }, "en": { "role": { "documentation": "The proportion of ownership interests in a subsidiary held by non-controlling interests. [Refer: Total for all subsidiaries [member]; Non-controlling interests]" } } }, "auth_ref": [ "r53" ] }, "ifrs-full_PurchaseOfInvestmentProperty": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PurchaseOfInvestmentProperty", "crdr": "credit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow", "http://www.quantumbiopharma.com/role/InvestmentsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of investments", "terseLabel": "Purchased guaranteed investment certificate amount", "label": "Purchase of investment property" } }, "en": { "role": { "documentation": "The cash outflow for the purchase of investment property. [Refer: Investment property]" } } }, "auth_ref": [ "r249" ] }, "qntm_PurchaseOfInvestmentShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "PurchaseOfInvestmentShares", "presentation": [ "http://www.quantumbiopharma.com/role/InvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase of investment shares (in Shares)", "documentation": "Purchase of investment shares.", "label": "Purchase Of Investment Shares" } } }, "auth_ref": [] }, "ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod", "crdr": "credit", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofinvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Additions", "label": "Purchase of investments other than investments accounted for using equity method" } }, "en": { "role": { "documentation": "The cash outflow for the purchase of investments other than investments accounted for using equity method. [Refer: Investments accounted for using equity method; Investments other than investments accounted for using equity method]" } } }, "auth_ref": [ "r249" ] }, "qntm_PurchasesOfDigitalAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "PurchasesOfDigitalAssets", "crdr": "debit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Purchases of digital assets", "documentation": "The amount of Purchases of digital assets.", "label": "Purchases Of Digital Assets" } } }, "auth_ref": [] }, "qntm_RHCapitalFinanceCOLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "RHCapitalFinanceCOLLCMember", "presentation": [ "http://www.quantumbiopharma.com/role/NotespayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "RH Capital Finance CO LLC [Member]", "label": "RHCapital Finance COLLCMember" } } }, "auth_ref": [] }, "qntm_RSUsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "RSUsExercised", "presentation": [ "http://www.quantumbiopharma.com/role/SharecapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "RSUs exercised", "documentation": "RSUs exercised.", "label": "RSUs Exercised" } } }, "auth_ref": [] }, "qntm_RSUsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "RSUsMember", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleoffairvaluesofPSUsgrantedusingtheBlackScholesoptionpricingmodelTable", "http://www.quantumbiopharma.com/role/ScheduleoflosspershareTable", "http://www.quantumbiopharma.com/role/ScheduleofsharebasedcompensationTable" ], "lang": { "en-us": { "role": { "terseLabel": "RSUs [Member]", "label": "RSUs Member" } } }, "auth_ref": [] }, "ifrs-full_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RangeAxis", "presentation": [ "http://www.quantumbiopharma.com/role/ConvertibledebenturesDetails", "http://www.quantumbiopharma.com/role/InvestmentsDetails", "http://www.quantumbiopharma.com/role/NatureofbusinessDetails", "http://www.quantumbiopharma.com/role/RelatedpartytransactionsDetails", "http://www.quantumbiopharma.com/role/ScheduleoffairvaluedeterminedusingblackscholesoptionTable", "http://www.quantumbiopharma.com/role/ScheduleoffairvaluesofoptionsgrantedusingtheBlackScholesoptionpricingmodelTable", "http://www.quantumbiopharma.com/role/ScheduleofgainonchangeinfairvalueTable", "http://www.quantumbiopharma.com/role/SharecapitalDetails" ], "lang": { "en-us": { "role": { "label": "Range [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r44", "r72", "r78", "r89", "r124", "r222", "r223", "r255" ] }, "ifrs-full_RangeDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RangeDomain", "presentation": [ "http://www.quantumbiopharma.com/role/ConvertibledebenturesDetails", "http://www.quantumbiopharma.com/role/InvestmentsDetails", "http://www.quantumbiopharma.com/role/NatureofbusinessDetails", "http://www.quantumbiopharma.com/role/RelatedpartytransactionsDetails", "http://www.quantumbiopharma.com/role/ScheduleoffairvaluedeterminedusingblackscholesoptionTable", "http://www.quantumbiopharma.com/role/ScheduleoffairvaluesofoptionsgrantedusingtheBlackScholesoptionpricingmodelTable", "http://www.quantumbiopharma.com/role/ScheduleofgainonchangeinfairvalueTable", "http://www.quantumbiopharma.com/role/SharecapitalDetails" ], "lang": { "en-us": { "role": { "label": "Range [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used." } } }, "auth_ref": [ "r44", "r72", "r78", "r89", "r124", "r222", "r223", "r255" ] }, "ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RangesOfExercisePricesForOutstandingShareOptionsAxis", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofcompanysshareoptionsoutstandingTable" ], "lang": { "en-us": { "role": { "label": "Ranges of exercise prices for outstanding share options [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r89" ] }, "ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RangesOfExercisePricesForOutstandingShareOptionsDomain", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofcompanysshareoptionsoutstandingTable" ], "lang": { "en-us": { "role": { "label": "Ranges of exercise prices for outstanding share options [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated ranges of exercise prices for outstanding share options that are meaningful for assessing the number and timing of additional shares that may be issued and the cash that may be received upon exercise of those options. It also represents the standard value for the 'Ranges of exercise prices for outstanding share options' axis if no other member is used. [Refer: Range [domain]]" } } }, "auth_ref": [ "r89" ] }, "qntm_RealizedGainOnSaleOfDigitalAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "RealizedGainOnSaleOfDigitalAssets", "crdr": "credit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "ifrs-full_ProfitLossAttributableToNoncontrollingInterests", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedIncomeStatement", "http://www.quantumbiopharma.com/role/DigitalassetsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Realized (gain) on sale of digital assets", "terseLabel": "Gain on sale of digital assets", "documentation": "The amount of realized gain on sale of digital assets.", "label": "Realized Gain On Sale Of Digital Assets" } } }, "auth_ref": [] }, "qntm_RealizedGainsOnSaleOfDigitalAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "RealizedGainsOnSaleOfDigitalAssets", "crdr": "credit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 15.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Realized (gain) on sale of digital assets", "documentation": "Realized loss on sale of digital assets.", "label": "Realized Gains On Sale Of Digital Assets" } } }, "auth_ref": [] }, "qntm_ReceivedTotalProceeds": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ReceivedTotalProceeds", "crdr": "debit", "presentation": [ "http://www.quantumbiopharma.com/role/SharecapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Received total proceeds", "documentation": "The amount of received total proceeds.", "label": "Received Total Proceeds" } } }, "auth_ref": [] }, "ifrs-full_RelatedPartiesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RelatedPartiesMember", "presentation": [ "http://www.quantumbiopharma.com/role/ConvertibledebenturesDetails", "http://www.quantumbiopharma.com/role/RelatedpartytransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total for all related parties [member]", "label": "Total for all related parties [member]" } }, "en": { "role": { "documentation": "This member stands for related parties. Related parties are persons or entities that are related to the entity that is preparing its financial statements (the reporting entity). (a) A person or a close member of that person\u2019s family is related to a reporting entity if that person: (i) has control or joint control over the reporting entity; (ii) has significant influence over the reporting entity; or (iii) is a member of the key management personnel of the reporting entity or of a parent of the reporting entity. (b) An entity is related to a reporting entity if any of the following conditions applies: (i) The entity and the reporting entity are members of the same group (which means that each parent, subsidiary and fellow subsidiary is related to the others). (ii) One entity is an associate or joint venture of the other entity (or an associate or joint venture of a member of a group of which the other entity is a member). (iii) Both entities are joint ventures of the same third party. (iv) One entity is a joint venture of a third entity and the other entity is an associate of the third entity. (v) The entity is a post-employment benefit plan for the benefit of employees of either the reporting entity or an entity related to the reporting entity. If the reporting entity is itself such a plan, the sponsoring employers are also related to the reporting entity. (vi) The entity is controlled or jointly controlled by a person identified in (a). (vii) A person identified in (a)(i) has significant influence over the entity or is a member of the key management personnel of the entity (or of a parent of the entity). (viii) The entity, or any member of a group of which it is a part, provides key management personnel services to the reporting entity or to the parent of the reporting entity. [Refer: Total for all joint ventures [member]; Key management personnel of entity or parent [member]]" } } }, "auth_ref": [ "r12", "r133" ] }, "qntm_RelatedPartyTotalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "RelatedPartyTotalMember", "presentation": [ "http://www.quantumbiopharma.com/role/ConvertibledebenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Total [Member]", "label": "Related Party Total Member" } } }, "auth_ref": [] }, "ifrs-full_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related party transactions [abstract]" } } }, "auth_ref": [] }, "qntm_RelatedpartytransactionsDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "RelatedpartytransactionsDetailsLineItems", "presentation": [ "http://www.quantumbiopharma.com/role/RelatedpartytransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Related party transactions (Details) [Line Items]" } } }, "auth_ref": [] }, "qntm_RelatedpartytransactionsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "RelatedpartytransactionsDetailsTable", "presentation": [ "http://www.quantumbiopharma.com/role/RelatedpartytransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Related party transactions (Details) [Table]" } } }, "auth_ref": [] }, "qntm_RepaymentOfLoansFromTaxRebateRefund": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "RepaymentOfLoansFromTaxRebateRefund", "crdr": "credit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Repayment of loans from tax rebate refund", "documentation": "The amount of repayment of loans from tax rebate refund.", "label": "Repayment Of Loans From Tax Rebate Refund" } } }, "auth_ref": [] }, "qntm_RepaymentOfProceedsFromBitgoLoan": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "RepaymentOfProceedsFromBitgoLoan", "crdr": "credit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "(Repayment of) proceeds from Bitgo loan", "documentation": "(Repayment of) proceeds from Bitgo loan.", "label": "Repayment Of Proceeds From Bitgo Loan" } } }, "auth_ref": [] }, "ifrs-full_RepaymentsOfBondsNotesAndDebentures": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RepaymentsOfBondsNotesAndDebentures", "crdr": "credit", "presentation": [ "http://www.quantumbiopharma.com/role/NotespayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Repayment of outstanding principal balance", "label": "Repayments of bonds, notes and debentures" } }, "en": { "role": { "documentation": "The cash outflow for repayments of bonds, notes and debentures." } } }, "auth_ref": [ "r250" ] }, "ifrs-full_ReportableSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ReportableSegmentsMember", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofassetandincomebysegmentTable" ], "lang": { "en-us": { "role": { "terseLabel": "Reportable segments [member]", "label": "Reportable segments [member]" } }, "en": { "role": { "documentation": "This member stands for operating segments for which IFRS 8 requires information to be disclosed. The entity shall report separately information about an operating segment that meets any of the following quantitative thresholds: (a) reported revenue, including both sales to external customers and intersegment sales or transfers, is 10 per cent or more of the combined revenue, internal and external, of all operating segments; (b) the absolute amount of its reported profit or loss is 10 per cent or more of the greater, in absolute amount, of (i) the combined reported profit of all operating segments that did not report a loss and (ii) the combined reported loss of all operating segments that reported a loss; or (c) assets are 10 per cent or more of the combined assets of all operating segments. Additionally operating segments that do not meet any of the quantitative thresholds may be considered reportable, and separately disclosed, if management believes that information about the segment would be useful to users of the financial statements. [Refer: Operating segments [member]]" } } }, "auth_ref": [ "r73", "r107", "r115", "r214", "r227" ] }, "ifrs-full_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "External research and development fees", "label": "Research and development expense" } } }, "auth_ref": [ "r34", "r143" ] }, "ifrs-full_ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMember", "presentation": [ "http://www.quantumbiopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign exchange translation reserve", "label": "Reserve of change in value of foreign currency basis spreads [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing the accumulated change in the value of foreign currency basis spreads of financial instruments when excluding them from the designation of these financial instruments as hedging instruments." } } }, "auth_ref": [ "r114", "r234" ] }, "ifrs-full_ReserveOfExchangeDifferencesOnTranslation": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ReserveOfExchangeDifferencesOnTranslation", "crdr": "credit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign exchange translation reserve", "label": "Reserve of exchange differences on translation" } }, "en": { "role": { "documentation": "A component of equity representing exchange differences on translation of financial statements recognised in other comprehensive income and accumulated in equity. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r8", "r131" ] }, "qntm_RestrictedShareConversionToClassB": { "xbrltype": "sharesItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "RestrictedShareConversionToClassB", "presentation": [ "http://www.quantumbiopharma.com/role/SharebasedcompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "RSUs Converted to Class B Shares", "documentation": "Restricted Share Conversion To Class B.", "label": "Restricted Share Conversion To Class B" } } }, "auth_ref": [] }, "qntm_RestrictedShareFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "RestrictedShareFairValue", "crdr": "credit", "presentation": [ "http://www.quantumbiopharma.com/role/SharebasedcompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted share fair value (in Dollars)", "documentation": "Restricted share fair value.", "label": "Restricted Share Fair Value" } } }, "auth_ref": [] }, "qntm_RestrictedShareUnitIssued": { "xbrltype": "sharesItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "RestrictedShareUnitIssued", "presentation": [ "http://www.quantumbiopharma.com/role/SharebasedcompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted share unit issued", "documentation": "Restricted share unit issued.", "label": "Restricted Share Unit Issued" } } }, "auth_ref": [] }, "qntm_RestrictedShareUnitMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "RestrictedShareUnitMember", "presentation": [ "http://www.quantumbiopharma.com/role/SharebasedcompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Share Unit [Member]", "label": "Restricted Share Unit Member" } } }, "auth_ref": [] }, "ifrs-full_RestrictedShareUnitsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RestrictedShareUnitsMember", "presentation": [ "http://www.quantumbiopharma.com/role/SharebasedcompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted share units [member]", "label": "Restricted share units [member]" } }, "en": { "role": { "documentation": "This member stands for restricted share units." } } }, "auth_ref": [ "r244" ] }, "qntm_RestrictedStockSharesVested": { "xbrltype": "sharesItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "RestrictedStockSharesVested", "presentation": [ "http://www.quantumbiopharma.com/role/SharebasedcompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock shares vested", "documentation": "Restricted stock shares vested.", "label": "Restricted Stock Shares Vested" } } }, "auth_ref": [] }, "qntm_RestrictedStockUnitsOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "RestrictedStockUnitsOneMember", "presentation": [ "http://www.quantumbiopharma.com/role/SharecapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock Units One [Member]", "label": "Restricted Stock Units One Member" } } }, "auth_ref": [] }, "qntm_RestrictedStockUnitsTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "RestrictedStockUnitsTwoMember", "presentation": [ "http://www.quantumbiopharma.com/role/SharecapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock Units Two [Member]", "label": "Restricted Stock Units Two Member" } } }, "auth_ref": [] }, "qntm_RestrictedUnitPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "RestrictedUnitPerShare", "presentation": [ "http://www.quantumbiopharma.com/role/SharebasedcompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted unit per share (in Dollars per share)", "documentation": "Restricted Unit Per Share,", "label": "Restricted Unit Per Share" } } }, "auth_ref": [] }, "ifrs-full_RetainedEarnings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RetainedEarnings", "crdr": "credit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained earnings" } }, "en": { "role": { "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit." } } }, "auth_ref": [ "r231", "r238", "r239" ] }, "ifrs-full_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RetainedEarningsMember", "presentation": [ "http://www.quantumbiopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained earnings [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit." } } }, "auth_ref": [ "r183", "r234" ] }, "ifrs-full_RevenueFromInterest": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RevenueFromInterest", "crdr": "credit", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofassetandincomebysegmentTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest expense (income)", "label": "Interest income" } }, "en": { "role": { "documentation": "The amount of income arising from interest." } } }, "auth_ref": [ "r64", "r104", "r111", "r258" ] }, "qntm_ReversalOfWarrantLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ReversalOfWarrantLiability", "crdr": "debit", "presentation": [ "http://www.quantumbiopharma.com/role/SharecapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reversal Of Warrant Liability (in Dollars)", "documentation": "The amount of reversal of warrant liability.", "label": "Reversal Of Warrant Liability" } } }, "auth_ref": [] }, "ifrs-full_RightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RightofuseAssets", "crdr": "debit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet", "http://www.quantumbiopharma.com/role/RelatedpartytransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use asset, net", "verboseLabel": "Rright-of-use asset recognized", "label": "Right-of-use assets" } }, "en": { "role": { "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee." } } }, "auth_ref": [ "r74", "r76", "r116" ] }, "ifrs-full_RightsPreferencesAndRestrictionsAttachingToClassOfShareCapital": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RightsPreferencesAndRestrictionsAttachingToClassOfShareCapital", "presentation": [ "http://www.quantumbiopharma.com/role/SharecapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rights, preferences and restrictions attaching to class of share capital", "label": "Rights, preferences and restrictions attaching to class of share capital" } }, "en": { "role": { "documentation": "The description of the rights, preferences and restrictions attaching to a class of share capital including restrictions on the distribution of dividends and the repayment of capital. [Refer: Classes of share capital [domain]]" } } }, "auth_ref": [ "r120", "r173", "r203" ] }, "qntm_RiskFreeInterestRateOfWarrant": { "xbrltype": "percentItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "RiskFreeInterestRateOfWarrant", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleoffairvaluedeterminedusingblackscholesoptionTable", "http://www.quantumbiopharma.com/role/ScheduleoffairvalueofwarrantsoptionpricingmodelassumptionsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Risk free interest rate", "documentation": "Risk free interest rate of warrants.", "label": "Risk Free Interest Rate Of Warrant" } } }, "auth_ref": [] }, "qntm_RiskFreeInterestRateOfWarrants": { "xbrltype": "percentItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "RiskFreeInterestRateOfWarrants", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofgainonchangeinfairvalueTable" ], "lang": { "en-us": { "role": { "terseLabel": "Risk free interest rate", "documentation": "Risk free interest rate percentage.", "label": "Risk Free Interest Rate Of Warrants" } } }, "auth_ref": [] }, "qntm_RodmanAndRenshawLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "RodmanAndRenshawLLCMember", "presentation": [ "http://www.quantumbiopharma.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rodman and Renshaw LLC [Member]", "label": "Rodman And Renshaw LLCMember" } } }, "auth_ref": [] }, "qntm_RoyalBankOfCanadaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "RoyalBankOfCanadaMember", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofinvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Royal Bank of Canada [Member]", "label": "Royal Bank Of Canada Member" } } }, "auth_ref": [] }, "qntm_SLVSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "SLVSharesMember", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofinvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "SLV Shares [Member]", "label": "SLVShares Member" } } }, "auth_ref": [] }, "qntm_SUIMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "SUIMember", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofchangesindigitalassetsbalanceTable" ], "lang": { "en-us": { "role": { "terseLabel": "SUI [Member]", "label": "SUIMember" } } }, "auth_ref": [] }, "qntm_ScheduleOfAccruedLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ScheduleOfAccruedLiabilitiesAbstract", "lang": { "en-us": { "role": { "label": "Schedule of accrued liabilities [Abstract]" } } }, "auth_ref": [] }, "qntm_ScheduleOfAssetAndIncomeBySegmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ScheduleOfAssetAndIncomeBySegmentAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Asset And Income By Segment Abstract" } } }, "auth_ref": [] }, "qntm_ScheduleOfChangesInDigitalAssetsBalanceAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ScheduleOfChangesInDigitalAssetsBalanceAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Changes In Digital Assets Balance Abstract" } } }, "auth_ref": [] }, "qntm_ScheduleOfChangesInShareCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ScheduleOfChangesInShareCapitalAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Changes In Share Capital Abstract" } } }, "auth_ref": [] }, "qntm_ScheduleOfChangesInWarrantsOutstandingAndWeightedAverageExercisePriceAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ScheduleOfChangesInWarrantsOutstandingAndWeightedAverageExercisePriceAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Changes In Warrants Outstanding And Weighted Average Exercise Price Abstract" } } }, "auth_ref": [] }, "qntm_ScheduleOfCompanySShareOptionsOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ScheduleOfCompanySShareOptionsOutstandingAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Company SShare Options Outstanding Abstract" } } }, "auth_ref": [] }, "qntm_ScheduleOfConvertibleDebenturesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ScheduleOfConvertibleDebenturesAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Convertible Debentures Abstract" } } }, "auth_ref": [] }, "qntm_ScheduleOfFairValueDeterminedUsingBlackScholesOptionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ScheduleOfFairValueDeterminedUsingBlackScholesOptionAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Fair Value Determined Using Black Scholes Option Abstract" } } }, "auth_ref": [] }, "qntm_ScheduleOfFairValueHierarchyAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ScheduleOfFairValueHierarchyAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Fair Value Hierarchy Abstract" } } }, "auth_ref": [] }, "qntm_ScheduleOfFairValueOfWarrantsOptionPricingModelAssumptionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ScheduleOfFairValueOfWarrantsOptionPricingModelAssumptionsAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Fair Value Of Warrants Option Pricing Model Assumptions Abstract" } } }, "auth_ref": [] }, "qntm_ScheduleOfFairValuesOfOptionsGrantedUsingTheBlackScholesOptionPricingModelAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ScheduleOfFairValuesOfOptionsGrantedUsingTheBlackScholesOptionPricingModelAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Fair Values Of Options Granted Using The Black Scholes Option Pricing Model Abstract" } } }, "auth_ref": [] }, "qntm_ScheduleOfFairValuesOfPsusGrantedUsingTheBlackScholesOptionPricingModelAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ScheduleOfFairValuesOfPsusGrantedUsingTheBlackScholesOptionPricingModelAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Fair Values Of Psus Granted Using The Black Scholes Option Pricing Model Abstract" } } }, "auth_ref": [] }, "qntm_ScheduleOfGainOnChangeInFairValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ScheduleOfGainOnChangeInFairValueAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Gain On Change In Fair Value Abstract" } } }, "auth_ref": [] }, "qntm_ScheduleOfGeneralAndAdministrativeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ScheduleOfGeneralAndAdministrativeExpenseAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of General And Administrative Expense Abstract" } } }, "auth_ref": [] }, "qntm_ScheduleOfIntangibleAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ScheduleOfIntangibleAssetsAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Intangible Assets Abstract" } } }, "auth_ref": [] }, "qntm_ScheduleOfInvestmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ScheduleOfInvestmentAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Investment Abstract" } } }, "auth_ref": [] }, "qntm_ScheduleOfKeyManagementPersonnelCompensationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ScheduleOfKeyManagementPersonnelCompensationAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Key Management Personnel Compensation Abstract" } } }, "auth_ref": [] }, "qntm_ScheduleOfLossPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ScheduleOfLossPerShareAbstract", "lang": { "en-us": { "role": { "label": "Schedule of loss per share [Abstract]" } } }, "auth_ref": [] }, "qntm_ScheduleOfNumberOfShareOptionsOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ScheduleOfNumberOfShareOptionsOutstandingAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Number Of Share Options Outstanding Abstract" } } }, "auth_ref": [] }, "qntm_ScheduleOfNumberOfWarrantsOutstandingAndExercisePriceAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ScheduleOfNumberOfWarrantsOutstandingAndExercisePriceAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Number Of Warrants Outstanding And Exercise Price Abstract" } } }, "auth_ref": [] }, "qntm_ScheduleOfOtherReceivablesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ScheduleOfOtherReceivablesAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Other Receivables Abstract" } } }, "auth_ref": [] }, "qntm_ScheduleOfOwnershipPercentageInSubsidiariesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ScheduleOfOwnershipPercentageInSubsidiariesAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Ownership Percentage In Subsidiaries Abstract" } } }, "auth_ref": [] }, "qntm_ScheduleOfReconciliationOfNonControllingInterestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ScheduleOfReconciliationOfNonControllingInterestAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Reconciliation of Non Controlling Interest [Abstract]" } } }, "auth_ref": [] }, "qntm_ScheduleOfShareBasedCompensationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ScheduleOfShareBasedCompensationAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Share Based Compensation Abstract" } } }, "auth_ref": [] }, "qntm_ScheduleOfTradeAndOtherPayablesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ScheduleOfTradeAndOtherPayablesAbstract", "lang": { "en-us": { "role": { "label": "Schedule of trade and other payables [Abstract]" } } }, "auth_ref": [] }, "qntm_SecondVestingTrancheShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "SecondVestingTrancheShares", "presentation": [ "http://www.quantumbiopharma.com/role/SharebasedcompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Second vesting tranche shares", "documentation": "Second vesting tranche shares.", "label": "Second Vesting Tranche Shares" } } }, "auth_ref": [] }, "qntm_SecuredDebentureWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "SecuredDebentureWarrantsMember", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofgainonchangeinfairvalueTable" ], "lang": { "en-us": { "role": { "terseLabel": "Secured Debenture Warrants [Member]", "label": "Secured Debenture Warrants Member" } } }, "auth_ref": [] }, "qntm_SecuredDebenturesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "SecuredDebenturesMember", "presentation": [ "http://www.quantumbiopharma.com/role/ConvertibledebenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Secured debentures [Member]", "label": "Secured Debentures Member" } } }, "auth_ref": [] }, "qntm_SecuredMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "SecuredMember", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofconvertibledebenturesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Secured [Member]", "label": "Secured Member" } } }, "auth_ref": [] }, "qntm_SegmentinformationScheduleofassetandincomebysegmentDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "SegmentinformationScheduleofassetandincomebysegmentDetailsLineItems", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofassetandincomebysegmentTable" ], "lang": { "en-us": { "role": { "label": "Segment information - Schedule of asset and income by segment (Details) [Line Items]" } } }, "auth_ref": [] }, "qntm_SegmentinformationScheduleofassetandincomebysegmentDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "SegmentinformationScheduleofassetandincomebysegmentDetailsTable", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofassetandincomebysegmentTable" ], "lang": { "en-us": { "role": { "label": "Segment information - Schedule of asset and income by segment (Details) [Table]" } } }, "auth_ref": [] }, "ifrs-full_SegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SegmentsAxis", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofassetandincomebysegmentTable", "http://www.quantumbiopharma.com/role/SharecapitalDetails" ], "lang": { "en-us": { "role": { "label": "Segments [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r25", "r73", "r107", "r115", "r214", "r227" ] }, "ifrs-full_SegmentsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SegmentsDomain", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofassetandincomebysegmentTable", "http://www.quantumbiopharma.com/role/SharecapitalDetails" ], "lang": { "en-us": { "role": { "label": "Segments [domain]" } }, "en": { "role": { "documentation": "This member stands for all segments of an entity. It also represents the standard value for the 'Segments' axis if no other member is used." } } }, "auth_ref": [ "r25", "r73", "r112", "r115", "r214", "r227" ] }, "ifrs-full_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "General and administrative", "label": "Selling, general and administrative expense" } } }, "auth_ref": [ "r264" ] }, "qntm_SettledAnAggregateAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "SettledAnAggregateAmount", "crdr": "credit", "presentation": [ "http://www.quantumbiopharma.com/role/SharecapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Settled an aggregate amount (in Dollars)", "documentation": "The amount of settled an aggregate amount.", "label": "Settled An Aggregate Amount" } } }, "auth_ref": [] }, "qntm_SettlementOfDebtAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "SettlementOfDebtAmount", "crdr": "credit", "presentation": [ "http://www.quantumbiopharma.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Settlement of debt amount (in Dollars)", "documentation": "Settlement of debt amount.", "label": "Settlement Of Debt Amount" } } }, "auth_ref": [] }, "qntm_ShareBasedCompensationAggregateAmountIncludingOptionsAndUnitsAggregateShareOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ShareBasedCompensationAggregateAmountIncludingOptionsAndUnitsAggregateShareOutstanding", "presentation": [ "http://www.quantumbiopharma.com/role/SharebasedcompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance share unit, outstanding", "documentation": "Share based compensation aggregate amount including options and units aggregate share outstanding.", "label": "Share Based Compensation Aggregate Amount Including Options And Units Aggregate Share Outstanding" } } }, "auth_ref": [] }, "qntm_ShareBasedCompensationArrangementsByShareBasedPaymentAwardExpectedDividendYield": { "xbrltype": "sharesItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardExpectedDividendYield", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleoffairvaluedeterminedusingblackscholesoptionTable", "http://www.quantumbiopharma.com/role/ScheduleoffairvalueofwarrantsoptionpricingmodelassumptionsTable", "http://www.quantumbiopharma.com/role/ScheduleofgainonchangeinfairvalueTable" ], "lang": { "en-us": { "role": { "terseLabel": "Expected dividend yield", "verboseLabel": "Expected dividend yield (in Shares)", "documentation": "Expected dividend yield.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Expected Dividend Yield" } } }, "auth_ref": [] }, "qntm_ShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ShareBasedCompensationExpense", "crdr": "credit", "presentation": [ "http://www.quantumbiopharma.com/role/SharebasedcompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation expense (in Dollars)", "documentation": "Share-based compensation expense.", "label": "Share Based Compensation Expense" } } }, "auth_ref": [] }, "qntm_ShareBasedCompensationExpenseVestedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ShareBasedCompensationExpenseVestedPricePerShare", "presentation": [ "http://www.quantumbiopharma.com/role/SharebasedcompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share based compensation expense vested price per share (in Dollars per share)", "documentation": "Share based compensation expense vested price per share.", "label": "Share Based Compensation Expense Vested Price Per Share" } } }, "auth_ref": [] }, "qntm_ShareBasedCompensationExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ShareBasedCompensationExpenses", "crdr": "debit", "presentation": [ "http://www.quantumbiopharma.com/role/SharebasedcompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation expense (in Dollars)", "documentation": "Share-based compensation expense.", "label": "Share Based Compensation Expenses" } } }, "auth_ref": [] }, "qntm_ShareCapitalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ShareCapitalAmount", "crdr": "debit", "presentation": [ "http://www.quantumbiopharma.com/role/SharecapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share capital (in Dollars)", "documentation": "Share capital amount.", "label": "Share Capital Amount" } } }, "auth_ref": [] }, "qntm_ShareCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ShareCapitalMember", "presentation": [ "http://www.quantumbiopharma.com/role/SharecapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share Capital [Member]", "label": "Share Capital Member" } } }, "auth_ref": [] }, "ifrs-full_ShareIssueRelatedCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ShareIssueRelatedCost", "crdr": "debit", "presentation": [ "http://www.quantumbiopharma.com/role/SharecapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net cash upon control of subsidiary (in Dollars)", "label": "Share issue related cost" } } }, "auth_ref": [ "r257" ] }, "qntm_ShareOptionsExchangeExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ShareOptionsExchangeExercisePrice", "presentation": [ "http://www.quantumbiopharma.com/role/SharecapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share options exchange, exercise price", "documentation": "Share options exchange, exercise price.", "label": "Share Options Exchange Exercise Price" } } }, "auth_ref": [] }, "qntm_ShareOptionsExercisedShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ShareOptionsExercisedShares", "presentation": [ "http://www.quantumbiopharma.com/role/SharecapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share options exercised", "documentation": "The number of share options exercised.", "label": "Share Options Exercised Shares" } } }, "auth_ref": [] }, "qntm_ShareOptionsGrantedInSharebasedPaymentArrangement": { "xbrltype": "sharesItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ShareOptionsGrantedInSharebasedPaymentArrangement", "presentation": [ "http://www.quantumbiopharma.com/role/SharebasedcompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based payment granted share optiion", "documentation": "Share options granted in share-based payment arrangement.", "label": "Share Options Granted In Sharebased Payment Arrangement" } } }, "auth_ref": [] }, "ifrs-full_ShareOptionsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ShareOptionsMember", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleoflosspershareTable", "http://www.quantumbiopharma.com/role/ScheduleofsharebasedcompensationTable" ], "lang": { "en-us": { "role": { "terseLabel": "Share options [member]", "verboseLabel": "Share Options [Member]", "label": "Share options [member]" } }, "en": { "role": { "documentation": "This member stands for share options." } } }, "auth_ref": [ "r244" ] }, "ifrs-full_SharePremium": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SharePremium", "crdr": "credit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Contributed surplus", "label": "Share premium" } }, "en": { "role": { "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value." } } }, "auth_ref": [ "r231", "r238" ] }, "qntm_SharePriceCAD": { "xbrltype": "perShareItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "SharePriceCAD", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofgainonchangeinfairvalueTable" ], "lang": { "en-us": { "role": { "terseLabel": "Share price (CAD) (in Dollars per share)", "documentation": "Shares price per share.", "label": "Share Price CAD" } } }, "auth_ref": [] }, "qntm_SharePriceOFWarrant": { "xbrltype": "perShareItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "SharePriceOFWarrant", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleoffairvaluedeterminedusingblackscholesoptionTable", "http://www.quantumbiopharma.com/role/ScheduleoffairvalueofwarrantsoptionpricingmodelassumptionsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Share price (CDN)", "verboseLabel": "Share price", "documentation": "Share price.", "label": "Share Price OFWarrant" } } }, "auth_ref": [] }, "qntm_SharePricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "SharePricePerShare", "presentation": [ "http://www.quantumbiopharma.com/role/ConvertibledebenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share price", "documentation": "Share price.", "label": "Share Price Per Share" } } }, "auth_ref": [] }, "qntm_ShareToBeIssuedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ShareToBeIssuedAmount", "crdr": "credit", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofchangesinsharecapitalTable" ], "lang": { "en-us": { "role": { "terseLabel": "Shares to be issued, amount (in Dollars)", "documentation": "The amount of shares to be issued, amount.", "label": "Share To Be Issued Amount" } } }, "auth_ref": [] }, "qntm_SharebasedPaymentsAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "SharebasedPaymentsAmount", "crdr": "credit", "presentation": [ "http://www.quantumbiopharma.com/role/SharecapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share based payments (in Dollars)", "documentation": "Share-based payments, amount.", "label": "Sharebased Payments Amount" } } }, "auth_ref": [] }, "qntm_SharebasedPaymentsShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "SharebasedPaymentsShares", "presentation": [ "http://www.quantumbiopharma.com/role/SharecapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share based payments", "documentation": "The number of share-based payments shares.", "label": "Sharebased Payments Shares" } } }, "auth_ref": [] }, "qntm_SharebasedcompensationDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "SharebasedcompensationDetailsLineItems", "presentation": [ "http://www.quantumbiopharma.com/role/SharebasedcompensationDetails" ], "lang": { "en-us": { "role": { "label": "Share-based compensation (Details) [Line Items]" } } }, "auth_ref": [] }, "qntm_SharebasedcompensationDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "SharebasedcompensationDetailsTable", "presentation": [ "http://www.quantumbiopharma.com/role/SharebasedcompensationDetails" ], "lang": { "en-us": { "role": { "label": "Share-based compensation (Details) [Table]" } } }, "auth_ref": [] }, "qntm_SharebasedcompensationScheduleofcompanysshareoptionsoutstandingDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "SharebasedcompensationScheduleofcompanysshareoptionsoutstandingDetailsLineItems", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofcompanysshareoptionsoutstandingTable" ], "lang": { "en-us": { "role": { "label": "Share-based compensation - Schedule of company\u2019s share options outstanding (Details) [Line Items]" } } }, "auth_ref": [] }, "qntm_SharebasedcompensationScheduleofcompanysshareoptionsoutstandingDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "SharebasedcompensationScheduleofcompanysshareoptionsoutstandingDetailsTable", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofcompanysshareoptionsoutstandingTable" ], "lang": { "en-us": { "role": { "label": "Share-based compensation - Schedule of company\u2019s share options outstanding (Details) [Table]" } } }, "auth_ref": [] }, "qntm_SharebasedcompensationScheduleoffairvaluesofPSUsgrantedusingtheBlackScholesoptionpricingmodelDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "SharebasedcompensationScheduleoffairvaluesofPSUsgrantedusingtheBlackScholesoptionpricingmodelDetailsLineItems", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleoffairvaluesofPSUsgrantedusingtheBlackScholesoptionpricingmodelTable" ], "lang": { "en-us": { "role": { "label": "Share-based compensation - Schedule of fair values of PSUs granted using the Black-Scholes option pricing model (Details) [Line Items]" } } }, "auth_ref": [] }, "qntm_SharebasedcompensationScheduleoffairvaluesofPSUsgrantedusingtheBlackScholesoptionpricingmodelDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "SharebasedcompensationScheduleoffairvaluesofPSUsgrantedusingtheBlackScholesoptionpricingmodelDetailsTable", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleoffairvaluesofPSUsgrantedusingtheBlackScholesoptionpricingmodelTable" ], "lang": { "en-us": { "role": { "label": "Share-based compensation - Schedule of fair values of PSUs granted using the Black-Scholes option pricing model (Details) [Table]" } } }, "auth_ref": [] }, "qntm_SharebasedcompensationScheduleoffairvaluesofoptionsgrantedusingtheBlackScholesoptionpricingmodelDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "SharebasedcompensationScheduleoffairvaluesofoptionsgrantedusingtheBlackScholesoptionpricingmodelDetailsLineItems", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleoffairvaluesofoptionsgrantedusingtheBlackScholesoptionpricingmodelTable" ], "lang": { "en-us": { "role": { "label": "Share-based compensation - Schedule of fair values of options granted using the Black-Scholes option pricing model (Details) [Line Items]" } } }, "auth_ref": [] }, "qntm_SharebasedcompensationScheduleoffairvaluesofoptionsgrantedusingtheBlackScholesoptionpricingmodelDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "SharebasedcompensationScheduleoffairvaluesofoptionsgrantedusingtheBlackScholesoptionpricingmodelDetailsTable", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleoffairvaluesofoptionsgrantedusingtheBlackScholesoptionpricingmodelTable" ], "lang": { "en-us": { "role": { "label": "Share-based compensation - Schedule of fair values of options granted using the Black-Scholes option pricing model (Details) [Table]" } } }, "auth_ref": [] }, "qntm_SharebasedcompensationScheduleofsharebasedcompensationDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "SharebasedcompensationScheduleofsharebasedcompensationDetailsLineItems", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofsharebasedcompensationTable" ], "lang": { "en-us": { "role": { "label": "Share-based compensation - Schedule of share-based compensation (Details) [Line Items]" } } }, "auth_ref": [] }, "qntm_SharebasedcompensationScheduleofsharebasedcompensationDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "SharebasedcompensationScheduleofsharebasedcompensationDetailsTable", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofsharebasedcompensationTable" ], "lang": { "en-us": { "role": { "label": "Share-based compensation - Schedule of share-based compensation (Details) [Table]" } } }, "auth_ref": [] }, "qntm_SharecapitalDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "SharecapitalDetailsLineItems", "presentation": [ "http://www.quantumbiopharma.com/role/SharecapitalDetails" ], "lang": { "en-us": { "role": { "label": "Share capital (Details) [Line Items]" } } }, "auth_ref": [] }, "qntm_SharecapitalDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "SharecapitalDetailsTable", "presentation": [ "http://www.quantumbiopharma.com/role/SharecapitalDetails" ], "lang": { "en-us": { "role": { "label": "Share capital (Details) [Table]" } } }, "auth_ref": [] }, "qntm_SharecapitalScheduleofchangesinsharecapitalDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "SharecapitalScheduleofchangesinsharecapitalDetailsLineItems", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofchangesinsharecapitalTable" ], "lang": { "en-us": { "role": { "label": "Share capital - Schedule of changes in share capital (Details) [Line Items]" } } }, "auth_ref": [] }, "qntm_SharecapitalScheduleofchangesinsharecapitalDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "SharecapitalScheduleofchangesinsharecapitalDetailsTable", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofchangesinsharecapitalTable" ], "lang": { "en-us": { "role": { "label": "Share capital - Schedule of changes in share capital (Details) [Table]" } } }, "auth_ref": [] }, "qntm_SharecapitalScheduleofnumberofwarrantsoutstandingandexercisepriceDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "SharecapitalScheduleofnumberofwarrantsoutstandingandexercisepriceDetailsLineItems", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofnumberofwarrantsoutstandingandexercisepriceTable" ], "lang": { "en-us": { "role": { "label": "Share capital - Schedule of number of warrants outstanding and exercise price (Details) [Line Items]" } } }, "auth_ref": [] }, "qntm_SharecapitalScheduleofnumberofwarrantsoutstandingandexercisepriceDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "SharecapitalScheduleofnumberofwarrantsoutstandingandexercisepriceDetailsTable", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofnumberofwarrantsoutstandingandexercisepriceTable" ], "lang": { "en-us": { "role": { "label": "Share capital - Schedule of number of warrants outstanding and exercise price (Details) [Table]" } } }, "auth_ref": [] }, "qntm_SharesForDebAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "SharesForDebAmount", "crdr": "credit", "presentation": [ "http://www.quantumbiopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Shares for debt", "documentation": "The amount of shares for debt.", "label": "Shares For Deb Amount" } } }, "auth_ref": [] }, "qntm_SharesForDebtShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "SharesForDebtShares", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofchangesinsharecapitalTable", "http://www.quantumbiopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Shares for debt (in Shares)", "verboseLabel": "Shares issued for debt, shares", "documentation": "Shares for debt, shares", "label": "Shares For Debt Shares" } } }, "auth_ref": [] }, "qntm_SharesIssuedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "SharesIssuedAmount", "crdr": "credit", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofchangesinsharecapitalTable" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued - convertible, amount (in Dollars)", "documentation": "Shares issued, amount.", "label": "Shares Issued Amount" } } }, "auth_ref": [] }, "qntm_SharesIssuedConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "SharesIssuedConvertibleDebt", "crdr": "credit", "presentation": [ "http://www.quantumbiopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued - convertible debt", "documentation": "Amount of shares issued convertible debt.", "label": "Shares Issued Convertible Debt" } } }, "auth_ref": [] }, "qntm_SharesIssuedConvertibleDebtinShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "SharesIssuedConvertibleDebtinShares", "presentation": [ "http://www.quantumbiopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued - convertible debt (in Shares)", "documentation": "Shares of issued convertible debt.", "label": "Shares Issued Convertible Debtin Shares" } } }, "auth_ref": [] }, "qntm_SharesIssuedForDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "SharesIssuedForDebt", "crdr": "debit", "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued for debt", "documentation": "Shares issued for debt.", "label": "Shares Issued For Debt" } } }, "auth_ref": [] }, "qntm_SharesIssuedForDebtAmountinDollars": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "SharesIssuedForDebtAmountinDollars", "crdr": "credit", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofchangesinsharecapitalTable" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued for deb, amount (in Dollars)", "documentation": "The amount of shares issued for debt, amount.", "label": "Shares Issued For Debt Amountin Dollars" } } }, "auth_ref": [] }, "qntm_SharesIssuedShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "SharesIssuedShares", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofchangesinsharecapitalTable", "http://www.quantumbiopharma.com/role/SharecapitalDetails", "http://www.quantumbiopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued (in Shares)", "verboseLabel": "Shares issued - convertible, shares", "netLabel": "Shares issued", "documentation": "Shares issued, shares.", "label": "Shares Issued Shares" } } }, "auth_ref": [] }, "qntm_SharesOfStockAllegesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "SharesOfStockAllegesSold", "crdr": "debit", "presentation": [ "http://www.quantumbiopharma.com/role/CommitmentsandcontingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares of stock alleges sold.", "documentation": "Shares of stock alleges sold.", "label": "Shares Of Stock Alleges Sold" } } }, "auth_ref": [] }, "qntm_SharesToBeIssuedSharesinDollars": { "xbrltype": "sharesItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "SharesToBeIssuedSharesinDollars", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofchangesinsharecapitalTable" ], "lang": { "en-us": { "role": { "terseLabel": "Shares to be issued, shares", "documentation": "Number of shares to be issued, shares.", "label": "Shares To Be Issued Sharesin Dollars" } } }, "auth_ref": [] }, "ifrs-full_SignificantInvestmentsInAssociatesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SignificantInvestmentsInAssociatesAxis", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofinvestmentsTable" ], "lang": { "en-us": { "role": { "label": "Associates [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r16", "r18", "r67", "r167" ] }, "ifrs-full_SignificantInvestmentsInAssociatesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SignificantInvestmentsInAssociatesDomain", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofinvestmentsTable" ], "lang": { "en-us": { "role": { "label": "Associates [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Associates' axis if no other member is used." } } }, "auth_ref": [ "r16", "r18", "r67", "r167" ] }, "ifrs-full_SignificantInvestmentsInSubsidiariesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SignificantInvestmentsInSubsidiariesAxis", "presentation": [ "http://www.quantumbiopharma.com/role/NatureofbusinessDetails", "http://www.quantumbiopharma.com/role/ScheduleofownershippercentageinsubsidiariesTable" ], "lang": { "en-us": { "role": { "label": "Subsidiaries [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r16", "r18", "r66", "r166" ] }, "ifrs-full_SignificantInvestmentsInSubsidiariesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SignificantInvestmentsInSubsidiariesDomain", "presentation": [ "http://www.quantumbiopharma.com/role/NatureofbusinessDetails" ], "lang": { "en-us": { "role": { "label": "Subsidiaries [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Subsidiaries' axis if no other member is used." } } }, "auth_ref": [ "r16", "r18", "r66", "r166" ] }, "qntm_SolanaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "SolanaMember", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofchangesindigitalassetsbalanceTable" ], "lang": { "en-us": { "role": { "terseLabel": "Solana [Member]", "label": "Solana Member" } } }, "auth_ref": [] }, "qntm_SoldAnAggregateGrossProceeds": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "SoldAnAggregateGrossProceeds", "crdr": "debit", "presentation": [ "http://www.quantumbiopharma.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sold an aggregate in gross proceeds (in Dollars)", "documentation": "The amount of sold an aggregate in gross proceeds.", "label": "Sold An Aggregate Gross Proceeds" } } }, "auth_ref": [] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementLineItems", "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of cash flows [abstract]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfChangesInEquityLineItems", "presentation": [ "http://www.quantumbiopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "label": "Statement of changes in equity [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfChangesInEquityTable", "presentation": [ "http://www.quantumbiopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "label": "Statement of changes in equity [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to changes in equity." } } }, "auth_ref": [ "r183" ] }, "ifrs-full_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of financial position [abstract]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfIFRSCompliance": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfIFRSCompliance", "presentation": [ "http://www.quantumbiopharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Statement of compliance", "label": "Statement of IFRS compliance [text block]" } } }, "auth_ref": [ "r185" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementTable", "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "auth_ref": [] }, "qntm_StrategicInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "StrategicInvestmentsMember", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofassetandincomebysegmentTable" ], "lang": { "en-us": { "role": { "terseLabel": "Strategic Investments [Member]", "label": "Strategic Investments Member" } } }, "auth_ref": [] }, "qntm_SubordinateVotingShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "SubordinateVotingShares", "presentation": [ "http://www.quantumbiopharma.com/role/WarrantsLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class B subordinate voting shares (in Shares)", "documentation": "Subordinate voting shares.", "label": "Subordinate Voting Shares" } } }, "auth_ref": [] }, "qntm_SubscribedShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "SubscribedShares", "presentation": [ "http://www.quantumbiopharma.com/role/NatureofbusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subscribed shares (in Shares)", "documentation": "The number odd shares subscribed from the third party.", "label": "Subscribed Shares" } } }, "auth_ref": [] }, "qntm_SubscriptionPrice": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "SubscriptionPrice", "crdr": "debit", "presentation": [ "http://www.quantumbiopharma.com/role/ConvertibledebenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subscription price", "documentation": "Subscription price.", "label": "Subscription Price" } } }, "auth_ref": [] }, "qntm_SubscriptionReceivablesAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "SubscriptionReceivablesAmount", "crdr": "debit", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofotherreceivablesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Subscription receivables", "documentation": "The amount of subscription receivables.", "label": "Subscription Receivables Amount" } } }, "auth_ref": [] }, "qntm_SubsequentEventsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "SubsequentEventsMember", "presentation": [ "http://www.quantumbiopharma.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events [Member]", "label": "Subsequent Events Member" } } }, "auth_ref": [] }, "qntm_SubsequenteventsDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "SubsequenteventsDetailsLineItems", "presentation": [ "http://www.quantumbiopharma.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent events (Details) [Line Items]" } } }, "auth_ref": [] }, "qntm_SubsequenteventsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "SubsequenteventsDetailsTable", "presentation": [ "http://www.quantumbiopharma.com/role/SubsequenteventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent events (Details) [Table]" } } }, "auth_ref": [] }, "qntm_SubsidiariesFiveMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "SubsidiariesFiveMember", "presentation": [ "http://www.quantumbiopharma.com/role/NatureofbusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsidiaries Five [Member]", "label": "Subsidiaries Five Member" } } }, "auth_ref": [] }, "ifrs-full_TopOfRangeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TopOfRangeMember", "presentation": [ "http://www.quantumbiopharma.com/role/InvestmentsDetails", "http://www.quantumbiopharma.com/role/RelatedpartytransactionsDetails", "http://www.quantumbiopharma.com/role/ScheduleoffairvaluedeterminedusingblackscholesoptionTable", "http://www.quantumbiopharma.com/role/ScheduleoffairvaluesofoptionsgrantedusingtheBlackScholesoptionpricingmodelTable", "http://www.quantumbiopharma.com/role/ScheduleofgainonchangeinfairvalueTable", "http://www.quantumbiopharma.com/role/SharecapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Top of range [member]", "label": "Top of range [member]" } }, "en": { "role": { "documentation": "This member stands for top of a range." } } }, "auth_ref": [ "r44", "r72", "r78", "r89", "r124", "r222", "r223", "r255" ] }, "qntm_TotalAmountOfWarrantsIssued": { "xbrltype": "sharesItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "TotalAmountOfWarrantsIssued", "presentation": [ "http://www.quantumbiopharma.com/role/SharecapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total Amount Of Warrants Issued", "documentation": "Total amount of warrants issued.", "label": "Total Amount Of Warrants Issued" } } }, "auth_ref": [] }, "qntm_TotalAmountOfWarrantsOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "TotalAmountOfWarrantsOutstanding", "presentation": [ "http://www.quantumbiopharma.com/role/SharecapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "warrants outstanding", "documentation": "The number of warrants outstanding shares.", "label": "Total Amount Of Warrants Outstanding" } } }, "auth_ref": [] }, "qntm_TotalAmountTransferredToShareCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "TotalAmountTransferredToShareCapital", "crdr": "debit", "presentation": [ "http://www.quantumbiopharma.com/role/SharecapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total Amount Transferred To Share Capital (in Dollars)", "documentation": "Total amount transferred to share capital.", "label": "Total Amount Transferred To Share Capital" } } }, "auth_ref": [] }, "qntm_TotalConsolidatedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "TotalConsolidatedMember", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofassetandincomebysegmentTable" ], "lang": { "en-us": { "role": { "terseLabel": "Total Consolidated [Member]", "label": "Total Consolidated Member" } } }, "auth_ref": [] }, "qntm_TotalWarrantsOutstandingExercisedShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "TotalWarrantsOutstandingExercisedShares", "presentation": [ "http://www.quantumbiopharma.com/role/WarrantsLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total warrants outstanding were exercised (in Shares)", "documentation": "Total warrants outstanding were exercised.", "label": "Total Warrants Outstanding Exercised Shares" } } }, "auth_ref": [] }, "ifrs-full_TradeAndOtherCurrentPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherCurrentPayables", "crdr": "credit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 1.0 }, "http://www.quantumbiopharma.com/role/ScheduleoftradeandotherpayablesTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet", "http://www.quantumbiopharma.com/role/ScheduleoftradeandotherpayablesTable" ], "lang": { "en-us": { "role": { "totalLabel": "Trade and other payables", "terseLabel": "Trade and other payables", "label": "Trade and other current payables" } }, "en": { "role": { "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]" } } }, "auth_ref": [ "r192" ] }, "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherCurrentPayablesToTradeSuppliers", "crdr": "credit", "calculation": { "http://www.quantumbiopharma.com/role/ScheduleoftradeandotherpayablesTable": { "parentTag": "ifrs-full_TradeAndOtherCurrentPayables", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleoftradeandotherpayablesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Trade payables", "label": "Current trade payables" } }, "en": { "role": { "documentation": "The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]" } } }, "auth_ref": [ "r236", "r263" ] }, "ifrs-full_TradeAndOtherPayablesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherPayablesAbstract", "lang": { "en-us": { "role": { "label": "Trade and other payables [abstract]" } } }, "auth_ref": [] }, "ifrs-full_TradeAndOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherReceivables", "crdr": "debit", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofotherreceivablesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Trade and other receivables", "label": "Trade and other receivables" } }, "en": { "role": { "documentation": "The amount of trade receivables and other receivables. [Refer: Trade receivables; Other receivables]" } } }, "auth_ref": [ "r176", "r190", "r199" ] }, "ifrs-full_TradeAndOtherReceivablesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherReceivablesAbstract", "lang": { "en-us": { "role": { "label": "Other receivables [abstract]" } } }, "auth_ref": [] }, "qntm_TradingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "TradingExpenses", "crdr": "debit", "presentation": [ "http://www.quantumbiopharma.com/role/SharecapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trading expenses (in Dollars)", "documentation": "Trading expenses.", "label": "Trading Expenses" } } }, "auth_ref": [] }, "qntm_Tranche1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "Tranche1Member", "presentation": [ "http://www.quantumbiopharma.com/role/ConvertibledebenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tranche 1 [Member]", "label": "Tranche1 Member" } } }, "auth_ref": [] }, "qntm_Tranche2Member": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "Tranche2Member", "presentation": [ "http://www.quantumbiopharma.com/role/ConvertibledebenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tranche 2 [Member]", "label": "Tranche2 Member" } } }, "auth_ref": [] }, "qntm_Tranche3Member": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "Tranche3Member", "presentation": [ "http://www.quantumbiopharma.com/role/ConvertibledebenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tranche 3 [Member]", "label": "Tranche3 Member" } } }, "auth_ref": [] }, "qntm_TrancheNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "TrancheNameAxis", "presentation": [ "http://www.quantumbiopharma.com/role/ConvertibledebenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tranche Name [Axis]", "label": "Tranche Name Axis" } } }, "auth_ref": [] }, "qntm_TrancheNameDomainDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "TrancheNameDomainDomain", "presentation": [ "http://www.quantumbiopharma.com/role/ConvertibledebenturesDetails" ], "lang": { "en-us": { "role": { "label": "TrancheNameDomain [Domain]" } } }, "auth_ref": [] }, "ifrs-full_TypesOfAntidilutiveInstrumentsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfAntidilutiveInstrumentsAxis", "presentation": [ "http://www.quantumbiopharma.com/role/SharebasedcompensationDetails", "http://www.quantumbiopharma.com/role/SharecapitalDetails" ], "lang": { "en-us": { "role": { "label": "Types of antidilutive instruments [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r22" ] }, "ifrs-full_TypesOfAntidilutiveInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfAntidilutiveInstrumentsDomain", "presentation": [ "http://www.quantumbiopharma.com/role/SharebasedcompensationDetails", "http://www.quantumbiopharma.com/role/SharecapitalDetails" ], "lang": { "en-us": { "role": { "label": "Types of antidilutive instruments [domain]" } }, "en": { "role": { "documentation": "This member stands for antidilutive instruments. Instruments are antidilutive when their conversion to ordinary shares would increase earnings per share or decrease loss per share from continuing operations. The calculation of diluted earnings per share does not assume conversion, exercise, or other issue of potential ordinary shares that would have an antidilutive effect on earnings per share. It also represents the standard value for the \u2018Types of antidilutive instruments' axis if no other member is used." } } }, "auth_ref": [ "r22" ] }, "ifrs-full_TypesOfInvestmentPropertyAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfInvestmentPropertyAxis", "presentation": [ "http://www.quantumbiopharma.com/role/InvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Types of investment property [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r258" ] }, "ifrs-full_TypesOfInvestmentPropertyDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfInvestmentPropertyDomain", "presentation": [ "http://www.quantumbiopharma.com/role/InvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Types of investment property [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Types of investment property' axis if no other member is used." } } }, "auth_ref": [ "r258" ] }, "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfSharebasedPaymentArrangementsAxis", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleoffairvaluesofPSUsgrantedusingtheBlackScholesoptionpricingmodelTable", "http://www.quantumbiopharma.com/role/ScheduleofintangibleassetsTable", "http://www.quantumbiopharma.com/role/ScheduleoflosspershareTable", "http://www.quantumbiopharma.com/role/ScheduleofsharebasedcompensationTable", "http://www.quantumbiopharma.com/role/SharecapitalDetails" ], "lang": { "en-us": { "role": { "label": "Types of share-based payment arrangements [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r90", "r160" ] }, "ifrs-full_TypesOfSharebasedPaymentArrangementsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfSharebasedPaymentArrangementsDomain", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleoflosspershareTable", "http://www.quantumbiopharma.com/role/ScheduleofsharebasedcompensationTable", "http://www.quantumbiopharma.com/role/SharecapitalDetails" ], "lang": { "en-us": { "role": { "label": "Types of share-based payment arrangements [domain]" } }, "en": { "role": { "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used." } } }, "auth_ref": [ "r90", "r160" ] }, "qntm_UnbuzzdWellnessIncInCanadaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "UnbuzzdWellnessIncInCanadaMember", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofownershippercentageinsubsidiariesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Unbuzzd Wellness Inc in Canada [Member]", "label": "Unbuzzd Wellness Inc In Canada Member" } } }, "auth_ref": [] }, "qntm_UnpaidAccruedInteres": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "UnpaidAccruedInteres", "crdr": "debit", "presentation": [ "http://www.quantumbiopharma.com/role/ConvertibledebenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unpaid accrued interes (in Dollars)", "documentation": "Unpaid accrued interes.", "label": "Unpaid Accrued Interes" } } }, "auth_ref": [] }, "qntm_UnrealizedForeignExchangeGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "UnrealizedForeignExchangeGainLoss", "crdr": "credit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 13.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Unrealized foreign exchange (gain)", "documentation": "Unrealized foreign exchange (gain) loss.", "label": "Unrealized Foreign Exchange Gain Loss" } } }, "auth_ref": [] }, "qntm_UnrealizedLossGainOnChangeInFairValueOfDigitalAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "UnrealizedLossGainOnChangeInFairValueOfDigitalAssets", "crdr": "credit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "ifrs-full_ProfitLossAttributableToNoncontrollingInterests", "weight": 1.0, "order": 6.0 }, "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 14.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedCashFlow", "http://www.quantumbiopharma.com/role/ConsolidatedIncomeStatement", "http://www.quantumbiopharma.com/role/DigitalassetsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Unrealized loss (gain) on change in fair value of digital assets", "terseLabel": "Unrealized loss gain in change in fair value of digital assets", "documentation": "Unrealized loss on change in fair value of digital assets.", "label": "Unrealized Loss Gain On Change In Fair Value Of Digital Assets" } } }, "auth_ref": [] }, "qntm_UnrealizedlossOnChangeInFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "UnrealizedlossOnChangeInFairValue", "crdr": "credit", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofchangesindigitalassetsbalanceTable" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized (loss) gain", "documentation": "The amount of unrealized (loss) on change in fair value.", "label": "Unrealizedloss On Change In Fair Value" } } }, "auth_ref": [] }, "qntm_UnsecuredDebentureWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "UnsecuredDebentureWarrantsMember", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofgainonchangeinfairvalueTable" ], "lang": { "en-us": { "role": { "terseLabel": "Unsecured Debenture Warrants [Member]", "label": "Unsecured Debenture Warrants Member" } } }, "auth_ref": [] }, "qntm_UnsecuredMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "UnsecuredMember", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofconvertibledebenturesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Unsecured [Member]", "label": "Unsecured Member" } } }, "auth_ref": [] }, "ifrs-full_ValueAddedTaxReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ValueAddedTaxReceivables", "crdr": "debit", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofotherreceivablesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Sales tax recoverable", "label": "Value added tax receivables" } }, "en": { "role": { "documentation": "The amount of receivables related to a value added tax." } } }, "auth_ref": [ "r261" ] }, "qntm_ValueOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "ValueOfWarrants", "crdr": "credit", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofconvertibledebenturesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Value of warrants", "documentation": "The amount of value of warrants.", "label": "Value Of Warrants" } } }, "auth_ref": [] }, "qntm_VariableInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "VariableInterestRate", "presentation": [ "http://www.quantumbiopharma.com/role/InvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable interest rate (as a percent)", "documentation": "Percentage of variable interest rate.", "label": "Variable Interest Rate" } } }, "auth_ref": [] }, "ifrs-full_WagesAndSalaries": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WagesAndSalaries", "crdr": "debit", "calculation": { "http://www.quantumbiopharma.com/role/ScheduleofgeneralandadministrativeexpenseTable": { "parentTag": "qntm_GeneralAndAdministrativeExpenseContinuedAndDiscontinuedOperations", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofgeneralandadministrativeexpenseTable" ], "lang": { "en-us": { "role": { "terseLabel": "Salaries, wages and benefits", "label": "Wages and salaries, operating" } } }, "auth_ref": [ "r242" ] }, "qntm_WarrantPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "WarrantPeriod", "presentation": [ "http://www.quantumbiopharma.com/role/ConvertibledebenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant period", "documentation": "Warrant period.", "label": "Warrant Period" } } }, "auth_ref": [] }, "ifrs-full_WarrantReserve": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WarrantReserve", "crdr": "credit", "calculation": { "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants", "label": "Warrant reserve" } }, "en": { "role": { "documentation": "A component of equity resulting from issuing share purchase warrants, other than those resulting from share-based payment arrangements. [Refer: Reserve of share-based payments]" } } }, "auth_ref": [ "r262" ] }, "qntm_Warrants0.40Member": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "Warrants0.40Member", "presentation": [ "http://www.quantumbiopharma.com/role/InvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant [Member]", "label": "Warrants0.40 Member" } } }, "auth_ref": [] }, "qntm_Warrants1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "Warrants1Member", "presentation": [ "http://www.quantumbiopharma.com/role/SharecapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants [Member]", "label": "Warrants1 Member" } } }, "auth_ref": [] }, "qntm_WarrantsByExpiryDateAtMarch20Th2031Member": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "WarrantsByExpiryDateAtMarch20Th2031Member", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofnumberofwarrantsoutstandingandexercisepriceTable" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants By Expiry Date At March 20Th 2031 [Member]", "label": "Warrants By Expiry Date At March20 Th2031 Member" } } }, "auth_ref": [] }, "qntm_WarrantsExpiredAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "WarrantsExpiredAmount", "crdr": "credit", "presentation": [ "http://www.quantumbiopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants expired", "documentation": "The amount of warrants expired.", "label": "Warrants Expired Amount" } } }, "auth_ref": [] }, "qntm_WarrantsExpiredShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "WarrantsExpiredShares", "presentation": [ "http://www.quantumbiopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants expired (in Shares)", "documentation": "The number of warrants expired shares.", "label": "Warrants Expired Shares" } } }, "auth_ref": [] }, "qntm_WarrantsExpiredUnexercised": { "xbrltype": "sharesItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "WarrantsExpiredUnexercised", "presentation": [ "http://www.quantumbiopharma.com/role/SharecapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants expired unexercised", "documentation": "Warrants expired unexercised.", "label": "Warrants Expired Unexercised" } } }, "auth_ref": [] }, "qntm_WarrantsExpiredValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "WarrantsExpiredValue", "crdr": "credit", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofchangesinsharecapitalTable" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants expired, amount (in Dollars)", "documentation": "The amount of warrants expired.", "label": "Warrants Expired Value" } } }, "auth_ref": [] }, "qntm_WarrantsGrossProceed": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "WarrantsGrossProceed", "crdr": "debit", "presentation": [ "http://www.quantumbiopharma.com/role/ConvertibledebenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants gross proceeds", "documentation": "Warrants gross proceeds.", "label": "Warrants Gross Proceed" } } }, "auth_ref": [] }, "qntm_WarrantsInstrumentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "WarrantsInstrumentMember", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofinvestmentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants Instrument [Member]", "label": "Warrants Instrument Member" } } }, "auth_ref": [] }, "qntm_WarrantsIssuedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "WarrantsIssuedAmount", "crdr": "credit", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofchangesinsharecapitalTable" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants issued, amount (in Dollars)", "documentation": "Warrants issued, amount.", "label": "Warrants Issued Amount" } } }, "auth_ref": [] }, "qntm_WarrantsIssuedInConnectionWithConvertibleDebentures": { "xbrltype": "sharesItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "WarrantsIssuedInConnectionWithConvertibleDebentures", "presentation": [ "http://www.quantumbiopharma.com/role/SharecapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants issued in connection with convertible debentures", "documentation": "Warrants issued in connection with convertible debentures.", "label": "Warrants Issued In Connection With Convertible Debentures" } } }, "auth_ref": [] }, "qntm_WarrantsIssuedShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "WarrantsIssuedShares", "presentation": [ "http://www.quantumbiopharma.com/role/SharecapitalDetails", "http://www.quantumbiopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants issued (in Shares)", "verboseLabel": "Warrants issued", "documentation": "The number of warrants issued shares.", "label": "Warrants Issued Shares" } } }, "auth_ref": [] }, "qntm_WarrantsLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "WarrantsLiability", "crdr": "credit", "presentation": [ "http://www.quantumbiopharma.com/role/WarrantsLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants liability", "documentation": "Amount of warrants liability.", "label": "Warrants Liability" } } }, "auth_ref": [] }, "qntm_WarrantsLiabilityDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "WarrantsLiabilityDetailsLineItems", "presentation": [ "http://www.quantumbiopharma.com/role/WarrantsLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Warrants Liability (Details) [Line Items]" } } }, "auth_ref": [] }, "qntm_WarrantsLiabilityDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "WarrantsLiabilityDetailsTable", "presentation": [ "http://www.quantumbiopharma.com/role/WarrantsLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Warrants Liability (Details) [Table]" } } }, "auth_ref": [] }, "qntm_WarrantsLiabilityScheduleoffairvaluedeterminedusingblackscholesoptionDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "WarrantsLiabilityScheduleoffairvaluedeterminedusingblackscholesoptionDetailsLineItems", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleoffairvaluedeterminedusingblackscholesoptionTable" ], "lang": { "en-us": { "role": { "label": "Warrants Liability - Schedule of fair value determined using black-scholes option (Details) [Line Items]" } } }, "auth_ref": [] }, "qntm_WarrantsLiabilityScheduleoffairvaluedeterminedusingblackscholesoptionDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "WarrantsLiabilityScheduleoffairvaluedeterminedusingblackscholesoptionDetailsTable", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleoffairvaluedeterminedusingblackscholesoptionTable" ], "lang": { "en-us": { "role": { "label": "Warrants Liability - Schedule of fair value determined using black-scholes option (Details) [Table]" } } }, "auth_ref": [] }, "ifrs-full_WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WarrantsMember", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleoflosspershareTable", "http://www.quantumbiopharma.com/role/SharecapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants [Member]", "verboseLabel": "Warrants [member]", "label": "Warrants [member]" } }, "en": { "role": { "documentation": "This member stands for warrants." } } }, "auth_ref": [ "r244" ] }, "qntm_WarrantsPerDebenturePerUnit": { "xbrltype": "perShareItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "WarrantsPerDebenturePerUnit", "presentation": [ "http://www.quantumbiopharma.com/role/ConvertibledebenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants per debenture per unit (in Dollars per share)", "documentation": "Warrants per debenture per unit", "label": "Warrants Per Debenture Per Unit" } } }, "auth_ref": [] }, "qntm_WarrantsSharesExpired": { "xbrltype": "sharesItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "WarrantsSharesExpired", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofchangesinsharecapitalTable" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants expired, shares", "documentation": "The number of warrants shares expired.", "label": "Warrants Shares Expired" } } }, "auth_ref": [] }, "qntm_WarrantsSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "WarrantsSharesIssued", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofchangesinsharecapitalTable" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants issued, shares", "documentation": "The number of warrants shares issued.", "label": "Warrants Shares Issued" } } }, "auth_ref": [] }, "qntm_WarrantsSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "WarrantsSharesMember", "presentation": [ "http://www.quantumbiopharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants", "label": "Warrants Shares Member" } } }, "auth_ref": [] }, "qntm_WarrantsWereExpiredShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "WarrantsWereExpiredShares", "presentation": [ "http://www.quantumbiopharma.com/role/SharecapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants were expired shares", "documentation": "Number of warrants were expired shares.", "label": "Warrants Were Expired Shares" } } }, "auth_ref": [] }, "ifrs-full_WarrantyContingentLiabilityMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WarrantyContingentLiabilityMember", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleoffairvaluedeterminedusingblackscholesoptionTable", "http://www.quantumbiopharma.com/role/ScheduleoffairvalueofwarrantsoptionpricingmodelassumptionsTable", "http://www.quantumbiopharma.com/role/WarrantsLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warranty contingent liability [member]", "verboseLabel": "Warranty Liability [Member]", "label": "Warranty contingent liability [member]" } }, "en": { "role": { "documentation": "This member stands for a contingent liability for estimated costs of making good under warranties for products sold. [Refer: Classes of contingent liabilities [domain]]" } } }, "auth_ref": [ "r216" ] }, "qntm_WeightedAverageExercisePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "WeightedAverageExercisePeriod", "presentation": [ "http://www.quantumbiopharma.com/role/SharebasedcompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based payment arrangements exercisable period", "documentation": "Weighted average exercise period.", "label": "Weighted Average Exercise Period" } } }, "auth_ref": [] }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofcompanysshareoptionsoutstandingTable", "http://www.quantumbiopharma.com/role/ScheduleofnumberofshareoptionsoutstandingTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average exercise price, Exercisable", "verboseLabel": "Options exercisable, Exercise price\t(in Dollars per share)", "label": "Weighted average exercise price of share options exercisable in share-based payment arrangement" } }, "en": { "role": { "documentation": "The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r87", "r159" ] }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofnumberofshareoptionsoutstandingTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average exercise price, Expired", "label": "Weighted average exercise price of share options expired in share-based payment arrangement" } }, "en": { "role": { "documentation": "The weighted average exercise price of share options expired in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r85", "r157" ] }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofnumberofshareoptionsoutstandingTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average exercise price, Cancelled", "label": "Weighted average exercise price of share options forfeited in share-based payment arrangement" } }, "en": { "role": { "documentation": "The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r83", "r155" ] }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofnumberofshareoptionsoutstandingTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average exercise price, Granted", "label": "Weighted average exercise price of share options granted in share-based payment arrangement" } }, "en": { "role": { "documentation": "The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r82", "r154" ] }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019", "presentation": [ "http://www.quantumbiopharma.com/role/SharebasedcompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable price per share (in Dollars per share)", "label": "Weighted average share price for share options in share-based payment arrangement exercised during period at date of exercise" } }, "en": { "role": { "documentation": "The weighted average share price at the date of exercise for share options that are exercised in a share-based payment arrangement. [Refer: Types of share-based payment arrangements [domain]; Weighted average [member]]" } } }, "auth_ref": [ "r88" ] }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofnumberofshareoptionsoutstandingTable" ], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted average exercise price, Outstanding Ending", "periodEndLabel": "Weighted average exercise price, Outstanding Ending", "label": "Weighted average exercise price of share options outstanding in share-based payment arrangement" } }, "en": { "role": { "documentation": "The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r81", "r86", "r153", "r158" ] }, "qntm_WeightedAverageExercisePriceWarrantOutstanding": { "xbrltype": "perShareItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "WeightedAverageExercisePriceWarrantOutstanding", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofchangesinwarrantsoutstandingandweightedaverageexercisepriceTable", "http://www.quantumbiopharma.com/role/WarrantsLiabilityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted average exercise price, Outstanding", "periodEndLabel": "Weighted average exercise price, Outstanding", "terseLabel": "Weighted average exercise price, Outstanding (in Dollars) (in Dollars per share)", "documentation": "Weighted average exercise price warrants outstanding.", "label": "Weighted Average Exercise Price Warrant Outstanding" } } }, "auth_ref": [] }, "qntm_WeightedAverageExercisePriceWarrantsOutstanding": { "xbrltype": "perShareItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "WeightedAverageExercisePriceWarrantsOutstanding", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofnumberofwarrantsoutstandingandexercisepriceTable" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price warrants outstanding", "documentation": "Represents weighted average exercise Price warrants outstanding.", "label": "Weighted Average Exercise Price Warrants Outstanding" } } }, "auth_ref": [] }, "qntm_WeightedAverageExercisePricesWarrantExercised": { "xbrltype": "perShareItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "WeightedAverageExercisePricesWarrantExercised", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofchangesinwarrantsoutstandingandweightedaverageexercisepriceTable" ], "lang": { "en-us": { "role": { "terseLabel": "Exercised", "documentation": "Represents weighted average exercise price warrants exercised.", "label": "Weighted Average Exercise Prices Warrant Exercised" } } }, "auth_ref": [] }, "qntm_WeightedAverageExercisePricesWarrantExpired": { "xbrltype": "perShareItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "WeightedAverageExercisePricesWarrantExpired", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofchangesinwarrantsoutstandingandweightedaverageexercisepriceTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average exercise price, Expired", "documentation": "Represents weighted average exercise price warrants expired.", "label": "Weighted Average Exercise Prices Warrant Expired" } } }, "auth_ref": [] }, "qntm_WeightedAverageExercisePricesWarrantIssued": { "xbrltype": "perShareItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "WeightedAverageExercisePricesWarrantIssued", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofchangesinwarrantsoutstandingandweightedaverageexercisepriceTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average exercise price, Issued", "documentation": "Represents weighted average exercise price warrants issued.", "label": "Weighted Average Exercise Prices Warrant Issued" } } }, "auth_ref": [] }, "qntm_WeightedAverageNumberOfShareOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "WeightedAverageNumberOfShareOutstandingBasic", "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average number of shares outstanding \u2013 basic (in Shares)", "documentation": "Weighted average number of shares outstanding.", "label": "Weighted Average Number Of Share Outstanding Basic" } } }, "auth_ref": [] }, "qntm_WeightedAverageNumberOfShareOutstandingDiluted": { "xbrltype": "sharesItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "WeightedAverageNumberOfShareOutstandingDiluted", "presentation": [ "http://www.quantumbiopharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average number of shares outstanding \u2013 diluted (in Shares)", "documentation": "Weighted average number of shares outstanding diluted.", "label": "Weighted Average Number Of Share Outstanding Diluted" } } }, "auth_ref": [] }, "ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019": { "xbrltype": "durationItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofcompanysshareoptionsoutstandingTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining contractual life [years]", "label": "Weighted average remaining contractual life of outstanding share options" } }, "en": { "role": { "documentation": "The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r89" ] }, "qntm_XRPMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "XRPMember", "presentation": [ "http://www.quantumbiopharma.com/role/ScheduleofchangesindigitalassetsbalanceTable" ], "lang": { "en-us": { "role": { "terseLabel": "XRP [Member]", "label": "XRPMember" } } }, "auth_ref": [] }, "qntm_lossOnChangeInFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "lossOnChangeInFairValue", "crdr": "debit", "presentation": [ "http://www.quantumbiopharma.com/role/InvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "loss on change in fair value", "documentation": "loss on change in fair value.", "label": "loss On Change In Fair Value" } } }, "auth_ref": [] }, "qntm_lossOnIssuanceOfConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "lossOnIssuanceOfConvertibleDebt", "crdr": "credit", "presentation": [ "http://www.quantumbiopharma.com/role/ConvertibledebenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "loss on issuance of convertible debt", "documentation": "loss on issuance of convertible debt.", "label": "loss On Issuance Of Convertible Debt" } } }, "auth_ref": [] }, "qntm_warrantLiabilityOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quantumbiopharma.com/20260630", "localname": "warrantLiabilityOutstanding", "crdr": "credit", "presentation": [ "http://www.quantumbiopharma.com/role/WarrantsLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant liability outstanding", "documentation": "The amount of warrant liability outstanding.", "label": "warrant Liability Outstanding" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "10", "IssueDate": "2025-01-01", "Paragraph": "21", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2025-en-r&anchor=para_21&doctype=Standard", "URIDate": "2025-03-27" }, "r1": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "10", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS10_g17-22_TI", "URIDate": "2025-03-27" }, "r2": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_d&doctype=Standard", "URIDate": "2025-03-27" }, "r3": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_e&doctype=Standard", "URIDate": "2025-03-27" }, "r4": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "75", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_75_b&doctype=Standard", "URIDate": "2025-03-27" }, "r5": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "142", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_142&doctype=Standard", "URIDate": "2025-03-27" }, "r6": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "36", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2025-en-r&anchor=para_36_b&doctype=Standard", "URIDate": "2025-03-27" }, "r7": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2025-01-01", "Paragraph": "52", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2025-en-r&anchor=para_52_a&doctype=Standard", "URIDate": "2025-03-27" }, "r8": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2025-01-01", "Paragraph": "52", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2025-en-r&anchor=para_52_b&doctype=Standard", "URIDate": "2025-03-27" }, "r9": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2025-03-27" }, "r10": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2025-03-27" }, "r11": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "17", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_17&doctype=Standard", "URIDate": "2025-03-27" }, "r12": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "19", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_19&doctype=Standard", "URIDate": "2025-03-27" }, "r13": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Section": "Disclosures", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI", "URIDate": "2025-03-27" }, "r14": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "26", "IssueDate": "2025-01-01", "Paragraph": "35", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2025-en-r&anchor=para_35_b_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r15": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2025-01-01", "Paragraph": "16", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_16_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r16": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2025-01-01", "Paragraph": "16", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_16_b&doctype=Standard", "URIDate": "2025-03-27" }, "r17": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_17_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r18": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_17_b&doctype=Standard", "URIDate": "2025-03-27" }, "r19": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_66&doctype=Standard", "URIDate": "2025-03-27" }, "r20": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "67", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_67&doctype=Standard", "URIDate": "2025-03-27" }, "r21": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "70", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_70_a&doctype=Standard", "URIDate": "2025-03-27" }, "r22": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "70", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_70_c&doctype=Standard", "URIDate": "2025-03-27" }, "r23": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS33_g70-73A_TI", "URIDate": "2025-03-27" }, "r24": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "126", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_126&doctype=Standard", "URIDate": "2025-03-27" }, "r25": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "130", "Subparagraph": "d", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_130_d_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r26": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "130", "Subparagraph": "f", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_130_f_i&doctype=Standard", "URIDate": "2025-03-27" }, "r27": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "134", "Subparagraph": "e", "Clause": "iiA", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_134_e_iiA&doctype=Standard", "URIDate": "2025-03-27" }, "r28": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "37", "IssueDate": "2025-01-01", "Paragraph": "86", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2025-en-r&anchor=para_86&doctype=Standard", "URIDate": "2025-03-27" }, "r29": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "37", "IssueDate": "2025-01-01", "Paragraph": "88", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2025-en-r&anchor=para_88&doctype=Standard", "URIDate": "2025-03-27" }, "r30": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_c&doctype=Standard", "URIDate": "2025-03-27" }, "r31": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "e", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e_i&doctype=Standard", "URIDate": "2025-03-27" }, "r32": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e&doctype=Standard", "URIDate": "2025-03-27" }, "r33": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118&doctype=Standard", "URIDate": "2025-03-27" }, "r34": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "126", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_126&doctype=Standard", "URIDate": "2025-03-27" }, "r35": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS38_g118-128_TI", "URIDate": "2025-03-27" }, "r36": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2025-01-01", "Paragraph": "32A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_32A&doctype=Standard", "URIDate": "2025-03-27" }, "r37": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2025-01-01", "Paragraph": "76", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_76_d&doctype=Standard", "URIDate": "2025-03-27" }, "r38": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2025-01-01", "Paragraph": "76", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_76&doctype=Standard", "URIDate": "2025-03-27" }, "r39": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_79_c&doctype=Standard", "URIDate": "2025-03-27" }, "r40": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_79_d&doctype=Standard", "URIDate": "2025-03-27" }, "r41": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "41", "IssueDate": "2025-01-01", "Paragraph": "50", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2025-en-r&anchor=para_50&doctype=Standard", "URIDate": "2025-03-27" }, "r42": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "41", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2025-en-r&anchor=para_54_f&doctype=Standard", "URIDate": "2025-03-27" }, "r43": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "10", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_10&doctype=Standard", "URIDate": "2025-03-27" }, "r44": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "44H", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_44H_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r45": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r46": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "50", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_50_d&doctype=Standard", "URIDate": "2025-03-27" }, "r47": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "30", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2025-en-r&anchor=para_30_b&doctype=Standard", "URIDate": "2025-03-27" }, "r48": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2025-03-27" }, "r49": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2025-03-27" }, "r50": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "32", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_32_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r51": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "32", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_32_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r52": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "10", "IssueDate": "2025-01-01", "Paragraph": "22", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=10&code=ifrs-tx-2025-en-r&anchor=para_22&doctype=Standard", "URIDate": "2025-03-27" }, "r53": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "12", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_12_c&doctype=Standard", "URIDate": "2025-03-27" }, "r54": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "12", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_12_e&doctype=Standard", "URIDate": "2025-03-27" }, "r55": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "12", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_12_f&doctype=Standard", "URIDate": "2025-03-27" }, "r56": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "19B", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_19B_c&doctype=Standard", "URIDate": "2025-03-27" }, "r57": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r58": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r59": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r60": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_vi&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r61": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "viii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r62": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B13", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r63": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B13", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_d&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r64": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B13", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_e&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r65": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B13", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_f&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r66": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B4", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B4_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r67": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B4", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B4_d&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r68": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_a&doctype=Standard", "URIDate": "2025-03-27" }, "r69": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_b&doctype=Standard", "URIDate": "2025-03-27" }, "r70": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_e&doctype=Standard", "URIDate": "2025-03-27" }, "r71": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93&doctype=Standard", "URIDate": "2025-03-27" }, "r72": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "14", "IssueDate": "2025-01-01", "Paragraph": "33", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2025-en-r&anchor=para_33_b&doctype=Standard", "URIDate": "2025-03-27" }, "r73": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "115", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_115&doctype=Standard", "URIDate": "2025-03-27" }, "r74": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_47_a&doctype=Standard", "URIDate": "2025-03-27" }, "r75": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2025-03-27" }, "r76": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "53", "Subparagraph": "j", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53_j&doctype=Standard", "URIDate": "2025-03-27" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "53", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53&doctype=Standard", "URIDate": "2025-03-27" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "120", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_120&doctype=Standard", "URIDate": "2025-03-27" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "44", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_44&doctype=Standard", "URIDate": "2025-03-27" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_a&doctype=Standard", "URIDate": "2025-03-27" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "v", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_v&doctype=Standard", "URIDate": "2025-03-27" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_vi&doctype=Standard", "URIDate": "2025-03-27" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "vii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_vii&doctype=Standard", "URIDate": "2025-03-27" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_c&doctype=Standard", "URIDate": "2025-03-27" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_d&doctype=Standard", "URIDate": "2025-03-27" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_47_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_47_a&doctype=Standard", "URIDate": "2025-03-27" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2025-03-27" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2025-01-01", "Paragraph": "B64", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_B64_c&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2025-01-01", "Paragraph": "B67", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_B67_c&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2025-01-01", "Paragraph": "B67", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35H", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35H&doctype=Standard", "URIDate": "2025-03-27" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35I", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35I&doctype=Standard", "URIDate": "2025-03-27" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35K", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35K&doctype=Standard", "URIDate": "2025-03-27" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35M", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35M&doctype=Standard", "URIDate": "2025-03-27" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "36", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_36&doctype=Standard", "URIDate": "2025-03-27" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B52", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B52&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Section": "Scope", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IFRS07_g3-5A_TI", "URIDate": "2025-03-27" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_c&doctype=Standard", "URIDate": "2025-03-27" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_d&doctype=Standard", "URIDate": "2025-03-27" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_e&doctype=Standard", "URIDate": "2025-03-27" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23&doctype=Standard", "URIDate": "2025-03-27" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2025-03-27" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_c&doctype=Standard", "URIDate": "2025-03-27" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_d&doctype=Standard", "URIDate": "2025-03-27" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_e&doctype=Standard", "URIDate": "2025-03-27" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28&doctype=Standard", "URIDate": "2025-03-27" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_32&doctype=Standard", "URIDate": "2025-03-27" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "9", "IssueDate": "2025-01-01", "Paragraph": "6.5.16", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2025-en-r&anchor=para_6.5.16&doctype=Standard", "URIDate": "2025-03-27" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "104", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_104&doctype=Standard", "URIDate": "2025-03-27" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "115", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115_i&doctype=Standard", "URIDate": "2025-03-27" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "115", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115&doctype=Standard", "URIDate": "2025-03-27" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "a", "Clause": "v", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_v&doctype=Standard", "URIDate": "2025-03-27" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a&doctype=Standard", "URIDate": "2025-03-27" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160&doctype=Standard", "URIDate": "2025-03-27" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "164", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_164_b&doctype=Standard", "URIDate": "2025-03-27" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "168", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_168_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "169", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_169&doctype=Standard", "URIDate": "2025-03-27" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "180", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_180_b&doctype=Standard", "URIDate": "2025-03-27" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "190", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_190&doctype=Standard", "URIDate": "2025-03-27" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "200", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_d&doctype=Standard", "URIDate": "2025-03-27" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "200", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_e&doctype=Standard", "URIDate": "2025-03-27" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "218", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_218_a&doctype=Standard", "URIDate": "2025-03-27" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "218", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_218_b&doctype=Standard", "URIDate": "2025-03-27" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "227", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_227&doctype=Standard", "URIDate": "2025-03-27" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "231", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_231&doctype=Standard", "URIDate": "2025-03-27" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2025-03-27" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2025-03-27" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "250", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_250&doctype=Standard", "URIDate": "2025-03-27" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "254", "Subparagraph": "e", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_254_e_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "259", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_259&doctype=Standard", "URIDate": "2025-03-27" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_c&doctype=Standard", "URIDate": "2025-03-27" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "Subparagraph": "e", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_e_i&doctype=Standard", "URIDate": "2025-03-27" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_e&doctype=Standard", "URIDate": "2025-03-27" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263&doctype=Standard", "URIDate": "2025-03-27" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "266", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_266&doctype=Standard", "URIDate": "2025-03-27" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "269", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_269_d&doctype=Standard", "URIDate": "2025-03-27" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "269", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_269&doctype=Standard", "URIDate": "2025-03-27" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "271", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_271_c&doctype=Standard", "URIDate": "2025-03-27" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "271", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_271_d&doctype=Standard", "URIDate": "2025-03-27" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "273", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_273&doctype=Standard", "URIDate": "2025-03-27" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "274", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_274_e&doctype=Standard", "URIDate": "2025-03-27" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_28_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_28_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_a&doctype=Standard", "URIDate": "2025-03-27" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "Clause": "v", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_v&doctype=Standard", "URIDate": "2025-03-27" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_vi&doctype=Standard", "URIDate": "2025-03-27" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "Clause": "vii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_vii&doctype=Standard", "URIDate": "2025-03-27" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31&doctype=Standard", "URIDate": "2025-03-27" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "35", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_35_c&doctype=Standard", "URIDate": "2025-03-27" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "37", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_37&doctype=Standard", "URIDate": "2025-03-27" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_66&doctype=Standard", "URIDate": "2025-03-27" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "70", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_70&doctype=Standard", "URIDate": "2025-03-27" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "71", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_71&doctype=Standard", "URIDate": "2025-03-27" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "75", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_75_a&doctype=Standard", "URIDate": "2025-03-27" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "75", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_75_c&doctype=Standard", "URIDate": "2025-03-27" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "95", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95_a&doctype=Standard", "URIDate": "2025-03-27" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "95", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95_b&doctype=Standard", "URIDate": "2025-03-27" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "95", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95&doctype=Standard", "URIDate": "2025-03-27" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_iii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_iv&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "a", "Clause": "v", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_v&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_f&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "104", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_104&doctype=Standard", "URIDate": "2025-03-27" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_a&doctype=Standard", "URIDate": "2025-03-27" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_i&doctype=Standard", "URIDate": "2025-03-27" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106&doctype=Standard", "URIDate": "2025-03-27" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "134", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_134&doctype=Standard", "URIDate": "2025-03-27" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "16", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_16&doctype=Standard", "URIDate": "2025-03-27" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_35&doctype=Standard", "URIDate": "2025-03-27" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_a&doctype=Standard", "URIDate": "2025-03-27" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_c&doctype=Standard", "URIDate": "2025-03-27" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_g&doctype=Standard", "URIDate": "2025-03-27" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_h&doctype=Standard", "URIDate": "2025-03-27" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_i&doctype=Standard", "URIDate": "2025-03-27" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "k", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_k&doctype=Standard", "URIDate": "2025-03-27" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "q", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_q&doctype=Standard", "URIDate": "2025-03-27" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "r", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_r&doctype=Standard", "URIDate": "2025-03-27" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_55&doctype=Standard", "URIDate": "2025-03-27" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_66&doctype=Standard", "URIDate": "2025-03-27" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "69", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_69&doctype=Standard", "URIDate": "2025-03-27" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_7&doctype=Standard", "URIDate": "2025-03-27" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_b&doctype=Standard", "URIDate": "2025-03-27" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard", "URIDate": "2025-03-27" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "v", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_v&doctype=Standard", "URIDate": "2025-03-27" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a&doctype=Standard", "URIDate": "2025-03-27" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79&doctype=Standard", "URIDate": "2025-03-27" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81A", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_a&doctype=Standard", "URIDate": "2025-03-27" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81A", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_b&doctype=Standard", "URIDate": "2025-03-27" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81B", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81B_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81B", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81B_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "82", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_b&doctype=Standard", "URIDate": "2025-03-27" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "91", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_91_a&doctype=Standard", "URIDate": "2025-03-27" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "98", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_98_d&doctype=Standard", "URIDate": "2025-03-27" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "99", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_99&doctype=Standard", "URIDate": "2025-03-27" }, "r214": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "138", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_138_d&doctype=Standard", "URIDate": "2025-03-27" }, "r215": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "32", "IssueDate": "2025-01-01", "Paragraph": "IE33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2025-en-r&anchor=para_IE33&doctype=Illustrative%20Examples", "URIDate": "2025-03-27" }, "r216": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "37", "IssueDate": "2025-01-01", "Paragraph": "88", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2025-en-r&anchor=para_88&doctype=Standard", "URIDate": "2025-03-27" }, "r217": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "16", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_16_b&doctype=Standard", "URIDate": "2025-03-27" }, "r218": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2025-03-27" }, "r219": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_c&doctype=Standard", "URIDate": "2025-03-27" }, "r220": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2025-03-27" }, "r221": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r222": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "B6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_B6&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r223": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "IE63", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_IE63&doctype=Illustrative%20Examples", "URIDate": "2025-03-27" }, "r224": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "B89", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_B89_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r225": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "B89", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_B89_e&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r226": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "113", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_113_b&doctype=Standard", "URIDate": "2025-03-27" }, "r227": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "96", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_96_c&doctype=Standard", "URIDate": "2025-03-27" }, "r228": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "103", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103_a&doctype=Standard", "URIDate": "2025-03-27" }, "r229": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "103", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103_e&doctype=Standard", "URIDate": "2025-03-27" }, "r230": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r231": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_f&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r232": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "102", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_102&doctype=Standard", "URIDate": "2025-03-27" }, "r233": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_103&doctype=Standard", "URIDate": "2025-03-27" }, "r234": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_108&doctype=Standard", "URIDate": "2025-03-27" }, "r235": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "68", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_68&doctype=Standard", "URIDate": "2025-03-27" }, "r236": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "70", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_70&doctype=Standard", "URIDate": "2025-03-27" }, "r237": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_b&doctype=Standard", "URIDate": "2025-03-27" }, "r238": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard", "URIDate": "2025-03-27" }, "r239": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "IG6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_IG6&doctype=Implementation%20Guidance", "URIDate": "2025-03-27" }, "r240": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r241": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_d&doctype=Standard", "URIDate": "2025-03-27" }, "r242": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "9", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_9&doctype=Standard", "URIDate": "2025-03-27" }, "r243": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "70", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_70_b&doctype=Standard", "URIDate": "2025-03-27" }, "r244": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "70", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_70_c&doctype=Standard", "URIDate": "2025-03-27" }, "r245": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_c&doctype=Standard", "URIDate": "2025-03-27" }, "r246": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "40", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_79_c&doctype=Standard", "URIDate": "2025-03-27" }, "r247": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "41", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2025-en-r&anchor=para_54_f&doctype=Standard", "URIDate": "2025-03-27" }, "r248": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "14", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_14&doctype=Standard", "URIDate": "2025-03-27" }, "r249": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "16", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_16&doctype=Standard", "URIDate": "2025-03-27" }, "r250": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17&doctype=Standard", "URIDate": "2025-03-27" }, "r251": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20_a&doctype=Standard", "URIDate": "2025-03-27" }, "r252": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20_b&doctype=Standard", "URIDate": "2025-03-27" }, "r253": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20&doctype=Standard", "URIDate": "2025-03-27" }, "r254": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r255": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_7&doctype=Standard", "URIDate": "2025-03-27" }, "r256": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "10", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_10_e&doctype=Standard", "URIDate": "2025-03-27" }, "r257": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d&doctype=Standard", "URIDate": "2025-03-27" }, "r258": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "112", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_112_c&doctype=Standard", "URIDate": "2025-03-27" }, "r259": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "117", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_117&doctype=Standard", "URIDate": "2025-03-27" }, "r260": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_55&doctype=Standard", "URIDate": "2025-03-27" }, "r261": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_b&doctype=Standard", "URIDate": "2025-03-27" }, "r262": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard", "URIDate": "2025-03-27" }, "r263": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78&doctype=Standard", "URIDate": "2025-03-27" }, "r264": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "85", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_85&doctype=Standard", "URIDate": "2025-03-27" } } }